Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-18-236651.txt : 20180802 0001193125-18-236651.hdr.sgml : 20180802 20180802163055 ACCESSION NUMBER: 0001193125-18-236651 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180802 DATE AS OF CHANGE: 20180802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDNAX, INC. CENTRAL INDEX KEY: 0000893949 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOSPITALS [8060] IRS NUMBER: 263667538 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12111 FILM NUMBER: 18988804 BUSINESS ADDRESS: STREET 1: 1301 CONCORD TERRACE CITY: SUNRISE STATE: FL ZIP: 33323 BUSINESS PHONE: 9543840175 MAIL ADDRESS: STREET 1: 1301 CONCORD TERRACE CITY: SUNRISE STATE: FL ZIP: 33323 FORMER COMPANY: FORMER CONFORMED NAME: PEDIATRIX MEDICAL GROUP INC DATE OF NAME CHANGE: 19950801 10-Q 1 d558671d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2018

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-12111

MEDNAX, INC.

(Exact name of registrant as specified in its charter)


Florida		26-3667538
(State or other jurisdiction of Incorporation or organization)		(I.R.S. Employer Identification No.)

1301 Concord Terrace Sunrise, Florida		33323
(Address of principal executive offices)		(Zip Code)

(954) 384-0175

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

On July 27, 2018, the registrant had outstanding 93,466,848 shares of Common Stock, par value $.01 per share.

MEDNAX, INC.

INDEX


		Page
PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements		3

	Condensed Consolidated Balance Sheets as of June 30, 2018 and December 31, 2017 (Unaudited)		3

	Condensed Consolidated Statements of Income for the Three and Six Months Ended June 30, 2018 and 2017 (Unaudited)		4

	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2018 and 2017 (Unaudited)		5

	Notes to Condensed Consolidated Financial Statements (Unaudited)		6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		12

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		20

Item 4.	Controls and Procedures		20

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings		21

Item 1A.	Risk Factors		21

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		21

Item 5.	Other Information		22

Item 6.	Exhibits		23

SIGNATURES			24

PART I - FINANCIAL INFORMATION

Item 1.

Financial Statements

MEDNAX, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(Unaudited)


	June 30, 2018		December 31, 2017
ASSETS
Current assets:
Cash and cash equivalents	$	38,056	$	60,200
Restricted cash		19,000		—
Short-term investments		9,902		10,292
Accounts receivable, net		527,997		503,999
Prepaid expenses		15,752		15,584
Other current assets		14,223		37,160

Total current assets		624,930		627,235
Restricted cash		1,000		20,000
Investments		90,186		80,682
Property and equipment, net		131,922		123,536
Goodwill		4,304,740		4,283,963
Intangible assets, net		614,226		639,928
Other assets		92,634		91,934

Total assets	$	5,859,638	$	5,867,278

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	358,255	$	438,017
Current portion of long-term debt and capital lease obligations		860		1,401
Income taxes payable		52,098		92,007

Total current liabilities		411,213		531,425
Line of credit		1,149,500		1,110,500
Long-term debt and capital lease obligations, net		741,612		740,923
Long-term professional liabilities		207,687		212,274
Deferred income taxes		126,505		147,797
Other liabilities		36,199		57,905

Total liabilities		2,672,716		2,800,824

Commitments and contingencies

Shareholders’ equity:
Preferred stock; $.01 par value; 1,000 shares authorized; none issued		—		—
Common stock; $.01 par value; 200,000 shares authorized; 93,374 and 93,721 shares issued and outstanding, respectively		934		937
Additional paid-in capital		1,032,573		1,017,328
Retained earnings		2,153,415		2,048,189

Total shareholders’ equity		3,186,922		3,066,454

Total liabilities and shareholders’ equity	$	5,859,638	$	5,867,278

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

MEDNAX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share data)

(Unaudited)


	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Net revenue	$	915,918		$	842,944		$	1,817,775		$	1,678,541

Operating expenses:
Practice salaries and benefits		620,980			561,418			1,252,810			1,133,803
Practice supplies and other operating expenses		31,833			30,872			62,488			58,668
General and administrative expenses		107,908			103,015			216,684			206,780
Depreciation and amortization		26,518			25,735			52,681			51,349

Total operating expenses		787,239			721,040			1,584,663			1,450,600

Income from operations		128,679			121,904			233,112			227,941
Investment and other income		1,202			365			2,666			941
Interest expense		(21,604	)		(18,535	)		(41,539	)		(36,287	)
Equity in earnings of unconsolidated affiliates		1,257			689			2,782			1,486

Total non-operating expenses		(19,145	)		(17,481	)		(36,091	)		(33,860	)

Income before income taxes		109,534			104,423			197,021			194,081
Income tax provision		(30,122	)		(40,725	)		(54,181	)		(75,692	)

Net income	$	79,412		$	63,698		$	142,840		$	118,389

Per common and common equivalent share data:

Net income:

Basic	$	0.85		$	0.69		$	1.54		$	1.28

Diluted	$	0.85		$	0.69		$	1.53		$	1.27


Weighted average common shares:

Basic		92,987			92,181			92,922			92,270

Diluted		93,529			92,812			93,516			92,977

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

MEDNAX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)


	Six Months Ended June 30,
	2018			2017
Cash flows from operating activities:
Net income	$	142,840		$	118,389
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization		52,681			51,349
Amortization of premiums, discounts and issuance costs		2,212			2,740
Stock-based compensation expense		20,399			14,781
Deferred income taxes		(21,211	)		18,454
Other		(2,148	)		(3,407	)
Changes in assets and liabilities:
Accounts receivable		(23,998	)		18,361
Prepaid expenses and other current assets		(1,178	)		(666	)
Other long term assets		(317	)		(3,425	)
Accounts payable and accrued expenses		(100,442	)		(87,862	)
Income taxes payable		(39,909	)		(15,900	)
Payments of contingent consideration liabilities		(65	)		(299	)
Long-term professional liabilities		(5,863	)		1,016
Other liabilities		(1,397	)		2,282

Net cash provided from operating activities		21,604			115,813

Cash flows from investing activities:
Acquisition payments, net of cash acquired		(25,575	)		(113,746	)
Purchases of investments		(15,884	)		(15,324	)
Proceeds from maturities of investments		5,995			7,290
Purchases of property and equipment		(26,274	)		(21,909	)
Proceeds from sale of controlling interest in assets		22,764			—
Other		—			3,868

Net cash used in investing activities		(38,974	)		(139,821	)

Cash flows from financing activities:
Borrowings on credit agreement		821,500			821,000
Payments on credit agreement		(782,500	)		(754,000	)
Payments of contingent consideration liabilities		(367	)		(1,961	)
Payments on capital lease obligations		(636	)		(998	)
Proceeds from issuance of common stock		9,389			13,990
Repurchases of common stock		(52,160	)		(70,192	)
Contribution from noncontrolling interests		—			894

Net cash (used in) provided from financing activities		(4,774	)		8,733

Net decrease in cash and cash equivalents		(22,144	)		(15,275	)
Cash, cash equivalents and restricted cash at beginning of period		80,200			55,698

Cash, cash equivalents and restricted cash at end of period	$	58,056		$	40,423

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

MEDNAX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2018

(Unaudited)

1.	Basis of Presentation and New Accounting Pronouncements:

The accompanying unaudited Condensed Consolidated Financial Statements of the Company and the notes thereto presented in this Form 10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of MEDNAX, Inc. and its consolidated subsidiaries (collectively, “MDX”) together with the accounts of MDX’s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the “affiliated professional contractors”). Certain subsidiaries of MDX have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The terms “MEDNAX” and the “Company” refer collectively to MEDNAX, Inc., its subsidiaries and the affiliated professional contractors.

The Company is a party to a joint venture in which it owns a 37.5% economic interest. In January 2018, the Company entered into an additional joint venture in which it owns a 49.0% economic interest. The Company accounts for these joint ventures under the equity method of accounting because the Company exercises significant influence over, but does not control, these entities. See Note 5 for more information regarding the January 2018 joint venture.

The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Condensed Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company’s most recent Annual Report on Form 10-K (the “Form 10-K”).

Recently Adopted Accounting Pronouncements

In May 2014, the accounting guidance related to revenue recognition was amended to outline a single, comprehensive model for accounting for revenue from contracts with customers. The core principle of the new accounting guidance is to require an entity to recognize as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods or services as it transfers control to its customers. The guidance became effective for the Company on January 1, 2018 and was adopted on a full retrospective basis. The primary change for healthcare providers under the new guidance is the requirement to report the allowance for uncollectibles associated with patient responsibility amounts as a reduction in net revenue as opposed to bad debt expense, a component of operating expenses. The Company has historically included the allowance for uncollectibles associated with patient responsibility amounts with its allowance for contractual adjustments as a reduction in net revenue as such amounts are not material. Accordingly, the adoption of this guidance did not have an impact on our Consolidated Financial Statements, other than increased financial statement disclosures. The guidance requires increased disclosures, including qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. See Note 4 for more information.

New Accounting Pronouncements

In February 2016, the accounting guidance related to leases was issued that will require an entity to recognize leased assets and the rights and obligations created by those leased assets on the balance sheet and to disclose key information about the entity’s leasing arrangements. This guidance will become effective for the Company on January 1, 2019, with early adoption permitted. The Company expects that the adoption of this guidance will have a material impact on its Consolidated Balance Sheets and related disclosures, resulting from the recognition of significant right of use assets and related liabilities primarily related to its operating lease arrangements for space in hospitals and certain other facilities for its business and medical offices. The Company has completed the review of its existing lease portfolio and is accumulating all of the necessary information required to properly account for leases under the new guidance. The Company has selected a software application, inclusive of a lease administration module and an accounting module, and has begun the implementation process. The Company is in the process of designing workflows, business processes and internal controls surrounding the lease accounting process in order to meet the reporting and disclosure requirements. The Company’s implementation and continued evaluation of this new guidance and its impacts are expected to continue through the third quarter of 2018.

2.	Cash Equivalents and Investments:

As of June 30, 2018 and December 31, 2017, the Company’s cash equivalents consisted entirely of money market funds totaling $2.4 million and $9.2 million, respectively.

Investments consist of municipal debt securities, federal home loan securities and certificates of deposit. Investments with remaining maturities of less than one year are classified as short-term investments. Investments classified as long-term have maturities of one year to six years.

The Company intends and has the ability to hold its securities to maturity, and therefore carries such investments at amortized cost in accordance with the provisions of the accounting guidance for investments in debt and equity securities.

Investments held at June 30, 2018 and December 31, 2017 are summarized as follows (in thousands):


	June 30, 2018				December 31, 2017
	Short-Term		Long-Term		Short-Term		Long-Term
Municipal debt securities	$	8,432	$	48,613	$	8,312	$	46,195
Federal home loan securities		—		36,393		1,000		30,322
Certificates of deposit		1,470		5,180		980		4,165

	$	9,902	$	90,186	$	10,292	$	80,682

Contractual maturities of long-term investments are summarized as follows (in thousands):


	June 30, 2018		December 31, 2017
Due after one year through five years	$	89,186	$	78,561
Due after five years through six years		1,000		2,121

	$	90,186	$	80,682

3.	Fair Value Measurements:

In accordance with the accounting guidance for fair value measurements and disclosures, the Company carries its money market funds included in cash and cash equivalents at fair value. In accordance with the three-tier fair value hierarchy under this guidance, the Company determined the fair value using quoted market prices, a Level 1 input as defined under the accounting guidance for fair value measurements. At June 30, 2018 and December 31, 2017, the Company’s money market funds had a carrying amount of $2.4 million and $9.2 million, respectively.

The Company also carries the cash surrender value of life insurance related to its deferred compensation arrangements at fair value. The investments underlying the life insurance contracts consist primarily of exchange-traded equity securities and mutual funds with quoted prices in active markets. In accordance with the three-tier fair value hierarchy, the Company determined the fair value using the cash surrender value of the life insurance, a Level 2 input as defined under the accounting guidance for fair value measurements. At June 30, 2018 and December 31, 2017, the Company’s cash surrender value of life insurance had a carrying amount of $15.7 million and $15.6 million, respectively.

In addition, the Company carries its contingent consideration liabilities related to acquisitions at fair value. In accordance with the three-tier fair value hierarchy, the Company determined the fair value of its contingent consideration liabilities using the income approach with assumed discount rates and payment probabilities. The income approach uses Level 3, or unobservable inputs as defined under the accounting guidance for fair value measurements. At June 30, 2018 and December 31, 2017, the Company’s contingent consideration liabilities had a fair value of $30.7 million and $30.5 million, respectively.

The carrying amounts of cash equivalents, short-term investments, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying values of long-term investments, line of credit and capital lease obligations approximate fair value. If the Company’s investments were measured at fair value, they would be categorized as Level 2 in the fair value hierarchy. If the Company’s line of credit was measured at fair value, it would be categorized as Level 2 in the fair value hierarchy. The estimated fair value of the Company’s 5.25% senior unsecured notes due 2023 was $735.0 million and $763.1 million, at June 30, 2018 and December 31, 2017, respectively, and was estimated using trading prices on such dates as Level 2 inputs to estimate fair value.

4.	Accounts Receivable and Net Revenue:

Accounts receivable, net consists of the following (in thousands):


	June 30, 2018			December 31, 2017
Gross accounts receivable	$	1,918,787		$	1,790,034
Allowance for contractual adjustments and uncollectibles		(1,390,790	)		(1,286,035	)

	$	527,997		$	503,999

Patient service revenue is recognized at the time services are provided by the Company’s affiliated physicians. The Company’s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company’s patient service revenue is reimbursed by government-sponsored healthcare programs and third-party insurance payors. Payments for services rendered to the Company’s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.

Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (“DSO”) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by government-sponsored healthcare programs and third-party insurance payors for such services.

Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the government-sponsored healthcare programs and third-party insurance payors within the various filing deadlines and typically occurs within 30 to 60 days of billing.

Some of the Company’s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital.

In addition, the Company generates revenue through its management services organization for services rendered under various coding and billing contracts. Contract terms are specific to each customer and may include a combination of a flat fee for coding of medical charts, a fixed fee per patient visit as well as a percentage of cash collections received by the providers. Revenue for flat and fixed fee arrangements is recognized in the month the coding occurs or the patient visit occurs. Revenue for percentage fees are recognized in the month that cash is collected for customers from payors.

The following table summarizes the Company’s net revenue by category (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Net patient service revenue	$	763,667	$	708,739	$	1,520,040	$	1,414,192
Hospital contract administrative fees		95,534		75,604		186,773		147,869
Management services and other		56,717		58,601		110,962		116,480

	$	915,918	$	842,944	$	1,817,775	$	1,678,541

The approximate percentage of net patient service revenue by type of payor was as follows:


	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Contracted managed care		70	%		71	%		70	%		71	%
Government		25			24			25			24
Other third-parties		4			4			4			4
Private-pay patients		1			1			1			1

		100	%		100	%		100	%		100	%

5.	Business Acquisitions, Joint Ventures and Goodwill:

During the six months ended June 30, 2018, the Company completed the acquisition of five physician group practices, including two radiology practices, one neonatology practice and two pediatric subspecialty practices. The acquisition-date fair value of the total consideration for the five acquisitions was $24.4 million. These acquisitions expanded the Company’s national network of physician practices. In connection with these acquisitions, the Company recorded goodwill of $15.5 million and other intangible assets consisting primarily of physician and hospital agreements of $8.9 million.

In addition, during the six months ended June 30, 2018, in connection with certain prior-period acquisitions, the Company paid $0.4 million for contingent consideration and $1.2 million for purchase consideration that had been held back pending satisfaction of certain conditions. All amounts except for the accretion recorded during 2018 were accrued as of December 31, 2017.

In connection with certain prior-period acquisitions, the Company also recorded a decrease in current assets of $1.2 million, a decrease in noncurrent assets of $1.5 million, an increase in current liabilities of $1.4 million and an increase in noncurrent liabilities of $1.2 million, with a corresponding net increase in goodwill of $5.3 million for measurement-period adjustments resulting from the finalization of acquisition accounting. The Company expects that $18.2 million of the goodwill recorded during the six months ended June 30, 2018 will be deductible for tax purposes.

In January 2018, the Company completed the sale of a controlling interest and the contribution of remaining assets to a joint venture related to the $46.0 million of assets held for sale at December 31, 2017. The Company accounts for its 49.0% economic interest in the joint venture as an equity method investment. The investment in this joint venture is included in other assets as presented in the Company’s Condensed Consolidated Balance Sheet.

The Company’s management services reporting unit has experienced lower operating results than previously forecasted primarily due to a slower rate of new customer bookings and an increase in customer termination activity. The Company continues to believe that the fair value of the reporting unit exceeds the carrying value, and accordingly the goodwill assigned to the management services reporting unit is not impaired Although the Company believes that the current assumptions and estimates used in its goodwill analysis are reasonable, supportable and appropriate, continued efforts to maintain or improve the performance of this business could be impacted by unfavorable or unforeseen changes which could impact the existing assumptions used in the impairment analysis. Various factors could reasonably be expected to unfavorably impact existing assumptions, primarily delays in new customer bookings and the related delay in revenue from new customers, increases in customer termination activity or increases in operating costs. Accordingly, there can be no assurance that the estimates and assumptions made for the purposes of the goodwill impairment analysis will prove to be accurate predictions of future performance. The carrying value of the Company’s management services reporting unit included goodwill of $321.6 million as of June 30, 2018. The Company will continue to closely monitor the performance of the management services reporting unit. If an impairment loss is required in a future period, it could have a material adverse effect on the Company’s business, financial condition, results of operations, cash flows and the trading price of the Company’s securities.

6.	Accounts Payable and Accrued Expenses:

Accounts payable and accrued expenses consist of the following (in thousands):


	June 30, 2018		December 31, 2017
Accounts payable	$	28,377	$	34,632
Accrued salaries and bonuses		144,911		225,429
Accrued payroll taxes and benefits		71,379		75,672
Accrued professional liabilities		35,253		37,912
Accrued contingent consideration		26,783		6,259
Accrued interest		5,077		4,495
Other accrued expenses		46,475		53,618

	$	358,255	$	438,017

The net decrease in accrued salaries and bonuses of $80.5 million from December 31, 2017 to June 30, 2018 is primarily due to the payment of performance-based incentive compensation, principally to the Company’s physicians, partially offset by performance-based incentive compensation accrued during the six months ended June 30, 2018. A majority of the Company’s payments for performance-based incentive compensation is paid annually during the first quarter.

7.	Common and Common Equivalent Shares:

Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock, deferred stock and stock options and is calculated using the treasury stock method.

The calculation of shares used in the basic and diluted net income per common share calculation for the three and six months ended June 30, 2018 and 2017 is as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Weighted average number of common shares outstanding		92,987		92,181		92,922		92,270
Weighted average number of dilutive common share equivalents		542		631		594		707

Weighted average number of common and common equivalent shares outstanding		93,529		92,812		93,516		92,977

Antidilutive securities not included in the diluted net income per common share calculation		392		8		197		5

8.	Stock Incentive Plans and Stock Purchase Plans:

The Company’s Amended and Restated 2008 Incentive Compensation Plan, as amended (the “Amended and Restated 2008 Incentive Plan”) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.

Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within 10 years from the date of grant and generally become exercisable on a pro rata basis over a three-year period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of three years upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the six months ended June 30, 2018, the Company granted 597,550 shares of restricted stock to its employees and non-employee directors under the Amended and Restated 2008 Incentive Plan. At June 30, 2018, the Company had 2.3 million shares available for future grants and awards under its Amended and Restated 2008 Incentive Plan.

Under the Company’s 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the “ESPP”), employees are permitted to purchase the Company’s common stock at 85% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company’s 2015 Non-Qualified Stock Purchase Plan (the “SPP”), certain eligible non-employee service providers are permitted to purchase the Company’s common stock at 90% of market value on January 1st, April 1st, July 1st and October 1st of each year.

Each of the ESPP and the SPP provide for the issuance of an aggregate of 2.6 million shares of the Company’s common stock less the number of shares of common stock purchased under the other plan. The Company recognizes stock-based compensation expense for the discount received by participating employees and non-employee service providers. During the six months ended June 30, 2018, 182,888 shares in aggregate were issued under the ESPP and SPP. At June 30, 2018, the Company had approximately 1.8 million shares in aggregate reserved for issuance under the ESPP and SPP.

During the three and six months ended June 30, 2018 and 2017, the Company recognized stock-based compensation expense of $10.5 million and $20.4 million, and $7.3 million and $14.8 million, respectively.

9.	Common Stock Repurchase Program:

In July 2013, the Company’s Board of Directors authorized the repurchase of shares of the Company’s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company’s equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company’s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company’s acquisition program. During the six months ended June 30, 2018, the Company repurchased 1.2 million shares of its common stock for $52.2 million, inclusive of 54,909 shares withheld to satisfy minimum statutory withholding obligations of $2.5 million in connection with the vesting of restricted stock and stock option exercises during the three months ended June 30, 2018. The shares repurchased by the Company during the second quarter of 2018 completed the repurchases under the program with respect to issuances of shares under the Company’s equity compensation programs during 2018. The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.

10.

Commitments and Contingencies:

The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company’s business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of June 30, 2018 in its Condensed Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time.

In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company’s affiliated physicians. The Company’s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company’s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company’s business, financial condition, results of operations, cash flows and the trading price of its securities.

Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company’s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company’s business, financial condition, results of operations, cash flows and the trading price of its securities.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion highlights the principal factors that have affected our financial condition and results of operations, as well as our liquidity and capital resources, for the periods described. This discussion should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our most recent Annual Report on Form 10-K. As used in this Quarterly Report, the terms “MEDNAX”, the “Company”, “we”, “us” and “our” refer to the parent company, MEDNAX, Inc., a Florida corporation, and the consolidated subsidiaries through which its businesses are actually conducted (collectively, “MDX”), together with MDX’s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (“affiliated professional contractors”). Certain subsidiaries of MDX have contracts with our affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The following discussion contains forward-looking statements. Please see the Company’s most recent Annual Report on Form 10-K, including Item 1A, Risk Factors, for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements. In addition, please see “Caution Concerning Forward-Looking Statements” below.

Overview

MEDNAX is a leading provider of physician services including newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in 39 states and Puerto Rico. Our affiliated physicians provide neonatal clinical care, primarily within hospital-based neonatal intensive care units, to babies born prematurely or with medical complications; anesthesia care to patients in connection with surgical and other procedures, as well as pain management; radiology services including diagnostic imaging and interventional radiology; and maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where our affiliated neonatal physicians practice. Our network also includes other pediatric subspecialists, including those who provide pediatric intensive care, pediatric cardiology care, hospital-based pediatric care, pediatric surgical care, pediatric ear, nose and throat, pediatric ophthalmology and pediatric urology services. MEDNAX also provides teleradiology services in all 50 states, the District of Columbia and Puerto Rico through a network of affiliated radiologists. In addition to our national physician network, we provide services nationwide to healthcare facilities and physicians, including ours, through complementary businesses, consisting of a management services organization focusing on full-service revenue cycle management and a consulting services company.

2018 Acquisition Activity

During the six months ended June 30, 2018, we completed the acquisitions of five physician group practices, including two radiology practices, one neonatology practice and two pediatric subspecialty practices. Based on our experience, we expect that we can improve the results of all of our acquired physician practices through improved managed care contracting, improved collections, identification of growth initiatives, as well as, operating and cost savings based upon the significant infrastructure that we have developed. In addition, we believe that we bring a unique value proposition to radiology physician groups, in that we can provide not only practice support, but also teleradiology capabilities that can enhance a physician group’s efficiency, provide subspecialty access and help them grow and remain competitive. We believe that radiology physician group practice physicians can complement the staffing needs for our teleradiology services business during certain times, such as nights and weekends, when the group practice physicians are not providing services at their practices. Our results of operations for the three and six months ended June 30, 2018 include the results for these five acquisitions from their respective dates of acquisition and therefore are not comparable in some respects to our results of operations for prior periods.

Corporate and Operational Initiatives

We have developed a number of strategic initiatives across our organization, in both our corporate functions and our operational infrastructure, with a goal of generating improvements in our general and administrative expenses and improvements through operational plans. In our corporate departments, we are focused on best-in-class cost and service excellence in order to improve processes, use our resources more efficiently and utilize our scale more effectively in all areas of our operations. Within our operational infrastructure, we have developed specific operational plans within each of our service lines and affiliated physician practices, with specific milestones and regular reporting, with the goal of generating long-term operational improvements and fostering even greater collaboration across our national medical group. We are targeting annualized financial improvements related to these initiatives of $40 million within general and administrative expenses and $80 million in operational improvements by the end of 2019, although there is no assurance that these improvements will be obtained. We believe these strategic initiatives, together with our continued plans to invest in focused, targeted and strategic organic and acquisitive growth, position us well to deliver a differentiated value proposition to our stakeholders while continuing to provide the highest quality care for our patients.

Common Stock Repurchase Program

In July 2013, our board of directors authorized the repurchase of shares of our common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under our equity compensation programs. The share repurchase program allows us to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of our common stock to offset the dilutive impact from the issuance of shares, if any, related to our acquisition program. During the six months ended June 30, 2018, we repurchased 1.2 million shares of our common stock for $52.2 million, inclusive of 54,909 shares withheld to satisfy minimum statutory withholding obligations of $2.5 million in connection with the vesting of restricted stock and exercises of stock options during the three months ended June 30, 2018. The shares repurchased by us during the second quarter of 2018 completed the repurchases under the repurchase program with respect to issuances of shares under our equity compensation programs during 2018.

We may utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.

General Economic Conditions and Other Factors

Our operations and performance depend significantly on economic conditions. During the three months ended June 30, 2018, the percentage of our patient service revenue being reimbursed under government-sponsored or funded healthcare programs (the “GHC Programs”), decreased as compared to the three months ended March 31, 2018 but increased as compared to the three months ended June 30, 2017. We could experience shifts toward GHC Programs and patient volumes could decline if economic conditions deteriorate or changes occur in population demographics within geographic locations in which we provide services. Payments received from GHC Programs are substantially less for equivalent services than payments received from commercial insurance payors. In addition, due to the rising costs of managed care premiums and patient responsibility amounts, we may experience lower net revenue resulting from increased bad debt due to patients’ inability to pay for certain services.

Healthcare Reform

The Patient Protection and Affordable Care Act (the “ACA”) contains a number of provisions that have affected us and, absent amendment or repeal, may continue to affect us over the next several years. These provisions include the establishment of health insurance exchanges to facilitate the purchase of qualified health plans, expanded Medicaid eligibility, subsidized insurance premiums and additional requirements and incentives for businesses to provide healthcare benefits. Other provisions have expanded the scope and reach of the Federal Civil False Claims Act (“FCA”) and other healthcare fraud and abuse laws. Moreover, we could be affected by potential changes to various aspects of the ACA, including subsidies, healthcare insurance marketplaces and Medicaid expansion.

The ACA remains subject to continuing legislative and administrative scrutiny, including efforts by the Republican-controlled Congress and the current Administration to amend or repeal a number of its provisions, as well as administrative actions delaying the effectiveness of key provisions. At the end of 2017, Congress repealed part of the ACA that required most individuals to purchase and maintain health insurance. If the ACA is repealed or further substantially modified, or if implementation of certain aspects of the ACA are diluted or delayed, such repeal, modification or delay may impact our business, financial condition, results of operations, cash flows and the trading price of our securities. We are unable to predict the impact of any repeal, modification or delay in the implementation of the ACA, including the repeal of the individual mandate, on us at this time.

In addition to the potential impacts to the ACA under the current Administration, there could be more sweeping changes to GHC Programs, such as a change in the structure of Medicaid by converting it into a block grant or instituting “per capita caps,” which could eliminate the guarantee that everyone who is eligible and applies for benefits would receive them and could potentially give states sweeping new authority to restrict eligibility, cut benefits and make it more difficult for people to enroll. Additionally, several states are considering and pursuing changes to their Medicaid programs, such as requiring recipients to engage in employment activities as a condition of eligibility for most adults, disenrolling recipients for failure to pay a premium, or adjusting premium amounts based on income.

As a result, we cannot predict with any assurance the ultimate effect of these laws and resulting changes to payments under GHC Programs, nor can we provide any assurance that they will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Further, any fiscal tightening impacting GHC Programs or changes to the structure of any GHC Programs could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities.

The Medicare Access and CHIP Reauthorization Act

Medicare pays for most physician services based upon a national service-specific fee schedule. In 2015, Congress enacted the Medicare Access and CHIP Reauthorization Act (“MACRA,”) which provides physicians 0.5% annual increases in reimbursement through 2019 as Medicare transitions to a payment system designed to reward physicians for the quality of care provided, rather than the quantity of procedures performed. MACRA will require physicians to choose to participate in one of two payment formulas, Merit-Based Incentive Payment System (“MIPS”) or Alternative Payment Models (“APMs”). Beginning in 2019, MIPS will allow eligible physicians to receive incentive payments based on the achievement of certain quality and cost metrics, among other measures, and be reduced for those who are underperforming against those same metrics and measures. As an alternative, physicians can choose to participate in an Advanced APM. Advanced APMs are exempt from the MIPS requirements, and physicians who are meaningful participants in APMs will receive bonus payments from Medicare pursuant to the law. We currently anticipate that our affiliated physicians will be eligible to receive bonus payments in 2019 through participation in the MIPS, although the amounts of such bonus payments are not expected to be material. We will continue to operationalize the provisions of MACRA and assess any further changes to the law or additional regulations enacted pursuant to the law.

We cannot predict the ultimate effect that these changes will have on us, nor can we provide any assurance that its provisions will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.

Medicaid Expansion

The ACA also allows states to expand their Medicaid programs through federal payments that fund most of the cost of increasing the Medicaid eligibility income limit from a state’s historic eligibility levels to 133% of the federal poverty level. To date, 32 states and the District of Columbia have expanded Medicaid eligibility to cover this additional low income patient population, and other states are considering expansion. All of the states in which we operate, however, already cover children in the first year of life and pregnant women if their household income is at or below 133% of the federal poverty level.

Medicare Sequestration

The Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012, required across-the-board cuts (“sequestrations”) to Medicare reimbursement rates. These annual reductions of 2%, on average, apply to mandatory and discretionary spending through 2025. Unless Congress takes action in the future to modify these sequestrations, Medicare reimbursements will be reduced by 2%, on average, annually. However, this reduction in Medicare reimbursement rates is not expected to have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our securities.

Non-GAAP Measures

In our analysis of our results of operations, we use certain non-GAAP financial measures. Earnings before interest, taxes and depreciation and amortization (“EBITDA”) consists of net income before interest expense, income tax provision and depreciation and amortization. Prior to the fourth quarter of 2017, the Company had included immaterial investment and other income and equity in earnings of unconsolidated affiliates as a component of the interest expense adjustment within EBITDA. Beginning with the fourth quarter of 2017, the Company began excluding these items such that the interest expense adjustment represents only interest expense and has conformed its historical EBITDA calculations with the current presentation. Adjusted earnings per common share (“Adjusted EPS”) consists of diluted net income per common and common equivalent share adjusted for amortization expense and stock-based compensation expense.

We believe these measures, in addition to income from operations, net income and diluted net income per common and common equivalent share, provide investors with useful supplemental information to compare and understand our underlying business trends and performance across reporting periods on a consistent basis. These measures should be considered a supplement to, and not a substitute for, financial performance measures determined in accordance with GAAP. In addition, since these non-GAAP measures are not determined in accordance with GAAP, they are susceptible to varying calculations and may not be comparable to other similarly titled measures of other companies.

For a reconciliation of each of EBITDA and Adjusted EPS to the most directly comparable GAAP measures for the three and six months ended June 30, 2018 and 2017, refer to the tables below (in thousands, except per share data). In addition, historical reconciliations of EBITDA and Adjusted EPS are available on our Internet website at www.mednax.com under the Investors tab. Our Internet website and the information contained therein or connected thereto are not incorporated into or deemed a part of this Form 10-Q.


	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Net income	$	79,412	$	63,698	$	142,840	$	118,389
Interest expense		21,604		18,535		41,539		36,287
Income tax provision		30,122		40,725		54,181		75,692
Depreciation and amortization		26,518		25,735		52,681		51,349

EBITDA	$	157,656	$	148,693	$	291,241	$	281,717


	Three Months Ended June 30,
	2018				2017
Weighted average diluted shares outstanding		93,529				92,812
Net income and diluted net income per share	$	79,412	$	0.85	$	63,698	$	0.69

Adjustments:
Amortization (net of tax of $4,822 and $6,800)		12,713		0.14		10,636		0.11
Stock-based compensation (net of tax of $2,894 and $2,826)		7,630		0.08		4,420		0.05

Adjusted net income and diluted EPS	$	99,755	$	1.07	$	78,754	$	0.85


	Six Months Ended June 30,
	2018				2017
Weighted average diluted shares outstanding		93,516				92,977
Net income and diluted net income per share	$	142,840	$	1.53	$	118,389	$	1.27

Adjustments:
Amortization (net of tax of $9,586 and $13,644)		25,273		0.27		21,340		0.23
Stock-based compensation (net of tax of $5,609 and $5,764)		14,790		0.16		9,017		0.10

Adjusted net income and diluted EPS	$	182,903	$	1.96	$	148,746	$	1.60

Results of Operations

Three Months Ended June 30, 2018 as Compared to Three Months Ended June 30, 2017

Our net revenue increased $73.0 million, or 8.7%, to $915.9 million for the three months ended June 30, 2018, as compared to $842.9 million for the same period in 2017. Of this $73.0 million increase, $46.7 million, or 5.5%, was attributable to revenue generated from acquisitions completed after March 31, 2017 and 26.3 million, or 3.2%, was attributable to an increase in same-unit net revenue. Same units are those units at which we provided services for the entire current period and the entire comparable period. The increase in same-unit net revenue was comprised of an increase of $15.5 million, or 1.9%, related to patient service volumes and a net increase of $10.8 million, or 1.3%, from net reimbursement-related factors. The increase in revenue of $15.5 million from patient service volumes was related to growth across all of our services. The net increase in revenue of $10.8 million related to net reimbursement-related factors was primarily due to modest improvements in managed care contracting and an increase in the administrative fees received from our hospital partners, partially offset by a decrease in revenue caused by an increase in the percentage of our patients enrolled in GHC Programs.

Practice salaries and benefits increased $59.6 million, or 10.6%, to $621.0 million for the three months ended June 30, 2018, as compared to $561.4 million for the same period in 2017. This $59.6 million increase was primarily attributable to increased costs associated with physicians and other staff to support organic-growth initiatives, acquisition-related growth and growth at our existing units, of which $50.2 million was related to salaries and $9.4 million was related to benefits and incentive compensation. We anticipate that we will continue to experience a higher rate of growth in clinician compensation expense at our existing units over historic averages, which could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our securities. We anticipate that practice salaries and benefits expense for the third and fourth quarters of 2018 will continue to include salaries and benefit costs for certain physicians who will remain employed through December 31, 2018 despite the non-renewal of an anesthesia services contract by one of our hospital partners effective July 1, 2018, under which they had previously provided services.

Practice supplies and other operating expenses increased $0.9 million, or 3.1%, to $31.8 million for the three months ended June 30, 2018, as compared to $30.9 million for the same period in 2017. The increase was primarily attributable to practice supply, rent and other costs related to our acquisitions, partially offset by decreases at our existing units.

General and administrative expenses include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the day-to-day operations of our physician practices and services, as well as those attributable to our non-physician service businesses. General and administrative expenses increased $4.9 million, or 4.8%, to $107.9 million for the three months ended June 30, 2018, as compared to $103.0 million for the same period in 2017. The increase of $4.9 million is attributable to the overall growth of the Company. Included within general and administrative expenses was an increase of $3.2 million of stock-based compensation expense primarily resulting from the change in timing of our annual equity grants from June to March in order to align the timing with other compensation related activities and a decrease of approximately $6.0 million in cost improvement as part of our corporate initiative. General and administrative expenses as a percentage of net revenue was 11.8% for the three months ended June 30, 2018, as compared to 12.2% for the same period in 2017.

Depreciation and amortization expense increased $0.8 million, or 3.0%, to $26.5 million for the three months ended June 30, 2018, as compared to $25.7 million for the same period in 2017. The increase was primarily attributable to the amortization of intangible assets related to acquisitions.

Income from operations increased $6.8 million, or 5.6%, to $128.7 million for the three months ended June 30, 2018, as compared to $121.9 million for the same period in 2017. Our operating margin was 14.1% for the three months ended June 30, 2018, as compared to 14.5% for the same period in 2017. The decrease of 41 basis points was primarily due to higher operating expense growth as compared to revenue growth.

Net non-operating expenses were $19.1 million for the three months ended June 30, 2018, as compared to $17.5 million for the same period in 2017. The net increase in non-operating expenses was primarily related to an increase in interest expense due to higher average interest rates on higher outstanding borrowings under our credit agreement (the “Credit Agreement”).

Our effective income tax rate was 27.5% and 39.0% for the three months ended June 30, 2018 and 2017, respectively. The decrease in our effective tax rate is primarily related to the reduction in the corporate tax rate enacted under the Tax Cuts and Jobs Act of 2017.

Net income was $79.4 million for the three months ended June 30, 2018, as compared to $63.7 million for the same period in 2017. EBITDA was $157.7 million for the three months ended June 30, 2018, as compared to $148.7 million for the same period in 2017.

Diluted net income per common and common equivalent share was $0.85 on weighted average shares outstanding of 93.5 million for the three months ended June 30, 2018, as compared to $0.69 on weighted average shares outstanding of 92.8 million for the same period in 2017. Adjusted EPS was $1.07 for the three months ended June 30, 2018, as compared to $0.85 for the same period in 2017.

Six Months Ended June 30, 2018 as Compared to Six Months Ended June 30, 2017

Our net revenue increased $139.2 million, or 8.3%, to $1.82 billion for the six months ended June 30, 2018, as compared to $1.68 billion for the same period in 2017. Of this $139.2 million increase, $84.6 million, or 4.9%, was attributable to revenue generated from acquisitions completed after December 31, 2016 and $54.6 million, or 3.4%, was attributable to an increase in same-unit net revenue. Same units are those units at which we provided services for the entire current period and the entire comparable period. The increase in same-unit net revenue was comprised of a net increase of $28.7 million, or 1.8%, related to patient service volumes and an increase of $25.9 million, or 1.6%, from net reimbursement-related factors. The increase in revenue of $28.7 million from patient service volumes was related to growth across almost all of our services. The net increase in revenue of $25.9 million related to net reimbursement-related factors was primarily due to modest improvements in managed care contracting and an increase in the administrative fees received from our hospital partners, partially offset by a decrease in revenue caused by an increase in the percentage of our patients enrolled in GHC Programs.

Practice salaries and benefits increased $119.0 million, or 10.5%, to $1.25 billion for the six months ended June 30, 2018, as compared to $1.13 billion for the same period in 2017. This $119.0 million increase was primarily attributable to increased costs associated with physicians and other staff primarily to support organic-growth initiatives, acquisition-related growth and growth at our existing units, of which $96.9 million was related to salaries and $22.1 million was related to benefits and incentive compensation. We anticipate that we will continue to experience a higher rate of growth in compensation expense at our existing units over historic averages, which could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our securities. We anticipate that practice salaries and benefits expense for the third and fourth quarters of 2018 will continue to include salaries and benefit costs for certain physicians who will remain employed through December 31, 2018 despite the non-renewal of an anesthesia services contract with one of our hospital partners effective July 1, 2018, under which they had previously provided services.

Practice supplies and other operating expenses increased $3.8 million, or 6.5%, to $62.5 million for the six months ended June 30, 2018, as compared to $58.7 million for the same period in 2017. The increase was primarily attributable to practice supply, rent and other costs related to our acquisitions, partially offset by decrease at our existing units.

General and administrative expenses include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the day-to-day operations of our physician practices and services, as well as those attributable to our non-physician service businesses. General and administrative expenses increased $9.9 million, or 4.8%, to $216.7 million for the six months ended June 30, 2018, as compared to $206.8 million for the same period in 2017. The net increase of $9.9 million is attributable to the overall growth of the Company, including growth from acquisitions. Included within general and administrative expenses was an increase of $5.4 million of stock-based compensation expense primarily resulting from the change in timing of our annual equity grants from June to March in order to align the timing with other compensation related activities and a decrease of $12.0 million in cost improvement as part of our corporate initiative. General and administrative expenses as a percentage of net revenue was 11.9% for the six months ended June 30, 2018, as compared to 12.3% for the same period in 2017.

Depreciation and amortization expense increased $1.4 million, or 2.6%, to $52.7 million for the six months ended June 30, 2018, as compared to $51.3 million for the same period in 2017. The increase was primarily attributable to the amortization of intangible assets related to acquisitions.

Income from operations increased $5.2 million, or 2.3%, to $233.1 million for the six months ended June 30, 2018, as compared to $227.9 million for the same period in 2017. Our operating margin was 12.8% for the six months ended June 30, 2018, as compared to 13.6% for the same period in 2017. The decrease of 76 basis points was due to higher operating expense growth as compared to revenue growth.

Net non-operating expenses were $36.1 million for the six months ended June 30, 2018, as compared to $33.9 million for the same period in 2018. The net increase in non-operating expenses was primarily related to an increase in interest expense due to higher average interest rates on higher outstanding borrowings under our Credit Agreement.

Our effective income tax rate was 27.5% and 39.0% for the six months ended June 30, 2018 and 2017, respectively. The decrease in our effective tax rate is primarily related to the reduction in the corporate tax rate enacted under the Tax Cuts and Jobs Act of 2017.

Net income was $142.8 million for the six months ended June 30, 2018, as compared to $118.4 million for the same period in 2017. EBITDA was $291.2 million for the six months ended June 30, 2018, as compared to $281.7 million for the same period in 2017.

Diluted net income per common and common equivalent share was $1.53 on weighted average shares outstanding of 93.5 million for the six months ended June 30, 2018, as compared to $1.27 on weighted average shares outstanding of 93.0 million for the same period in 2017. Adjusted EPS was $1.96 for the six months ended June 30, 2018, as compared to $1.60 for the same period in 2017.

Liquidity and Capital Resources

As of June 30, 2018, we had $38.1 million of cash and cash equivalents on hand as compared to $60.2 million at December 31, 2017. Additionally, we had working capital of $213.7 million at June 30, 2018, an increase of $117.9 million from working capital of $95.8 million at December 31, 2017. This net increase in working capital is primarily due to year-to-date earnings and net borrowings on our Credit Agreement, partially offset by the use of funds for repurchases of our common stock and acquisitions.

Cash Flows

Cash provided by (used in) operating, investing and financing activities is summarized as follows (in thousands):


	Six Months Ended June 30,
	2018			2017
Operating activities	$	21,604		$	115,813
Investing activities		(38,974	)		(139,821	)
Financing activities		(4,774	)		8,733

Operating Activities

During the six months ended June 30, 2018, our net cash provided from operating activities was $21.6 million, compared to $115.8 million for the same period in 2017. The net decrease in cash provided of $94.2 million was primarily due to increases in accounts receivable, a decrease in cash flow from income taxes resulting from tax payments made in the first quarter of 2018 for 2017 taxes that were deferred by the Internal Revenue Service for companies impacted by the 2017 hurricanes, partially offset by an increase in cash flow related to higher earnings.

During the six months ended June 30, 2018, cash flow from accounts receivable decreased by $24.0 million, as compared to an increase of $18.4 million for the same period in 2017. The decrease in cash flow from accounts receivable for the six months ended June 30, 2018 was primarily due to increased ending accounts receivable balances at existing units resulting from higher same-unit revenue.

Days sales outstanding (“DSO”) is one of the key factors that we use to evaluate the condition of our accounts receivable and the related allowances for contractual adjustments and uncollectibles. DSO reflects the timeliness of cash collections on billed revenue and the level of reserves on outstanding accounts receivable. Our DSO was 52.5 days at June 30, 2018 as compared to 50.9 days at December 31, 2017. The increase in our DSO primarily related to the increases in our accounts receivable balances at existing units.

Investing Activities

During the six months ended June 30, 2018, our net cash used in investing activities of $39.0 million primarily included capital expenditures of $26.3 million, acquisition payments of $25.6 million and net purchases of $9.9 million related to the purchase and maturity of investments, partially offset by proceeds of $22.8 million related to the sale of the controlling interest in a group of assets to a third party.

Financing Activities

During the six months ended June 30, 2018, our net cash used in financing activities of $4.8 million consisted primarily of the repurchase of $52.2 million of our common stock, partially offset by net borrowings on our Credit Agreement of $39.0 million and proceeds of $9.4 million from the exercise of employee stock options and the issuance of common stock under our 1996 Non-Qualified Employee Stock Purchase Plan, as amended, and 2015 Non-Qualified Stock Purchase Plan.

Liquidity

Our Credit Agreement provides for a $2.0 billion unsecured revolving credit facility and includes a $37.5 million sub-facility for the issuance of letters of credit. The Credit Agreement matures on October 31, 2022 and is guaranteed by substantially all of our subsidiaries and affiliated professional contractors. At our option, borrowings under the Credit Agreement will bear interest at (i) the alternate base rate (defined as the higher of (a) the prime rate, (b) the Federal Funds Rate plus 1/2 of 1.00% and (c) LIBOR for an interest period of one month plus 1.00%) plus an applicable margin rate ranging from 0.125% to 0.750% based on our consolidated leverage ratio or (ii) the LIBOR rate plus an applicable margin rate ranging from 1.125% to 1.750% based on our consolidated leverage ratio. The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee ranging from 0.150% to 0.300% of the unused lending commitments, based on our consolidated leverage ratio. The Credit Agreement contains customary covenants and restrictions, including covenants that require us to maintain a minimum interest charge ratio, not to exceed a specified consolidated leverage ratio and to comply with laws, and restrictions on the ability to pay dividends and make certain other distributions, as specified therein. Failure to comply with these covenants would constitute an event of default under the Credit Agreement, notwithstanding the ability of the company to meet its debt service obligations. The Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Credit Agreement.

At June 30, 2018, we had an outstanding principal balance of $1.1 billion on our Credit Agreement. We also had outstanding letters of credit of $0.2 million which reduced the amount available on our Credit Agreement to $850.3 million at June 30, 2018.

At June 30, 2018, the outstanding principal balance on our 5.25% senior unsecured notes due 2023 (the “2023 Senior Notes”) was $750.0 million. Our obligations under the 2023 Senior Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Credit Agreement. Interest on the 2023 Senior Notes accrues at the rate of 5.25% per annum, or $39.4 million, and is payable semi-annually in arrears on June 1 and December 1.

The indenture under which the 2023 Senior Notes are issued, among other things, limits our ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits our ability to merge or dispose of all or substantially all of our assets, in all cases, subject to a number of customary exceptions. Although we are not required to make mandatory redemption or sinking

fund payments with respect to the 2023 Senior Notes, upon the occurrence of a change in control of MEDNAX, we may be required to repurchase the 2023 Senior Notes at a purchase price equal to 101% of the aggregate principal amount of the 2023 Senior Notes repurchased plus accrued and unpaid interest.

At June 30, 2018, we believe we were in compliance, in all material respects, with the financial covenants and other restrictions applicable to us under our Credit Agreement and the 2023 Senior Notes. We believe we will be in compliance with these covenants throughout 2018.

We maintain professional liability insurance policies with third-party insurers, subject to self-insured retention, exclusions and other restrictions. We self-insure our liabilities to pay self-insured retention amounts under our professional liability insurance coverage through a wholly owned captive insurance subsidiary. We record liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Our total liability related to professional liability risks at June 30, 2018 was $242.9 million, of which $35.3 million is classified as a current liability within accounts payable and accrued expenses in the Condensed Consolidated Balance Sheet. In addition, there is a corresponding insurance receivable of $16.7 million recorded as a component of other assets for certain professional liability claims that are covered by insurance policies.

On August 2, 2018, we announced that our board of directors had authorized the repurchase of up to $500.0 million of shares of our common stock in addition to our existing share repurchase program. We intend to utilize various methods to effect the additional share repurchases, which are expected to commence in the near term. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.

We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Credit Agreement, will be sufficient to finance our working capital requirements, fund anticipated acquisitions and capital expenditures, fund our share repurchase programs and meet our contractual obligations for at least the next 12 months from the date of issuance of this Form 10-Q.

Caution Concerning Forward-Looking Statements

Certain information included or incorporated by reference in this Quarterly Report may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this Quarterly Report are made as of the date hereof, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K, including the section entitled “Risk Factors.”

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities. We intend to manage interest rate risk through the use of a combination of fixed rate and variable rate debt. We borrow under our Credit Agreement at various interest rate options based on the Alternate Base Rate or LIBOR rate depending on certain financial ratios. At June 30, 2018, the outstanding principal balance on our Credit Agreement was $1.1 billion. Considering the total outstanding balance of $1.1 billion, a 1.0% change in interest rates would result in an impact to income before income taxes of approximately $11 million per year.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to provide reasonable assurance that information required to be disclosed by the Company in reports it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of the end of the period covered by this report.

Changes in Internal Controls Over Financial Reporting

No changes in our internal control over financial reporting occurred during the quarter ended June 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings

We expect that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.

In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated physicians. Our contracts with hospitals generally require us to indemnify them and their affiliates for losses resulting from the negligence of our affiliated physicians and other clinicians. We may also become subject to other lawsuits that could involve large claims and significant defense costs. We believe, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.

Although we currently maintain liability insurance coverage intended to cover professional liability and certain other claims, we cannot assure that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us in the future where the outcomes of such claims are unfavorable to us. With respect to professional liability risk, we self-insure a significant portion of this risk through our wholly owned captive insurance subsidiary. Liabilities in excess of our insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.

On July 10, 2018, a securities class action lawsuit was filed against our company and certain of our officers and a director in the U.S. District Court for the Southern District of Florida (Case No. 0:18-cv-61572-WPD) that purports to state a claim for alleged violations of Sections 10(b) and 20(a) of the Exchange Act, and Rule 10b-5 thereunder, based on statements made by the defendants primarily concerning our anesthesiology business. The complaint seeks unspecified damages, interest, attorneys’ fees and other costs. We believe this lawsuit to be without merit and intend to vigorously defend against it. The lawsuit is in the very early stages and, at this time, no assessment can be made as to its likely outcome or whether the outcome will be material to us.

Item 1A.

Risk Factors

There have been no material changes to the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended June 30, 2018, the Company repurchased 1.2 million shares of its common stock for $52.2 million, inclusive of 54,909 shares withheld to satisfy minimum statutory withholding obligations of $2.5 million in connection with the vesting of restricted stock and stock option exercises during the three months ended June 30, 2018.


Period	Total Number of Shares Purchased		Average Price Paid per Share		Total Number of Shares Purchased as part of the Repurchase Program		Approximate Dollar Value of Shares that May Yet Be Purchased Under the Repurchase Programs
April 1 – April 30, 2018		—	$	—		—		(a	)
May 1 – May 31, 2018		—		—		—		(a	)
June 1 – June 30, 2018		1,154,909	$	45.16		1,100,000		(a	)

Total		1,154,909	$	45.16		1,100,000		(a	)

(a)

We have two active repurchase programs. Our July 2013 program allows us to repurchase shares of our common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under our equity compensation programs, which was estimated to be approximately 1.1 million shares for 2018. The shares repurchased by us during the second quarter of 2018 completed the repurchases under our repurchase program with respect to expected issuances of shares under our equity compensation programs during 2018. Our August 2018 repurchase program allows us to repurchase up to an additional $500.0 million of shares of our common stock.

The amount and timing of any future repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.

Item 5.

Other Information

On July 27, 2018, Ms. Vivian Lopez-Blanco informed the Company of her intent to retire as Chief Financial Officer and Treasurer of the Company. The Company intends to conduct a formal search to identify a successor to Ms. Lopez-Blanco. Ms. Lopez-Blanco will remain in her current role with the Company throughout the search process until the appointment of her successor, and for a transitional period thereafter.

Item 6.

Exhibits


Exhibit No.		Description

31.1+		Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2+		Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32+		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS+		XBRL Instance Document.

101.SCH+		XBRL Taxonomy Extension Schema Document.

101.CAL+		XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF+		XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB+		XBRL Taxonomy Extension Label Linkbase Document.

101.PRE+		XBRL Taxonomy Extension Presentation Linkbase Document.

+	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	MEDNAX, INC.

Date: August 2, 2018	By:	/s/ Roger J. Medel, M.D.
		Roger J. Medel, M.D.
		Chief Executive Officer
		(Principal Executive Officer)

Date: August 2, 2018	By:	/s/ Vivian Lopez-Blanco
		Vivian Lopez-Blanco
		Chief Financial Officer and Treasurer
		(Principal Financial Officer)

Date: August 2, 2018	By:	/s/ John C. Pepia
		John C. Pepia
		Chief Accounting Officer
		(Principal Accounting Officer)

EX-31.1 2 d558671dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION

I, Roger J. Medel, M.D., certify that:

I have reviewed this quarterly report on Form 10-Q of MEDNAX, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 2, 2018


By:		/s/ Roger J. Medel, M.D.
		Roger J. Medel, M.D.
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 d558671dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION

I, Vivian Lopez-Blanco, certify that:

I have reviewed this quarterly report on Form 10-Q of MEDNAX, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 2, 2018


By:		/s/ Vivian Lopez-Blanco
		Vivian Lopez-Blanco
		Chief Financial Officer and Treasurer
		(Principal Financial Officer)

EX-32 4 d558671dex32.htm EX-32 EX-32

Exhibit 32

Certification Pursuant to 18 U.S.C Section 1350

(Adopted by Section 906 of the Sarbanes-Oxley Act of 2002)

In connection with the Quarterly Report of MEDNAX, Inc. on Form 10-Q for the quarter ended June 30, 2018 (the “Report”), each of the undersigned hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that (i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of MEDNAX, Inc.

A signed original of this written statement required by Section 906 has been provided to MEDNAX, Inc. and will be retained by MEDNAX, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

August 2, 2018


By:		/s/ Roger J. Medel, M.D.
		Roger J. Medel, M.D.
		Chief Executive Officer
		(Principal Executive Officer)

By:		/s/ Vivian Lopez-Blanco
		Vivian Lopez-Blanco
		Chief Financial Officer and Treasurer
		(Principal Financial Officer)

EX-101.INS 5 md-20180630.xml XBRL INSTANCE DOCUMENT

0.490

93466848

40423000

624930000

46000000

52098000

1390790000

527997000

1032573000

358255000

28377000

1918787000

144911000

5859638000

30700000

15700000

38056000

58056000

200000000

93374000

0.01

93374000

934000

126505000

0.490

614226000

4304740000

9902000

1000000

89186000

90186000

5077000

411213000

2672716000

5859638000

860000

35253000

1149500000

207687000

2400000

46475000

14223000

92634000

15752000

36199000

131922000

0.01

1000000

19000000

2153415000

1000000

3186922000

358255000 71379000 741612000 26783000

1200000

1400000

18200000

1500000

8900000

15500000

2400000

0.0525

735000000

1470000

5180000

36393000

8432000

48613000

2300000

2600000

1800000

0.375

321600000

55698000

627235000

92007000

1286035000

503999000

1017328000

438017000

34632000

1790034000

225429000

5867278000

30500000

15600000

60200000

80200000

200000000

93721000

0.01

93721000

937000

147797000

639928000

4283963000

10292000

2121000

78561000

80682000

4495000

531425000

2800824000

5867278000

1401000

37912000

1110500000

212274000

9200000

53618000

37160000

91934000

15584000

57905000

123536000

0.01

1000000

2048189000

20000000

3066454000

438017000 75672000 740923000 6259000

9200000

763100000

980000

4165000

1000000

30322000

8312000

46195000

14800000

5000

2740000

-15275000

18454000

51349000

1.27

1.28

206780000

194081000

1486000

75692000

1016000

666000

-87862000

-15900000

3425000

-18361000

36287000

2282000

707000

941000

-33860000

-139821000

8733000

115813000

3407000

1450600000

227941000

15324000

21909000

70192000

113746000

1961000

299000

-3868000

13990000

894000

7290000

821000000

754000000

118389000

998000

14781000

92977000

92270000

58668000 1133803000 1.00 0.24 0.01 0.04 0.71

1678541000

1414192000

116480000

147869000

<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="4%" valign="top" align="left">6.</td> <td align="left" valign="top"> Accounts Payable and Accrued Expenses: </td> </tr> </table> Accounts payable and accrued expenses consist of the following (in thousands):   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> June 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accounts payable </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">28,377</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,632</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued salaries and bonuses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">144,911</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">225,429</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued payroll taxes and benefits </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71,379</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75,672</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued professional liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35,253</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,912</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued contingent consideration </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">26,783</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,259</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued interest </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,077</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,495</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">46,475</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">53,618</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">358,255</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">438,017</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The net decrease in accrued salaries and bonuses of $80.5 million from December 31, 2017 to June 30, 2018 is primarily due to the payment of performance-based incentive compensation, principally to the Company’s physicians, partially offset by performance-based incentive compensation accrued during the six months ended June 30, 2018. A majority of the Company’s payments for performance-based incentive compensation is paid annually during the first quarter. </div>

20400000

197000

false

2212000

24400000

-22144000

--12-31

-21211000

52681000

Q2 2018 10-Q

<div> The following table summarizes the Company’s net revenue by category (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net patient service revenue </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">763,667</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">708,739</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,520,040</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,414,192</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Hospital contract administrative fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">95,534</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75,604</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">186,773</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">147,869</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Management services and other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,717</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,601</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">110,962</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">116,480</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">915,918</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">842,944</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,817,775</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,678,541</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="4%" valign="top" align="left">7.</td> <td align="left" valign="top"> Common and Common Equivalent Shares: </td> </tr> </table> Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock, deferred stock and stock options and is calculated using the treasury stock method. The calculation of shares used in the basic and diluted net income per common share calculation for the three and six months ended June 30, 2018 and 2017 is as follows (in thousands):   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Weighted average number of common shares outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,987</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,181</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,922</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,270</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Weighted average number of dilutive common share equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">542</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">631</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">594</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">707</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Weighted average number of common and common equivalent shares outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">93,529</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,812</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">93,516</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,977</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Antidilutive securities not included in the diluted net income per common share calculation </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">392</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">197</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

1.53

0000893949 MEDNAX, INC.

2018-06-30

1.54

Large Accelerated Filer

216684000

197021000

2782000

54181000

-5863000

1178000

<div> Investments held at June 30, 2018 and December 31, 2017 are summarized as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">June 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Short-Term</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Long-Term</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Short-Term</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Long-Term</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Municipal debt securities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,432</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">48,613</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,312</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">46,195</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Federal home loan securities </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">36,393</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">30,322</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,470</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,180</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">980</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,165</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,902</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">90,186</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,292</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">80,682</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-100442000

-39909000

317000

23998000

41539000

-1397000

594000

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">2.</td> <td valign="top" align="left"> Cash Equivalents and Investments: </td> </tr> </table> As of June 30, 2018 and December 31, 2017, the Company’s cash equivalents consisted entirely of money market funds totaling $2.4 million and $9.2 million, respectively. Investments consist of municipal debt securities, federal home loan securities and certificates of deposit. Investments with remaining maturities of less than one year are classified as short-term investments. Investments classified as long-term have maturities of one year to six years. The Company intends and has the ability to hold its securities to maturity, and therefore carries such investments at amortized cost in accordance with the provisions of the accounting guidance for investments in debt and equity securities. Investments held at June 30, 2018 and December 31, 2017 are summarized as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">June 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Short-Term</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Long-Term</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Short-Term</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Long-Term</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Municipal debt securities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,432</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">48,613</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,312</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">46,195</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Federal home loan securities </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">36,393</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">30,322</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,470</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,180</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">980</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,165</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,902</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">90,186</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,292</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">80,682</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Contractual maturities of long-term investments are summarized as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Due after one year through five years </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">89,186</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">78,561</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Due after five years through six years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,121</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">90,186</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">80,682</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

2666000

<div> Contractual maturities of long-term investments are summarized as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Due after one year through five years </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">89,186</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">78,561</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Due after five years through six years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,121</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">90,186</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">80,682</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> New Accounting Pronouncements In February 2016, the accounting guidance related to leases was issued that will require an entity to recognize leased assets and the rights and obligations created by those leased assets on the balance sheet and to disclose key information about the entity’s leasing arrangements. This guidance will become effective for the Company on January 1, 2019, with early adoption permitted. The Company expects that the adoption of this guidance will have a material impact on its Consolidated Balance Sheets and related disclosures, resulting from the recognition of significant right of use assets and related liabilities primarily related to its operating lease arrangements for space in hospitals and certain other facilities for its business and medical offices. The Company has completed the review of its existing lease portfolio and is accumulating all of the necessary information required to properly account for leases under the new guidance. The Company has selected a software application, inclusive of a lease administration module and an accounting module, and has begun the implementation process. The Company is in the process of designing workflows, business processes and internal controls surrounding the lease accounting process in order to meet the reporting and disclosure requirements. The Company’s implementation and continued evaluation of this new guidance and its impacts are expected to continue through the third quarter of 2018. </div>

-36091000

-38974000

-4774000

21604000

2148000

1584663000

233112000

400000

15884000

26274000

52160000

25575000

367000

65000

9389000

5995000

821500000

22764000

782500000

142840000

636000

<div> Accounts payable and accrued expenses consist of the following (in thousands):   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> June 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accounts payable </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">28,377</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,632</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued salaries and bonuses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">144,911</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">225,429</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued payroll taxes and benefits </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71,379</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75,672</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued professional liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35,253</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,912</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued contingent consideration </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">26,783</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,259</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued interest </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,077</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,495</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">46,475</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">53,618</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">358,255</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">438,017</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Accounts receivable, net consists of the following (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Gross accounts receivable </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,918,787</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,790,034</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Allowance for contractual adjustments and uncollectibles </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,390,790</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,286,035</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">527,997</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">503,999</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

20399000

<div> The approximate percentage of net patient service revenue by type of payor was as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Contracted managed care </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Government </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other third-parties </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Private-pay patients </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">100</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">100</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">100</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">100</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The calculation of shares used in the basic and diluted net income per common share calculation for the three and six months ended June 30, 2018 and 2017 is as follows (in thousands):   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Weighted average number of common shares outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,987</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,181</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,922</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,270</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Weighted average number of dilutive common share equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">542</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">631</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">594</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">707</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Weighted average number of common and common equivalent shares outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">93,529</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,812</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">93,516</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,977</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Antidilutive securities not included in the diluted net income per common share calculation </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">392</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">197</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

52200000

93516000

92922000

1200000 62488000 80500000 1252810000 5 2 2 1 <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">4.</td> <td valign="top" align="left"> Accounts Receivable and Net Revenue: </td> </tr> </table> Accounts receivable, net consists of the following (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Gross accounts receivable </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,918,787</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,790,034</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Allowance for contractual adjustments and uncollectibles </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,390,790</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,286,035</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">527,997</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">503,999</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Patient service revenue is recognized at the time services are provided by the Company’s affiliated physicians. The Company’s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company’s patient service revenue is reimbursed by government-sponsored healthcare programs and third-party insurance payors. Payments for services rendered to the Company’s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts. Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (“DSO”) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by government-sponsored healthcare programs and third-party insurance payors for such services. Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the government-sponsored healthcare programs and third-party insurance payors within the various filing deadlines and typically occurs within 30 to 60 days of billing. Some of the Company’s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital. In addition, the Company generates revenue through its management services organization for services rendered under various coding and billing contracts. Contract terms are specific to each customer and may include a combination of a flat fee for coding of medical charts, a fixed fee per patient visit as well as a percentage of cash collections received by the providers. Revenue for flat and fixed fee arrangements is recognized in the month the coding occurs or the patient visit occurs. Revenue for percentage fees are recognized in the month that cash is collected for customers from payors. The following table summarizes the Company’s net revenue by category (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Net patient service revenue </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">763,667</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">708,739</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,520,040</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,414,192</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Hospital contract administrative fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">95,534</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75,604</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">186,773</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">147,869</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Management services and other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">56,717</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,601</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">110,962</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">116,480</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">915,918</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">842,944</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,817,775</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,678,541</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   The approximate percentage of net patient service revenue by type of payor was as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Contracted managed care </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Government </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other third-parties </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Private-pay patients </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">100</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">100</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">100</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">100</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="4%" valign="top" align="left">9.</td> <td align="left" valign="top"> Common Stock Repurchase Program: </td> </tr> </table> In July 2013, the Company’s Board of Directors authorized the repurchase of shares of the Company’s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company’s equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company’s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company’s acquisition program. During the six months ended June 30, 2018, the Company repurchased 1.2 million shares of its common stock for $52.2 million, inclusive of 54,909 shares withheld to satisfy minimum statutory withholding obligations of $2.5 million in connection with the vesting of restricted stock and stock option exercises during the three months ended June 30, 2018. The shares repurchased by the Company during the second quarter of 2018 completed the repurchases under the program with respect to issuances of shares under the Company’s equity compensation programs during 2018. The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions. </div> <div> Recently Adopted Accounting Pronouncements In May 2014, the accounting guidance related to revenue recognition was amended to outline a single, comprehensive model for accounting for revenue from contracts with customers. The core principle of the new accounting guidance is to require an entity to recognize as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods or services as it transfers control to its customers. The guidance became effective for the Company on January 1, 2018 and was adopted on a full retrospective basis. The primary change for healthcare providers under the new guidance is the requirement to report the allowance for uncollectibles associated with patient responsibility amounts as a reduction in net revenue as opposed to bad debt expense, a component of operating expenses. The Company has historically included the allowance for uncollectibles associated with patient responsibility amounts with its allowance for contractual adjustments as a reduction in net revenue as such amounts are not material. Accordingly, the adoption of this guidance did not have an impact on our Consolidated Financial Statements, other than increased financial statement disclosures. The guidance requires increased disclosures, including qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. See Note 4 for more information. </div> <div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="4%" valign="top" align="left">5.</td> <td align="left" valign="top"> Business Acquisitions, Joint Ventures and Goodwill: </td> </tr> </table> During the six months ended June 30, 2018, the Company completed the acquisition of five physician group practices, including two radiology practices, one neonatology practice and two pediatric subspecialty practices. The acquisition-date fair value of the total consideration for the five acquisitions was $24.4 million. These acquisitions expanded the Company’s national network of physician practices. In connection with these acquisitions, the Company recorded goodwill of $15.5 million and other intangible assets consisting primarily of physician and hospital agreements of $8.9 million. In addition, during the six months ended June 30, 2018, in connection with certain prior-period acquisitions, the Company paid $0.4 million for contingent consideration and $1.2 million for purchase consideration that had been held back pending satisfaction of certain conditions. All amounts except for the accretion recorded during 2018 were accrued as of December 31, 2017. In connection with certain prior-period acquisitions, the Company also recorded a decrease in current assets of $1.2 million, a decrease in noncurrent assets of $1.5 million, an increase in current liabilities of $1.4 million and an increase in noncurrent liabilities of $1.2 million, with a corresponding net increase in goodwill of $5.3 million for measurement-period adjustments resulting from the finalization of acquisition accounting. The Company expects that $18.2 million of the goodwill recorded during the six months ended June 30, 2018 will be deductible for tax purposes. In January 2018, the Company completed the sale of a controlling interest and the contribution of remaining assets to a joint venture related to the $46.0 million of assets held for sale at December 31, 2017. The Company accounts for its 49.0% economic interest in the joint venture as an equity method investment. The investment in this joint venture is included in other assets as presented in the Company’s Condensed Consolidated Balance Sheet. The Company’s management services reporting unit has experienced lower operating results than previously forecasted primarily due to a slower rate of new customer bookings and an increase in customer termination activity. The Company continues to believe that the fair value of the reporting unit exceeds the carrying value, and accordingly the goodwill assigned to the management services reporting unit is not impaired Although the Company believes that the current assumptions and estimates used in its goodwill analysis are reasonable, supportable and appropriate, continued efforts to maintain or improve the performance of this business could be impacted by unfavorable or unforeseen changes which could impact the existing assumptions used in the impairment analysis. Various factors could reasonably be expected to unfavorably impact existing assumptions, primarily delays in new customer bookings and the related delay in revenue from new customers, increases in customer termination activity or increases in operating costs. Accordingly, there can be no assurance that the estimates and assumptions made for the purposes of the goodwill impairment analysis will prove to be accurate predictions of future performance. The carrying value of the Company’s management services reporting unit included goodwill of $321.6 million as of June 30, 2018. The Company will continue to closely monitor the performance of the management services reporting unit. If an impairment loss is required in a future period, it could have a material adverse effect on the Company’s business, financial condition, results of operations, cash flows and the trading price of the Company’s securities. </div> 1.00

P10Y

2500000

54909

P3Y

5300000

0.25 0.01 0.04 0.70

597550

0.90

0.85

182888

1817775000

1520040000

110962000

186773000

P6Y P1Y P1Y

1200000

7300000

8000

25735000

0.69

103015000

104423000

689000

40725000

18535000

631000

365000

-17481000

721040000

121904000

63698000

92812000

92181000

30872000 561418000 1.00 0.24 0.01 0.04 0.71

842944000

708739000

58601000

75604000

10500000

392000

26518000

0.85

107908000

109534000

1257000

30122000

21604000

542000

1202000

-19145000

787239000

128679000

79412000

93529000

92987000

31833000 620980000 1.00 0.25 0.01 0.04 0.70

915918000

763667000

56717000

95534000

0000893949 md:HospitalsContractsMember 2018-04-01 2018-06-30 0000893949 us-gaap:ManagementServiceMember 2018-04-01 2018-06-30 0000893949 us-gaap:HealthCarePatientServiceMember 2018-04-01 2018-06-30 0000893949 us-gaap:HealthCareMember 2018-04-01 2018-06-30 0000893949 md:ContractedManagedCareMember 2018-04-01 2018-06-30 0000893949 us-gaap:ThirdPartyPayorMember 2018-04-01 2018-06-30 0000893949 us-gaap:SelfPayMember 2018-04-01 2018-06-30 0000893949 us-gaap:GovernmentMember 2018-04-01 2018-06-30 0000893949 2018-04-01 2018-06-30 0000893949 md:HospitalsContractsMember 2017-04-01 2017-06-30 0000893949 us-gaap:ManagementServiceMember 2017-04-01 2017-06-30 0000893949 us-gaap:HealthCarePatientServiceMember 2017-04-01 2017-06-30 0000893949 us-gaap:HealthCareMember 2017-04-01 2017-06-30 0000893949 md:ContractedManagedCareMember 2017-04-01 2017-06-30 0000893949 us-gaap:ThirdPartyPayorMember 2017-04-01 2017-06-30 0000893949 us-gaap:SelfPayMember 2017-04-01 2017-06-30 0000893949 us-gaap:GovernmentMember 2017-04-01 2017-06-30 0000893949 2017-04-01 2017-06-30 0000893949 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0000893949 srt:MinimumMember 2018-01-01 2018-06-30 0000893949 srt:MaximumMember 2018-01-01 2018-06-30 0000893949 md:HospitalsContractsMember 2018-01-01 2018-06-30 0000893949 us-gaap:ManagementServiceMember 2018-01-01 2018-06-30 0000893949 us-gaap:HealthCarePatientServiceMember 2018-01-01 2018-06-30 0000893949 us-gaap:HealthCareMember 2018-01-01 2018-06-30 0000893949 md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember 2018-01-01 2018-06-30 0000893949 md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember 2018-01-01 2018-06-30 0000893949 md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember 2018-01-01 2018-06-30 0000893949 md:AmendedAndRestatedTwoThousandEightPlanMember 2018-01-01 2018-06-30 0000893949 md:ContractedManagedCareMember 2018-01-01 2018-06-30 0000893949 us-gaap:ThirdPartyPayorMember 2018-01-01 2018-06-30 0000893949 us-gaap:SelfPayMember 2018-01-01 2018-06-30 0000893949 us-gaap:GovernmentMember 2018-01-01 2018-06-30 0000893949 md:PriorPeriodAcquisitionsMember 2018-01-01 2018-06-30 0000893949 us-gaap:RestrictedStockMember 2018-01-01 2018-06-30 0000893949 srt:MaximumMemberus-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0000893949 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0000893949 2018-01-01 2018-06-30 0000893949 md:HospitalsContractsMember 2017-01-01 2017-06-30 0000893949 us-gaap:ManagementServiceMember 2017-01-01 2017-06-30 0000893949 us-gaap:HealthCarePatientServiceMember 2017-01-01 2017-06-30 0000893949 us-gaap:HealthCareMember 2017-01-01 2017-06-30 0000893949 md:ContractedManagedCareMember 2017-01-01 2017-06-30 0000893949 us-gaap:ThirdPartyPayorMember 2017-01-01 2017-06-30 0000893949 us-gaap:SelfPayMember 2017-01-01 2017-06-30 0000893949 us-gaap:GovernmentMember 2017-01-01 2017-06-30 0000893949 2017-01-01 2017-06-30 0000893949 us-gaap:USStatesAndPoliticalSubdivisionsMember 2017-12-31 0000893949 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2017-12-31 0000893949 us-gaap:CertificatesOfDepositMember 2017-12-31 0000893949 md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember 2017-12-31 0000893949 us-gaap:CashEquivalentsMember 2017-12-31 0000893949 2017-12-31 0000893949 2016-12-31 0000893949 md:ManagementServicesReportingUnitMember 2018-06-30 0000893949 md:UnnamedCorporateJointVentureMember 2018-06-30 0000893949 md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember 2018-06-30 0000893949 md:AmendedAndRestatedTwoThousandEightPlanMember 2018-06-30 0000893949 us-gaap:USStatesAndPoliticalSubdivisionsMember 2018-06-30 0000893949 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2018-06-30 0000893949 us-gaap:CertificatesOfDepositMember 2018-06-30 0000893949 md:FivePointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentyThreeMember 2018-06-30 0000893949 us-gaap:CashEquivalentsMember 2018-06-30 0000893949 md:PhysicianGroupMember 2018-06-30 0000893949 md:PriorPeriodAcquisitionsMember 2018-06-30 0000893949 2018-06-30 0000893949 2017-06-30 0000893949 2018-07-27 0000893949 md:UnnamedCorporateJointVentureMember 2018-01-31 pure shares iso4217:USD iso4217:USD shares md:Company

EX-101.SCH 6 md-20180630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Income (Unaudited) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Basis of Presentation and New Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Cash Equivalents and Investments link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Accounts Receivable and Net Revenue link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Business Acquisitions, Joint Ventures and Goodwill link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Accounts Payable and Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Common and Common Equivalent Shares link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Stock Incentive Plans and Stock Purchase Plans link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Common Stock Repurchase Program link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Basis of Presentation and New Accounting Pronouncements (Policies) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Cash Equivalents and Investments (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Accounts Receivable and Net Revenue (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Common and Common Equivalent Shares (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Cash Equivalents and Investments - Schedule of Contractual Maturities of Long-Term Investments (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Business Acquisitions, Joint Ventures and Goodwill - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Common Stock Repurchase Program - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 md-20180630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 md-20180630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 md-20180630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses, total Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts Payable and Accrued Expenses Accounts payable and accrued liabilities excluding accrued income taxes current. Accounts Payable and Accrued Liabilities Excluding Accrued Income Taxes Current Accounts payable and accrued expenses Accounts Payable, Current Accounts payable Accounts receivable and net revenue disclosure. Accounts Receivable And Net Revenue Disclosure [Text Block] Accounts Receivable and Net Revenue Accounts Receivable, Gross, Current Gross accounts receivable Accounts Receivable, Net, Current Accounts receivable, net Accounts receivable, net Accrued contingent consideration liability current. Accrued Contingent Consideration Liability Current Accrued contingent consideration Accrued Income Taxes, Current Income taxes payable Accrued payroll taxes and benefits current. Accrued Payroll Taxes And Benefits Current Accrued payroll taxes and benefits Accrued Salaries, Current Accrued salaries and bonuses Additional Paid in Capital, Common Stock Additional paid-in capital Adjustments Related to Tax Withholding for Share-based Compensation Amount withheld to satisfy minimum statutory tax withholding obligations Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash from operating activities: Allocated Share-based Compensation Expense Stock-based compensation expense Allowance for Doubtful Accounts Receivable, Current Allowance for contractual adjustments and uncollectibles Amended and restated two thousand eight plan. Amended and Restated Two Thousand Eight Plan [Member] Amended and Restated 2008 Plan [Member] Amendment Flag Amendment Flag Amortization of Debt Issuance Costs and Discounts Amortization of premiums, discounts and issuance costs Amortized Cost and Fair Value Debt Securities [Abstract] Amortized Cost and Fair Value Debt Securities [Abstract] Amortized Cost and Fair Value Debt Securities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities not included in the diluted net income per common share calculation Assets Total assets Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current assets: Assets Held-for-sale, Not Part of Disposal Group Assets held for sale Award Type [Axis] Award Type [Axis] Basis Of Presentation [Line Items] Basis of Presentation [Line Items] Basis Of Presentation [Line Items] Basis Of Presentation [Table] Basis Of Presentation [Table] Basis Of Presentation [Table] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition [Line Items] Business Acquisition [Line Items] Business Acquisition, Goodwill, Expected Tax Deductible Amount Goodwill deductible for tax purposes Business acquisitions joint ventures and goodwill. Business Acquisitions Joint Ventures and Goodwill [Text Block] Business Acquisitions, Joint Ventures and Goodwill Business Combination, Consideration Transferred Total business acquisition consideration Business Combination, Liabilities Arising from Contingencies, Amount Recognized Contingent consideration liabilities related to acquisitions Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets Decrease in current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Decrease in current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Other intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets Decrease in noncurrent assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities Increase in noncurrent liabilities Business Combinations [Abstract] Business Combinations [Abstract] Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in cash and cash equivalents Cash equivalents and investments. Cash Equivalents And Investments [Line Items] Cash Equivalents And Investments [Line Items] Cash Equivalents [Member] Cash Equivalents [Member] Cash Surrender Value of Life Insurance Carrying amount of cash surrender value of life insurance Certificates of Deposit [Member] Certificates of Deposit [Member] Commitments and Contingencies Commitments and contingencies Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock, Capital Shares Reserved for Future Issuance Common stock, reserved for issuance Common Stock [Line Items] Common Stock [Line Items] Common Stock [Line Items] Common Stock [Member] Common Stock [Member] Common Stock, Par or Stated Value Per Share Common stock, par value Entire disclosure of common stock repurchases. Common Stock Repurchases [Text Block] Common Stock Repurchase Program Common Stock, Shares Authorized Common stock, aggregate shares authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock [Table] Common Stock [Table] Common Stock [Table] Common Stock, Value, Issued Common stock; $.01 par value; 200,000 shares authorized; 93,374 and 93,721 shares issued and outstanding, respectively Contracted Managed Care [Member] Contracted Managed Care [Member] Contracted Managed Care [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Debt Instrument, Interest Rate, Stated Percentage Debt instrument interest rate Deferred Income Tax Expense (Benefit) Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent Deferred income taxes Depreciation, Depletion and Amortization Depreciation and amortization Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Table Text Block] Schedule of Net Revenue Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Incentive Plans and Stock Purchase Plans Document And Entity Information. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Net income: Earnings Per Share, Basic Earnings per share, Basic Earnings Per Share, Basic, Other Disclosures [Abstract] Weighted average common shares: Earnings Per Share, Diluted Earnings per share, Diluted Earnings Per Share [Text Block] Common and Common Equivalent Shares Employee Stock Option [Member] Stock Option [Member] Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Investment, Name [Domain] Investment, Name [Domain] Equity Method Investment, Ownership Percentage Equity method ownership percentage in joint venture Sale of equity method investments Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Measurements Fair Value Measurements Disclosure [Line Items] Fair Value Measurements Disclosure [Line Items] Fair Value Measurements Disclosure [Line Items] Fair Value Measurements Disclosure [Table] Fair Value Measurements Disclosure [Table] Fair Value Measurements Disclosure [Table] Finite-Lived Intangible Assets, Net Intangible assets, net Five point two five percent senior unsecured notes due two thousand twenty three. Five Point Two Five Percent Senior Unsecured Notes Due Two Thousand Twenty Three [Member] 5.25% Senior Unsecured Notes Due 2023 [Member] General and Administrative Expense General and administrative expenses Goodwill Goodwill Goodwill, Purchase Accounting Adjustments Net increase in goodwill resulting from finalization of tax acquisition accounting Government [Member] Government [Member] Health Care [Member] Health Care Health Care Organization, Receivable and Revenue Disclosures [Line Items] Health Care Organization, Receivable and Revenue Disclosures [Line Items] Health Care Organization Revenue and Expense [Abstract] Health Care Organization Revenue and Expense [Abstract] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Domain] Health Care Organization, Revenue Sources [Domain] Health Care, Patient Service [Member] Net patient service revenue Debt Securities, Held-to-maturity, Current Short-Term Short-term investments Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost Due after five years through [six] years Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost Due after one year through five years Debt Securities, Held-to-maturity, Noncurrent Investments Total Long-Term Debt Securities, Held-to-maturity [Table Text Block] Schedule of Investments Hospitals Contracts [Member] Hospitals Contracts [Member] Hospital contract administrative fees Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income before income taxes Income (Loss) from Equity Method Investments Equity in earnings of unconsolidated affiliates Income Statement [Abstract] Income Statement [Abstract] Income Tax Expense (Benefit) Income tax provision Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Income Taxes Payable Income taxes payable Increase decrease in accrued payroll taxes and benefits. Increase Decrease In Accrued Payroll Taxes And Benefits Net decrease in accrued salaries and bonuses Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve Long-term professional liabilities Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities: Increase (Decrease) in Other Noncurrent Assets Other long term assets Increase (Decrease) in Other Operating Liabilities Other liabilities Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Weighted average number of dilutive common share equivalents Interest Expense Interest expense Interest Payable, Current Accrued interest Investment Income, Net Investment and other income Investments Classified by Contractual Maturity Date [Table Text Block] Schedule of Contractual Maturities of Long-Term Investments Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Cash Equivalents and Investments Investments Schedule [Abstract] Investments Schedule [Abstract] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Liabilities Total liabilities Liabilities and Equity Total liabilities and shareholders' equity Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: Long-term Debt and Capital Lease Obligations, Current Current portion of long-term debt and capital lease obligations Long term debt and capital lease obligations excluding long term line of credit. Long Term Debt and Capital Lease Obligations Excluding Long Term Line of Credit Long-term debt and capital lease obligations, net Long term investments maturity period. Long Term Investments Maturity Period Long-term investments maturity period, in years Long-term Line of Credit, Noncurrent Line of credit Malpractice Loss Contingency, Accrual, Undiscounted, Current Accrued professional liabilities Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent Long-term professional liabilities Management Service [Member] Management services and other Management Services Reporting Unit [Member] Management Services Reporting Unit [Member] Management Services Reporting Unit [Member] Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Money Market Funds, at Carrying Value Cash equivalents Money market funds carrying amount Net Cash Provided by (Used in) Financing Activities Net cash (used in) provided from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Net Cash Provided by (Used in) Operating Activities Net cash provided from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member] Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member] 1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member] 1996 non-qualified employee stock purchase plan. Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member] 1996 Non-Qualified Employee Stock Purchase Plan [Member] Nonoperating Income (Expense) Total non-operating expenses Notes Payable, Fair Value Disclosure Estimated fair value of notes Number of neonatology practices acquired. Number Of Neonatology Practices Acquired Number of neonatology practices acquired Number of other pediatric subspecialty practices acquired. Number Of Pediatric Subspecialty Practices Acquired Number of other pediatric subspecialty practices acquired Number of physician group practices acquired. Number Of Physician Group Practices Acquired Number of physician group practices acquired Number of radiology practices acquired. Number Of Radiology Practices Acquired Number of radiology practices acquired Operating Expenses Total operating expenses Operating Expenses [Abstract] Operating expenses: Operating Income (Loss) Income from operations Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Basis of Presentation and New Accounting Pronouncements Other Accrued Liabilities, Current Other accrued expenses Other Assets, Current Other current assets Other Assets, Noncurrent Other assets Other Liabilities, Noncurrent Other liabilities Other Noncash Income (Expense) Other Payables and Accruals [Abstract] Payables and Accruals [Abstract] Payment for Contingent Consideration Liability, Financing Activities Payments of contingent consideration liabilities Payment for Contingent Consideration Liability, Operating Activities Payments of contingent consideration liabilities Payment For Purchase Consideration Related To Prior Period Acquisitions Payment For Purchase Consideration Related To Prior Period Acquisitions Purchase consideration payments related to prior-period acquisitions Payments for Previous Acquisition Contingent consideration payments related to prior-period acquisitions Payments for (Proceeds from) Other Investing Activities Other Payments for Repurchase of Common Stock Repurchases of common stock Payments to Acquire Businesses, Net of Cash Acquired Acquisition payments, net of cash acquired Payments to Acquire Investments Purchases of investments Payments to Acquire Other Property, Plant, and Equipment Purchases of property and equipment Percentage of net patient service revenue by type payor. Percentage Of Net Patient Service Revenue By Type Of Payor Percentage of net patient service revenue Physician group. Physician Group [Member] Physician Group [Member] Plan Name [Axis] Plan Name [Axis] EX-101.PRE 10 md-20180630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2018	Jul. 27, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Trading Symbol	MD
Entity Registrant Name	MEDNAX, INC.
Entity Central Index Key	0000893949
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		93,466,848

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 38,056	$ 60,200
Restricted cash	19,000
Short-term investments	9,902	10,292
Accounts receivable, net	527,997	503,999
Prepaid expenses	15,752	15,584
Other current assets	14,223	37,160
Total current assets	624,930	627,235
Restricted cash	1,000	20,000
Investments	90,186	80,682
Property and equipment, net	131,922	123,536
Goodwill	4,304,740	4,283,963
Intangible assets, net	614,226	639,928
Other assets	92,634	91,934
Total assets	5,859,638	5,867,278
Current liabilities:
Accounts payable and accrued expenses	358,255	438,017
Current portion of long-term debt and capital lease obligations	860	1,401
Income taxes payable	52,098	92,007
Total current liabilities	411,213	531,425
Line of credit	1,149,500	1,110,500
Long-term debt and capital lease obligations, net	741,612	740,923
Long-term professional liabilities	207,687	212,274
Deferred income taxes	126,505	147,797
Other liabilities	36,199	57,905
Total liabilities	2,672,716	2,800,824
Commitments and contingencies
Shareholders' equity:
Preferred stock; $.01 par value; 1,000 shares authorized; none issued
Common stock; $.01 par value; 200,000 shares authorized; 93,374 and 93,721 shares issued and outstanding, respectively	934	937
Additional paid-in capital	1,032,573	1,017,328
Retained earnings	2,153,415	2,048,189
Total shareholders' equity	3,186,922	3,066,454
Total liabilities and shareholders' equity	$ 5,859,638	$ 5,867,278

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	93,374,000	93,721,000
Common stock, shares outstanding	93,374,000	93,721,000

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Operating expenses:
Practice salaries and benefits	$ 620,980	$ 561,418	$ 1,252,810	$ 1,133,803
Practice supplies and other operating expenses	31,833	30,872	62,488	58,668
General and administrative expenses	107,908	103,015	216,684	206,780
Depreciation and amortization	26,518	25,735	52,681	51,349
Total operating expenses	787,239	721,040	1,584,663	1,450,600
Income from operations	128,679	121,904	233,112	227,941
Investment and other income	1,202	365	2,666	941
Interest expense	(21,604)	(18,535)	(41,539)	(36,287)
Equity in earnings of unconsolidated affiliates	1,257	689	2,782	1,486
Total non-operating expenses	(19,145)	(17,481)	(36,091)	(33,860)
Income before income taxes	109,534	104,423	197,021	194,081
Income tax provision	(30,122)	(40,725)	(54,181)	(75,692)
Net income	$ 79,412	$ 63,698	$ 142,840	$ 118,389
Net income:
Earnings per share, Basic	$ 0.85	$ 0.69	$ 1.54	$ 1.28
Earnings per share, Diluted	$ 0.85	$ 0.69	$ 1.53	$ 1.27
Weighted average common shares:
Basic	92,987	92,181	92,922	92,270
Diluted	93,529	92,812	93,516	92,977
Health Care
Net revenue	$ 915,918	$ 842,944	$ 1,817,775	$ 1,678,541

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net income	$ 142,840	$ 118,389
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	52,681	51,349
Amortization of premiums, discounts and issuance costs	2,212	2,740
Stock-based compensation expense	20,399	14,781
Deferred income taxes	(21,211)	18,454
Other	(2,148)	(3,407)
Changes in assets and liabilities:
Accounts receivable	(23,998)	18,361
Prepaid expenses and other current assets	(1,178)	(666)
Other long term assets	(317)	(3,425)
Accounts payable and accrued expenses	(100,442)	(87,862)
Income taxes payable	(39,909)	(15,900)
Payments of contingent consideration liabilities	(65)	(299)
Long-term professional liabilities	(5,863)	1,016
Other liabilities	(1,397)	2,282
Net cash provided from operating activities	21,604	115,813
Cash flows from investing activities:
Acquisition payments, net of cash acquired	(25,575)	(113,746)
Purchases of investments	(15,884)	(15,324)
Proceeds from maturities of investments	5,995	7,290
Purchases of property and equipment	(26,274)	(21,909)
Proceeds from sale of controlling interest in assets	22,764
Other		3,868
Net cash used in investing activities	(38,974)	(139,821)
Cash flows from financing activities:
Borrowings on credit agreement	821,500	821,000
Payments on credit agreement	(782,500)	(754,000)
Payments of contingent consideration liabilities	(367)	(1,961)
Payments on capital lease obligations	(636)	(998)
Proceeds from issuance of common stock	9,389	13,990
Repurchases of common stock	(52,160)	(70,192)
Contribution from noncontrolling interests		894
Net cash (used in) provided from financing activities	(4,774)	8,733
Net decrease in cash and cash equivalents	(22,144)	(15,275)
Cash, cash equivalents and restricted cash at beginning of period	80,200	55,698
Cash, cash equivalents and restricted cash at end of period	$ 58,056	$ 40,423

XML 16 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation and New Accounting Pronouncements

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Basis of Presentation and New Accounting Pronouncements

1.	Basis of Presentation and New Accounting Pronouncements:

Recently Adopted Accounting Pronouncements

New Accounting Pronouncements

XML 17 R7.htm IDEA: XBRL DOCUMENT

Cash Equivalents and Investments

6 Months Ended

Jun. 30, 2018

Investments, Debt and Equity Securities [Abstract]

Cash Equivalents and Investments

2.	Cash Equivalents and Investments:

As of June 30, 2018 and December 31, 2017, the Company’s cash equivalents consisted entirely of money market funds totaling $2.4 million and $9.2 million, respectively.

Investments held at June 30, 2018 and December 31, 2017 are summarized as follows (in thousands):


	June 30, 2018				December 31, 2017
	Short-Term		Long-Term		Short-Term		Long-Term
Municipal debt securities	$	8,432	$	48,613	$	8,312	$	46,195
Federal home loan securities		—		36,393		1,000		30,322
Certificates of deposit		1,470		5,180		980		4,165

	$	9,902	$	90,186	$	10,292	$	80,682

Contractual maturities of long-term investments are summarized as follows (in thousands):


	June 30, 2018		December 31, 2017
Due after one year through five years	$	89,186	$	78,561
Due after five years through six years		1,000		2,121

	$	90,186	$	80,682

XML 18 R8.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

3.	Fair Value Measurements:

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 19 R9.htm IDEA: XBRL DOCUMENT

Accounts Receivable and Net Revenue

6 Months Ended

Jun. 30, 2018

Text Block [Abstract]

Accounts Receivable and Net Revenue

4.	Accounts Receivable and Net Revenue:

Accounts receivable, net consists of the following (in thousands):


	June 30, 2018			December 31, 2017
Gross accounts receivable	$	1,918,787		$	1,790,034
Allowance for contractual adjustments and uncollectibles		(1,390,790	)		(1,286,035	)

	$	527,997		$	503,999

The following table summarizes the Company’s net revenue by category (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Net patient service revenue	$	763,667	$	708,739	$	1,520,040	$	1,414,192
Hospital contract administrative fees		95,534		75,604		186,773		147,869
Management services and other		56,717		58,601		110,962		116,480

	$	915,918	$	842,944	$	1,817,775	$	1,678,541

The approximate percentage of net patient service revenue by type of payor was as follows:


	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Contracted managed care		70	%		71	%		70	%		71	%
Government		25			24			25			24
Other third-parties		4			4			4			4
Private-pay patients		1			1			1			1

		100	%		100	%		100	%		100	%

XML 20 R10.htm IDEA: XBRL DOCUMENT

Business Acquisitions, Joint Ventures and Goodwill

6 Months Ended

Jun. 30, 2018

Text Block [Abstract]

Business Acquisitions, Joint Ventures and Goodwill

5.	Business Acquisitions, Joint Ventures and Goodwill:

XML 21 R11.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses

6 Months Ended

Jun. 30, 2018

Payables and Accruals [Abstract]

Accounts Payable and Accrued Expenses

6.	Accounts Payable and Accrued Expenses:

Accounts payable and accrued expenses consist of the following (in thousands):


	June 30, 2018		December 31, 2017
Accounts payable	$	28,377	$	34,632
Accrued salaries and bonuses		144,911		225,429
Accrued payroll taxes and benefits		71,379		75,672
Accrued professional liabilities		35,253		37,912
Accrued contingent consideration		26,783		6,259
Accrued interest		5,077		4,495
Other accrued expenses		46,475		53,618

	$	358,255	$	438,017

XML 22 R12.htm IDEA: XBRL DOCUMENT

Common and Common Equivalent Shares

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Common and Common Equivalent Shares

7.	Common and Common Equivalent Shares:

The calculation of shares used in the basic and diluted net income per common share calculation for the three and six months ended June 30, 2018 and 2017 is as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Weighted average number of common shares outstanding		92,987		92,181		92,922		92,270
Weighted average number of dilutive common share equivalents		542		631		594		707

Weighted average number of common and common equivalent shares outstanding		93,529		92,812		93,516		92,977

Antidilutive securities not included in the diluted net income per common share calculation		392		8		197		5

XML 23 R13.htm IDEA: XBRL DOCUMENT

Stock Incentive Plans and Stock Purchase Plans

6 Months Ended

Jun. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Incentive Plans and Stock Purchase Plans

8.	Stock Incentive Plans and Stock Purchase Plans:

XML 24 R14.htm IDEA: XBRL DOCUMENT

Common Stock Repurchase Program

6 Months Ended

Jun. 30, 2018

Text Block [Abstract]

Common Stock Repurchase Program

9.	Common Stock Repurchase Program:

XML 25 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10.

Commitments and Contingencies:

XML 26 R16.htm IDEA: XBRL DOCUMENT

Basis of Presentation and New Accounting Pronouncements (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In May 2014, the accounting guidance related to revenue recognition was amended to outline a single, comprehensive model for accounting for revenue from contracts with customers. The core principle of the new accounting guidance is to require an entity to recognize as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods or services as it transfers control to its customers. The guidance became effective for the Company on January 1, 2018 and was adopted on a full retrospective basis. The primary change for healthcare providers under the new guidance is the requirement to report the allowance for uncollectibles associated with patient responsibility amounts as a reduction in net revenue as opposed to bad debt expense, a component of operating expenses. The Company has historically included the allowance for uncollectibles associated with patient responsibility amounts with its allowance for contractual adjustments as a reduction in net revenue as such amounts are not material. Accordingly, the adoption of this guidance did not have an impact on our Consolidated Financial Statements, other than increased financial statement disclosures. The guidance requires increased disclosures, including qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. See Note 4 for more information.
New Accounting Pronouncements	New Accounting Pronouncements In February 2016, the accounting guidance related to leases was issued that will require an entity to recognize leased assets and the rights and obligations created by those leased assets on the balance sheet and to disclose key information about the entity’s leasing arrangements. This guidance will become effective for the Company on January 1, 2019, with early adoption permitted. The Company expects that the adoption of this guidance will have a material impact on its Consolidated Balance Sheets and related disclosures, resulting from the recognition of significant right of use assets and related liabilities primarily related to its operating lease arrangements for space in hospitals and certain other facilities for its business and medical offices. The Company has completed the review of its existing lease portfolio and is accumulating all of the necessary information required to properly account for leases under the new guidance. The Company has selected a software application, inclusive of a lease administration module and an accounting module, and has begun the implementation process. The Company is in the process of designing workflows, business processes and internal controls surrounding the lease accounting process in order to meet the reporting and disclosure requirements. The Company’s implementation and continued evaluation of this new guidance and its impacts are expected to continue through the third quarter of 2018.

XML 27 R17.htm IDEA: XBRL DOCUMENT

Cash Equivalents and Investments (Tables)

6 Months Ended

Jun. 30, 2018

Investments, Debt and Equity Securities [Abstract]

Schedule of Investments

Investments held at June 30, 2018 and December 31, 2017 are summarized as follows (in thousands):


	June 30, 2018				December 31, 2017
	Short-Term		Long-Term		Short-Term		Long-Term
Municipal debt securities	$	8,432	$	48,613	$	8,312	$	46,195
Federal home loan securities		—		36,393		1,000		30,322
Certificates of deposit		1,470		5,180		980		4,165

	$	9,902	$	90,186	$	10,292	$	80,682

Schedule of Contractual Maturities of Long-Term Investments

Contractual maturities of long-term investments are summarized as follows (in thousands):


	June 30, 2018		December 31, 2017
Due after one year through five years	$	89,186	$	78,561
Due after five years through six years		1,000		2,121

	$	90,186	$	80,682

XML 28 R18.htm IDEA: XBRL DOCUMENT

Accounts Receivable and Net Revenue (Tables)

6 Months Ended

Jun. 30, 2018

Text Block [Abstract]

Schedule of Accounts Receivable, Net

Accounts receivable, net consists of the following (in thousands):


	June 30, 2018			December 31, 2017
Gross accounts receivable	$	1,918,787		$	1,790,034
Allowance for contractual adjustments and uncollectibles		(1,390,790	)		(1,286,035	)

	$	527,997		$	503,999

Schedule of Net Revenue

The following table summarizes the Company’s net revenue by category (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Net patient service revenue	$	763,667	$	708,739	$	1,520,040	$	1,414,192
Hospital contract administrative fees		95,534		75,604		186,773		147,869
Management services and other		56,717		58,601		110,962		116,480

	$	915,918	$	842,944	$	1,817,775	$	1,678,541

Schedule of Percentage of Net Patient Service Revenue

The approximate percentage of net patient service revenue by type of payor was as follows:


	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Contracted managed care		70	%		71	%		70	%		71	%
Government		25			24			25			24
Other third-parties		4			4			4			4
Private-pay patients		1			1			1			1

		100	%		100	%		100	%		100	%

XML 29 R19.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2018

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following (in thousands):


	June 30, 2018		December 31, 2017
Accounts payable	$	28,377	$	34,632
Accrued salaries and bonuses		144,911		225,429
Accrued payroll taxes and benefits		71,379		75,672
Accrued professional liabilities		35,253		37,912
Accrued contingent consideration		26,783		6,259
Accrued interest		5,077		4,495
Other accrued expenses		46,475		53,618

	$	358,255	$	438,017

XML 30 R20.htm IDEA: XBRL DOCUMENT

Common and Common Equivalent Shares (Tables)

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share

The calculation of shares used in the basic and diluted net income per common share calculation for the three and six months ended June 30, 2018 and 2017 is as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Weighted average number of common shares outstanding		92,987		92,181		92,922		92,270
Weighted average number of dilutive common share equivalents		542		631		594		707

Weighted average number of common and common equivalent shares outstanding		93,529		92,812		93,516		92,977

Antidilutive securities not included in the diluted net income per common share calculation		392		8		197		5

XML 31 R21.htm IDEA: XBRL DOCUMENT

Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)	Jun. 30, 2018	Jan. 31, 2018
Basis Of Presentation [Line Items]
Equity method ownership percentage in joint venture	49.00%
Unnamed Corporate Joint Venture [Member]
Basis Of Presentation [Line Items]
Equity method ownership percentage in joint venture	37.50%	49.00%

XML 32 R22.htm IDEA: XBRL DOCUMENT

Cash Equivalents and Investments - Additional Information (Detail) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Cash Equivalents And Investments [Line Items]
Cash equivalents	$ 2.4	$ 9.2
Cash Equivalents [Member]
Cash Equivalents And Investments [Line Items]
Cash equivalents	$ 2.4	$ 9.2
Maximum [Member]
Cash Equivalents And Investments [Line Items]
Long-term investments maturity period, in years	6 years
Short-Term investments maturity period, in years	1 year
Minimum [Member]
Cash Equivalents And Investments [Line Items]
Long-term investments maturity period, in years	1 year

XML 33 R23.htm IDEA: XBRL DOCUMENT

Cash Equivalents and Investments - Schedule of Investments (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Schedule of Held-to-maturity Securities [Line Items]
Short-Term	$ 9,902	$ 10,292
Long-Term	90,186	80,682
Municipal Debt Securities [Member]
Schedule of Held-to-maturity Securities [Line Items]
Short-Term	8,432	8,312
Long-Term	48,613	46,195
Federal Home Loan Securities [Member]
Schedule of Held-to-maturity Securities [Line Items]
Short-Term		1,000
Long-Term	36,393	30,322
Certificates of Deposit [Member]
Schedule of Held-to-maturity Securities [Line Items]
Short-Term	1,470	980
Long-Term	$ 5,180	$ 4,165

XML 34 R24.htm IDEA: XBRL DOCUMENT

Cash Equivalents and Investments - Schedule of Contractual Maturities of Long-Term Investments (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Due after one year through five years	$ 89,186	$ 78,561
Due after five years through [six] years	1,000	2,121
Total	$ 90,186	$ 80,682

XML 35 R25.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	Jun. 30, 2018	Dec. 31, 2017
Fair Value Measurements Disclosure [Line Items]
Money market funds carrying amount	$ 2.4	$ 9.2
Carrying amount of cash surrender value of life insurance	15.7	15.6
Contingent consideration liabilities related to acquisitions	30.7	30.5
5.25% Senior Unsecured Notes Due 2023 [Member]
Fair Value Measurements Disclosure [Line Items]
Estimated fair value of notes	$ 735.0	$ 763.1
Debt instrument interest rate	5.25%

XML 36 R26.htm IDEA: XBRL DOCUMENT

Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Receivables [Abstract]
Gross accounts receivable	$ 1,918,787	$ 1,790,034
Allowance for contractual adjustments and uncollectibles	(1,390,790)	(1,286,035)
Accounts receivable, net	$ 527,997	$ 503,999

XML 37 R27.htm IDEA: XBRL DOCUMENT

Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net patient service revenue
Disaggregation of Revenue [Abstract]
Net revenue	$ 763,667	$ 708,739	$ 1,520,040	$ 1,414,192
Hospital contract administrative fees
Disaggregation of Revenue [Abstract]
Net revenue	95,534	75,604	186,773	147,869
Management services and other
Disaggregation of Revenue [Abstract]
Net revenue	56,717	58,601	110,962	116,480
Health Care
Disaggregation of Revenue [Abstract]
Net revenue	$ 915,918	$ 842,944	$ 1,817,775	$ 1,678,541

XML 38 R28.htm IDEA: XBRL DOCUMENT

Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Percentage of net patient service revenue	100.00%	100.00%	100.00%	100.00%
Contracted Managed Care [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Percentage of net patient service revenue	70.00%	71.00%	70.00%	71.00%
Government [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Percentage of net patient service revenue	25.00%	24.00%	25.00%	24.00%
Other Third-Parties [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Percentage of net patient service revenue	4.00%	4.00%	4.00%	4.00%
Private-Pay Patients [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Percentage of net patient service revenue	1.00%	1.00%	1.00%	1.00%

XML 39 R29.htm IDEA: XBRL DOCUMENT

Business Acquisitions, Joint Ventures and Goodwill - Additional Information (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2018 USD ($) Company	Dec. 31, 2017 USD ($)
Business Acquisition [Line Items]
Number of physician group practices acquired \| Company	5
Number of neonatology practices acquired \| Company	1
Number of other pediatric subspecialty practices acquired \| Company	2
Number of radiology practices acquired \| Company	2
Total business acquisition consideration	$ 24,400
Goodwill	4,304,740	$ 4,283,963
Contingent consideration payments related to prior-period acquisitions	400
Purchase consideration payments related to prior-period acquisitions	1,200
Assets held for sale	$ 46,000
Sale of equity method investments	49.00%
Management Services Reporting Unit [Member]
Business Acquisition [Line Items]
Goodwill	$ 321,600
Physician Group [Member]
Business Acquisition [Line Items]
Goodwill	15,500
Other intangible assets	8,900
Prior-Period Acquisitions [Member]
Business Acquisition [Line Items]
Decrease in current assets	1,200
Decrease in noncurrent assets	1,500
Decrease in current liabilities	1,400
Increase in noncurrent liabilities	1,200
Net increase in goodwill resulting from finalization of tax acquisition accounting	5,300
Goodwill deductible for tax purposes	$ 18,200

XML 40 R30.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Accounts payable	$ 28,377	$ 34,632
Accrued salaries and bonuses	144,911	225,429
Accrued payroll taxes and benefits	71,379	75,672
Accrued professional liabilities	35,253	37,912
Accrued contingent consideration	26,783	6,259
Accrued interest	5,077	4,495
Other accrued expenses	46,475	53,618
Accounts payable and accrued expenses, total	$ 358,255	$ 438,017

XML 41 R31.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses - Additional Information (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2018 USD ($)
Payables and Accruals [Abstract]
Net decrease in accrued salaries and bonuses	$ 80.5

XML 42 R32.htm IDEA: XBRL DOCUMENT

Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Earnings Per Share [Abstract]
Weighted average number of common shares outstanding	92,987	92,181	92,922	92,270
Weighted average number of dilutive common share equivalents	542	631	594	707
Weighted average number of common and common equivalent shares outstanding	93,529	92,812	93,516	92,977
Antidilutive securities not included in the diluted net income per common share calculation	392	8	197	5

XML 43 R33.htm IDEA: XBRL DOCUMENT

Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, aggregate shares authorized	200,000,000		200,000,000		200,000,000
Stock-based compensation expense	$ 10.5	$ 7.3	$ 20.4	$ 14.8
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			10 years
Stock Option [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of options, maximum years			10 years
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			3 years
1996 Non-Qualified Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of market value of common stock at which employees are permitted to purchase			85.00%
2015 Non-Qualified Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of market value of common stock at which employees are permitted to purchase			90.00%
Amended and Restated 2008 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants and awards under Stock Incentive Plans	2,300,000		2,300,000
Restricted stock granted			597,550
1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number Shares issued under Stock Purchase Plans			182,888
Common stock, aggregate shares authorized	2,600,000		2,600,000
Common stock, reserved for issuance	1,800,000		1,800,000

XML 44 R34.htm IDEA: XBRL DOCUMENT

Common Stock Repurchase Program - Additional Information (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2018 USD ($) shares
Common Stock [Line Items]
Common stock repurchased \| $	$ 52.2
Common Stock [Member]
Common Stock [Line Items]
Repurchased common stock, shares \| shares	1,200,000
Restricted Stock [Member]
Common Stock [Line Items]
Number of shares withheld to satisfy minimum statutory tax withholding obligations \| shares	54,909
Amount withheld to satisfy minimum statutory tax withholding obligations \| $	$ 2.5

EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 46 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 69 167 1 false 26 0 false 5 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.mednax.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.mednax.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.mednax.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Income (Unaudited) Sheet http://www.mednax.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements of Income (Unaudited) Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.mednax.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 107 - Disclosure - Basis of Presentation and New Accounting Pronouncements Sheet http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Basis of Presentation and New Accounting Pronouncements Notes 6 false false R7.htm 108 - Disclosure - Cash Equivalents and Investments Sheet http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Cash Equivalents and Investments Notes 7 false false R8.htm 109 - Disclosure - Fair Value Measurements Sheet http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements Notes 8 false false R9.htm 110 - Disclosure - Accounts Receivable and Net Revenue Sheet http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsAccountsReceivableAndNetRevenueDisclosureTextBlock Accounts Receivable and Net Revenue Notes 9 false false R10.htm 111 - Disclosure - Business Acquisitions, Joint Ventures and Goodwill Sheet http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsBusinessAcquisitionsJointVenturesAndGoodwillTextBlock Business Acquisitions, Joint Ventures and Goodwill Notes 10 false false R11.htm 112 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accounts Payable and Accrued Expenses Notes 11 false false R12.htm 113 - Disclosure - Common and Common Equivalent Shares Sheet http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Common and Common Equivalent Shares Notes 12 false false R13.htm 114 - Disclosure - Stock Incentive Plans and Stock Purchase Plans Sheet http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock Incentive Plans and Stock Purchase Plans Notes 13 false false R14.htm 115 - Disclosure - Common Stock Repurchase Program Sheet http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsCommonStockRepurchasesTextBlock Common Stock Repurchase Program Notes 14 false false R15.htm 116 - Disclosure - Commitments and Contingencies Sheet http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies Notes 15 false false R16.htm 117 - Disclosure - Basis of Presentation and New Accounting Pronouncements (Policies) Sheet http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlockPolicies Basis of Presentation and New Accounting Pronouncements (Policies) Policies http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock 16 false false R17.htm 118 - Disclosure - Cash Equivalents and Investments (Tables) Sheet http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables Cash Equivalents and Investments (Tables) Tables http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock 17 false false R18.htm 119 - Disclosure - Accounts Receivable and Net Revenue (Tables) Sheet http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsAccountsReceivableAndNetRevenueDisclosureTextBlockTables Accounts Receivable and Net Revenue (Tables) Tables http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsAccountsReceivableAndNetRevenueDisclosureTextBlock 18 false false R19.htm 120 - Disclosure - Accounts Payable and Accrued Expenses (Tables) Sheet http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accounts Payable and Accrued Expenses (Tables) Tables http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock 19 false false R20.htm 121 - Disclosure - Common and Common Equivalent Shares (Tables) Sheet http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Common and Common Equivalent Shares (Tables) Tables http://www.mednax.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 20 false false R21.htm 122 - Disclosure - Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail) Sheet http://www.mednax.com/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncementsAdditionalInformation Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail) Details 21 false false R22.htm 123 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail) Sheet http://www.mednax.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsAdditionalInformation Cash Equivalents and Investments - Additional Information (Detail) Details 22 false false R23.htm 124 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail) Sheet http://www.mednax.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsScheduleOfInvestments Cash Equivalents and Investments - Schedule of Investments (Detail) Details 23 false false R24.htm 125 - Disclosure - Cash Equivalents and Investments - Schedule of Contractual Maturities of Long-Term Investments (Detail) Sheet http://www.mednax.com/taxonomy/role/DisclosureCashEquivalentsAndInvestmentsScheduleOfContractualMaturitiesOfLongTermInvestments Cash Equivalents and Investments - Schedule of Contractual Maturities of Long-Term Investments (Detail) Details 24 false false R25.htm 126 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.mednax.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation Fair Value Measurements - Additional Information (Detail) Details 25 false false R26.htm 127 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail) Sheet http://www.mednax.com/taxonomy/role/DisclosureAccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNet Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail) Details 26 false false R27.htm 128 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail) Sheet http://www.mednax.com/taxonomy/role/DisclosureAccountsReceivableAndNetRevenueScheduleOfNetRevenue Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail) Details 27 false false R28.htm 129 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail) Sheet http://www.mednax.com/taxonomy/role/DisclosureAccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayor Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail) Details 28 false false R29.htm 130 - Disclosure - Business Acquisitions, Joint Ventures and Goodwill - Additional Information (Detail) Sheet http://www.mednax.com/taxonomy/role/DisclosureBusinessAcquisitionsJointVenturesAndGoodwillAdditionalInformation Business Acquisitions, Joint Ventures and Goodwill - Additional Information (Detail) Details 29 false false R30.htm 131 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail) Sheet http://www.mednax.com/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpenses Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail) Details 30 false false R31.htm 132 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail) Sheet http://www.mednax.com/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesAdditionalInformation Accounts Payable and Accrued Expenses - Additional Information (Detail) Details 31 false false R32.htm 133 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail) Sheet http://www.mednax.com/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShare Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail) Details 32 false false R33.htm 134 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail) Sheet http://www.mednax.com/taxonomy/role/DisclosureStockIncentivePlansAndStockPurchasePlansAdditionalInformation Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail) Details 33 false false R34.htm 135 - Disclosure - Common Stock Repurchase Program - Additional Information (Detail) Sheet http://www.mednax.com/taxonomy/role/DisclosureCommonStockRepurchaseProgramAdditionalInformation Common Stock Repurchase Program - Additional Information (Detail) Details 34 false false All Reports Book All Reports md-20180630.xml md-20180630.xsd md-20180630_cal.xml md-20180630_def.xml md-20180630_lab.xml md-20180630_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 51 0001193125-18-236651-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-18-236651-xbrl.zip M4$L#!!0 ( /J# DW7=W^PXF\ #ZH! / ;60M,C Q.# V,S N>&UL M[+UI<]M(LBCZO2/\'_!TNF_T1! R]D4][1M<>SS';>O8FN7<+PZ(*(J8!@$. M%EF:7_\RJPHKP46D2($R8A:+)*I0N2]5E?GG__NP\(5[$L5>&/QZ(5]*%P() MIJ'K!7>_7J2QZ,13S[L0XL0)7,!_C@E BC<)HN2) (HC!/DN75V[??OGV[=&?Q-+R"8%PJZJ51^NESF ;NE:"7OAI&Q$G@<<&%)5P) MBB1;H@3_56YD]4K6KS3[_Y6?#I>/D7/PB1;5D_X M\&%X*?1]7_B,#\?"9X(K)>XEG^OA-O(%0%X0_WI1 A&_O@RCN[>*)*EO/8Z/ M"_;D%?[J;WC>]X(_;IVX>!Z_J#S_3:5/R[9MOZ6_9H]Z<:@ILKEI,>R)?.[8 M:YH9'I7?_O/W#U^F<[)PQ#H$P!)WCK/,1\Z<^):.XS^\9>B7157.AKBD>!%= M44RFEW?A_5OXH>'QA5M9UH*X@?- F0:?E0Q5*JTE>5R2N'$Q])>&Z7$%;E)= M$(=;?\M^K#SJ-3YJL$>][-$X64;-0.(O#PWW"06AT4>],UB/.F M^+A<6Q:Y REWU[*Y_38*??*6/Y:/2A?-(]PD>HN<\A:>()$WS0> 2M@^)@S$ MVK@TB38L#7[-P8Z2=\I9:&P^?0O <,R]Y36)IO#9N2/"- P2\I!\Q@63T/]Z/98E M2Y-$490M61+_1Y(DZ^N7F]%7Z2L%1E9E^%.53-LVK0=5L77;T"Z$-/#8',LT M@N6X9.HM'!^(IUX('G"CYWZ55=V2+%GYJMFFI%@331P9_;ZHF98E#C15$?6A M)8\523<,0_\J2Y+R5;IX)UUJMO3GMT\&C.$#-.C5.$A@R#!<+,+@2Q).__@R M=R(2?TH3:K3!D#\9":9BPMH*H&,Z8QGL]Q\GJX"K_8G2!W2)HXFMBYHVF8C6 M1!J)_9%D#2>Z/K !N*=K6J&86G6G]_N!D&5^D,GGN/_$%GWC@\(B<$Z M)R"&(/+X0S]PJU^4GGPB,DQD[PHRN!G]^K?%.DS1%A;<7W' 0H%6<]>.8)/&0&HCDR0QQ M [&BC$:]@>*:.L#302,C$5[ CB0%&T,?&;V#0'@)8!. M,8:::*M#T/6V.A+M@380-4D=F*HZT T%20Y&659M,"HUHC\%K!72UQ[[2)+V M4E]'XJ--K5-_+1 U<%W7PQC/\:\=#]AEZ"R]Q/%+-J.%0*LVD%U2%=VLJO7M MP#33^MIY1!R!TN=B\\%S;CT?YGH1P3<5334'VEC4@?E%K:_98M^RQJ(QE*2! M9$P&IJT"%L"RP0A%UQM)OP-,&Y'17KA!WRF6:C9S?'7UVT0;5'_\$A3>4;L! MI+(M6Z:U3;K+<#1:,C!\3M1J;D9-KFFV+#>9L=KRFQR6%JHI&96S!7&.:C6X M)%4@!FGL!02(&"YNO8"FW4H"VX\\^/EN$H6+(8 )?Y)@BM\OD!& #\*[P/L/ M<4_IE&GF1!Z.#$E4=,"$ILE]T3;[JFB,QXJJ6./^6-48#T/05W/*G@?:U>#E M"^4/ET1_=_R4?)I]\&;D?1"G$ATY6P%9A1NT?"U(Z2=#)XH> 7=TAA9*AP*,84'0O@+[5F!> M+F@]""^[!JTR#5KU1MP\4]"*'I%',R Q8KLL9,^+D8?8NPH\_]>+!-3X_JQB MK22J5I(:_329A]&S*,$=LS*[.JL&^"N25(]+-P"P!=)#$E#;03W$+;
?BBP/9L(D'BR,?O'M,LX%"N_,P MWJ:^_4?21I++ZL4[0]84I>I7;(:C"O-O8>A^\WR_C="!0ZFIDD:54@F\;,E5 M0# A?!/^[B1I!+3_0J;X[\L$R#O"ATK)EI0*;%N@V WD$;E-^+<89,T2$DV M&6[F49C>S6](\+_$B9 5,B>3 >]R5-XSF$NI_US%#OC=)/038WON9L4 H1JF7+EK$O3GS>,[#WT77"+F+K401DUISK=N Z4&>!CE6D]X&MF5D^> 'Y-!M"X.2UD2<4 MD Q9UFQ=:N:+\O(/('^K3;2B81[.-&J;:7L"6,-2&)#'WYWH#Y),TL ]6?:] M8>=A).L#51F9XLA4(0J>#%71E@ EH[ZM6/9('P]'$[Z)JM6X80L459 _)7,2 MG=-VN8&G@S2SFN[8#$43Q"T_[F7B-JI2.^ZVNO*UD+5:A&6,@16CEIIK7'T5 MP.N(+!W/'3\L21"_A%^](X &W0_4JT%^X^(;"'@VF4> 4C5DVUZEX@XIQ^LH M7)(H>;SVG0!]&73AEIBO:VG.C9Y0DVVE3M/U4*RP+LO(GO6^B%S?%]D-K$VH M:/NVG]*0C-H,P29HC^!'/,_>+-X:>KN=3JW MJW-@X^+K\"4.Q /NV(D"\/UB<(_21>JC<([(S)NV,L+1T*&5=563]1J\VX#9 M1-Q6VU&[0<&L6WX5R//(YH#-4&7+J)O.=?F;A;O3V=?QP]1/\>S!.9WQEZW* M6=]G [6,.7P"9HM"WZ>/P)0#$H",O$BXLV-0!T;6E%73+J%E.QPYU+NEQ7(T MGDNR!Q2_J08XZYR2YTD2^"OV7+RF7CK%^=A>EM%H(MQ2:RRS(T!; M3^T6QU/?N_"\-_.@$&I1STN!C+,JYI8-W$L I,S13MA]455(4 MP]HSDS3NCXWQ>"CV^[*%F:2QV#%GE?$HR3;C_@^+VJ. M1PE.ZD/.E9^: M*1*5!!R=$Q?W8"@+%>/9MZ7+PTTX!.$M,[4-=I-)V#@K\& M=Y#@?;@I74)V&@:S2>@F@HD<$3>=)O30SP&G$$Z-0CHF5X^&_..9V..HAZ+2U_5!O*!-S8DFZ"*\8@,.B&V(?*:$.%*L_ M &]?TFUV(<# 4SA'1'T)(<]YWN_4:$*=H-=9M/G\WU%V[!!>73+,!_P79&<_ M>.71I&\HDB&.QNH8X%5E<:"#FZ]/ALI8LB8Z_,S@/7@3#P,"+"T5T9I2V0F> MSTY"6#+VT .\B!!#DE6L]V&:BKWA0&]CKE6:]">R/C3$B:[J(M;_$/NZ9HKR MN-\W5:TO:8,!0P5+,.N*7C[*O"MP5:1\#!.2Q=43QV-7L$9>//7#.-TWU;X! M$T]@C=WQ :QAJGH]/;0%M!,R!-1UOL3O%XW M$0=8%449C4?Z4)+EL6VCT5+9M5)SMR.A3SHU>VAJ\-2(P+-1LK4;(M;E#4^ M"TO6E5T\F0-PH="KAX9JJT=!QG.)!V!"W3,3LBLFJ-JT-/4(A\J?ER6.CPB\ M/& 9\F$L0?>,!A!LN."4X6X]]R1(6JZ M-A(U9:B(@XDQ%@UP $:6.99D8\2*4\F8BJRA;9][H3RARY[/ZFD"OB8I<"[! M/4#M-/3N9U;-3S9)SN^>=M8/C.5BW MK0"XEBQ+ZGY.;%_NRV,)XCG=GBB@E'5+[ ]-1;1EVY*'IBX/)#,'&P+'NH0T M!W2G+ -@R I6,SQB&0"65H>P7]>-6F6OEM2N,P_!P4X[60JK76=Q"7'TF6J;=<2!R=Q#L -:*KLJ94X3M>[;*3 (6UR\#P6XJV#JJC MUBX[B8E4FG..[:E==A)59-.+-%6-W>[B9:=065B\S+3EJH)N1?&RDX@_+5XF MKR2CVU*\["0XT*A[J-0JKK>P>-E!Z?>=BI=1Q\ZN9UE?KGC9*30 G@12#;EJ M&TY:O.P47(X=S5B!TA,7+SN);U\O7[SL)!N4QRQ> M=NRMG'V+ESUS<:^3!,=XOT32+-FJGC)ZH>)>IP#9+C:?3U[=ZR0DQ>I>DF%H M>M5?:%MUKY.86:MR(O0\JGN=(NK!ZEZZ82HEM+2ZNM=)'%!:W4NRE;R U=E4 M]SH%RVAX942OUX/;J[C74?(BIRT1\0RIDN>MAE#"PNFJ(;"=0$.5:WAXP6H( M!1Y.501 QB( H#OL'6L G.:V]POA0<,./X:^$R).<_]_%1''KH1 !4-]0L>T ME^*(DR!"0W=450[; S\!2QRU$H+,BSE:JMRFDA OA A4$H9L'Z8E>,4YB,L; MRR'PO.CN"(&/%"6'M(A1!KHVT(>VJ-'_&\FJ:(/O*8[[9M^2^I*EZJ.O&KWD MH-7OX^\&3PT'X'RYGI\FWCTI,,8<4N*RZR*+99K0&3[-LF@^RZ,]]7S16A3M MEG^1=$F=V 8XWNK8$C5#!]]*M251,HUQ7[.445\> '94O,!9P['N"M SWA0!_'I8 M(F$:84 T(NQ?^,RB(:#/' N28%FP\6Q&IL_!:,^/3#R@#AI+J;4O.BUFFL]. MYWD'+OL\'&\E&G&+RJJGG+8 4H=Z&<%** ?#WSZA16T"M\S9IP5=&*=15C6[!OIV:&H%56IJ:X0:[RFY M\5U 7K.)H^P-O(QML2X5LU0_I1F.S<""N?.F;0?5H*!:ZT&E4-3.Q@.K1XZ/ ME'<77N"!QG#0CAW?/=F?H6D[/\.LA;-;(*F?646)QY,SQ9W5%%#U:8,(Q 03K1X_N$+*CG!R,Q(PE#LY.DK409WC.0;0V&U$Z_'@T- MF_#=7,+HQ,[,KIACSK"Q 6]KP&G"P L;RUUA5FGZO79M8RI4Y*G621@- M?<=;T NL[ _W7RE#%I^2U_9JI0>!M0%D25YAA,/!W89!?I(F\U;X8)BV=(2H MG2@#V<%B;YLQM@MXVU"TR[99.U$$BEFT3,M8D;4](-P!2[7]0CY;.U&CTLBG M7OW\"6!MPP=EL/U+\I\2%[AI7K_;L2- N\I.49RFE2BPD1LLU5CQ8+:"TWQ= MJKHUEBI5:O^K:PG=B;N[(!7>MUX-8=A!F7,,>:;/XH[875=6JG8=?"T0-5KRI&L^OH_#>/Q;C,:1 MX8B>&H*PN+V:0*$)3]6V:E>B=P=K)W3D*>B6HP-+6UBFJNZ"BP:8=L)%KE!; MC@N:S)-U2]X)&PU0-5P_0&\)!K^@4M@1>+PBH]5,P%H(:H!FF."_MC/3@NE+ M39?JQ=56%K\&MB(GTTKH\":S8M8-5\/J:X?2F=6.;T+>QNG%\F6[JF]:(4^M M7=C>!,86@"F/K[UXTDX<*'AGTY;LS3C8#%DS6B9A])DL>6>[3[.]JOZ>TGKA M05Y)KF42MP.SA2>R:I0$RW+ 0-SOY%W.6HD&>KM=5DW-V,P1&^!JQ CF&+<< M<#T7/T=!%-FUZ/X@,/?%V-EX0[@/9C?JF/V@7*MQ0$=-"7'I9@=56F<32V@8 M2%F&M4[][ +9RD7.?$36>>0,]##>YU0ILU2O#,AZL+\X/LF. -(ZK+Y/IG2C]-.L]9X9YI"4#2RP(W#KL8,7 M2^*GWZ Y)0[ #6>)A;58J !1OT6XY*H#ZSNW'E8+=W&U.JQK@5BAZ\Q+6AM. MH?&394NMW0LM5KV!6KM@)X TR[-ZEH)-RMY6CNUTKS^ M*HS_(-[=/"%N_Q[2)0.V%D9=1S M'75[5GQ@ &4K2JV=ZY- RF\Z7O.Z25_2Y=)GU=6JVTJMSI*IM%H<]VB? LTJ M_+Q%1^DB;2LAID7 5-62U!685R$HH,S[X'V:03!]#;B CU](= \#/Y-[$J1D M\'CSN(3?(2 (HV> O=[YK^$LYT"Q](EE3D033+.HF7U)M.V^)4KF:&@; +!M MV>R(HWR90?M42$Z/ [R@(ZL:7M Q95/7CX 3, $:Z_6M:&>(%DO2+/,(:%$0 M+6I6IN;\T")+FG$$M*B(%H6BY0RYA?;8W-12=&_%@FBA+47-@[BE<$'I$]GA M853+__"2^3"-DW"!R92L4 6F-&-:H_X0[&#[@@>&)?F()D?F6)(-T])K&S9[ M0-P.E.FJLF?)[0D>3M0FXG!B**)F#%2Q;TB&*-O]D6&IIJ:H"E-#F&/2X#^U M;/^YHDRUY%WZW.Z+,I5K;EDV-*L>HI\CQA3;T$WCB!C3N%+'B-"HUX,Z$&.[ M'*\M"D3< *(&_C[)7BMS&NL84"5M.!F-%=$<:H"!@2*+ UFS1-L8R):J2J/! M2/U*&R/_'S_YQ?7N_\]=\@N @)_H62\A3AY]\NO%X-/GT?BS./STX4/_^LOX M*OOC%V$&:Q5GSL+S'Z]NO 4$.!_)-^%SN' "_F/L_8=W8NX M.[]T%OUXDX?)"X'_[9);0$?CX+?YA7.*?;V^S+]\F M;G7&\LC*G*7'EMDB%TYTYP4B_'P%"!!^$?@7MV$"/(3?U9&T&:,;%IXQFY = MOX8P5>#\)F3QVE4-N&5IT55(WR91Y1-.N05" U?? "#_"I=\I?WTBX"\#31S MP2F@GY^ @ S).;#+$K .!Y:40NW8BQ,AG D0O<*\V \8$S,_>P%,DLS#-(:! M\9^N5I"1PU=:G *+JQ+TEQ5H:P2 M)S6"2-=3Y;$M2*F->-)8D"1DUH &"56FR4!F/)I) N890-_%H0]0_Q?;+2@# M1#707]. %.M0I5[Q 8W:%CW\"A$R(E."V<824N0J4LSG1 6 AJ)K_ M&@['X\GDXMDX6I;6LO0ZXRGL8CW+Q@613!95 R-F7SZ#E=EB,I^7Q?#''W?B M1?XQPKPU':98/=4T&\<&X;?(6?YZP?Z]>%DI.@!$5>L9JG(,$(^FT\]4 JA+ M%?.D./6S;L,@!??JY-+P1!6]PC.RIO5L63X/N3@46$71>YIBGT1".JO1)#-+ M5E=62/#R*!,91^&? M]L&JJSV#Y\1/9#U*?+5\^&6'[8@38'$O2>*9>'R&IN$?UJ3AUV_9G='23L_9 M+0&\Q4MKL_]V"@[9-\>O6^ QGXE^WQ-&3;5ZV;9>I]?W%E25":H;IGBVHEU* MY+G6=GZ:O:-*70IW.D=%#QJ=Z"#5S9P( 4GP)"6MA@=A$,1OUH M29=Z 36\P,?+?K,H7 B-AQ@$/+L@)*&P<$,:YDZ42)1\>$LUD,:+E]W/36RCMA>(8X-XWP ME!F^-/8>A 6081X+! CEKB* @G\I](&Z_Z*7QF$B?F"M><7\?B90-WH"2BB" M'7 >G"!(*8BE5GPPM==[8[V3K29K96#M?']NWF8WZ ME760K5V"/I]F-JLH>L:ZDK0OG&Q7;YD^8SL;EWA7?1 !EQ8E\9VGW[-=>UY: M'MCR9&Q9HCV1^Z(V&6AB7Y-&HF6I]L26576L2U]EO),P QR1/[]=6OKAM@?CX>B.E"L_L!2=$FW.2JTNK@_!:I:!Z)PL?!8W0M:$H/OY4R/ M?1W G Q5V;9!?(?&4-1,D-R!I5NB8H,N,X$G5,GLK@-D,0\]92E+YWH?H,1D MU(&KL-EKN0=P4WA)-(T]!6"3N9,(3NIZ2=P#=P@KG65.K,<*,65%.=!?A4GN MPGL2!=3+=-)D'C+;Q*X4<'P!X_B^$$[!<*&'C#Y3UJZ$^EEI!(X*>&VW7"=< M"E_2Z7RW5\4D? *2)P9 7'!=!@:83U(@N#]7YEMG3T@V=,L<,$H'L !.I2 MPY)@>1@!"&'>R@5>[<1S8>:'WQAP,#]"$SFT @:XX5.*&*P#$.=V_[)"N+D3 M"T&8H.M*O0&8)W.F807HYL*D 1 E6!%*(>NH=F11MS@NX#;7?2V$"FHE3&# MAZZ9,,E!^P+.!BM9W<,I$3'W$'X@@\,[*,(0!%@A1@9A@FXU#,-+84E:.JP" MGC0!S\[-L,OKY .ITN"/(/P&<9$#?(D@P4-3+YJF"RPB,249KT8>MDB,#R9IA"5";,T 1O!&"SCK\=5[F*O!)Y-YW#+'Q.84I; MK^ O"WAT"E. B['D!20 QSY%*\2=V<\QN_R,3+#D%84QMEPKC,!^P%ITEB)" MI5)#^;EAQ)3?4$15E1C3HCVQ<,=:6 '!(T*K/G(1S? %JT0"+0)O1A>T MR,08U%&^#!9M@F."*0"F" !#J"DPY$]H$N$.+!%H2[(Q>FT&K*;)%PZPLA^' MG)9"G-[^"]47+#6D.Y>^\RU.4?@,\1KB(7.G $R@$ M2''*F5,2)8X7)$Q;.0%HR1FX:A'U+PNSQQ)-88"2#W(896RU8-3>S=*M$Y;- M*"PA$)?P=!26$=@V==KW\=KCW;RB,PN3M4#2P/_BDGF#3VF$]HJZ.JPL$CU> M0Q-:()3TR^:3G(S*G.9,>G$6*II5O3^; M)4)LE%CW4L"[X<@Z2ZZJUN #%O5'KZ:#"QT=$W\F4I@1 ' [(BX,S$+C8+1? ME(),6+_-0^H6?D-[-G66-#%98 UT)T1#'EC.2Z'-53CC- 'SP&S;3BR0,T!9EC=KONU^:R'+E$^?[K=699FE8;=)\VIJ]&G! M_5FU)CY%UHFV)E846:M65WV)UL28W.,MZ2= .;PUD49B?R19PXFN#VQ51KP 6D19$56991W7+>RX795/P0$& M,H"LR-4:.2_?5OD@V'>J$:32MLJ*8=5!?VI;Y4+1T,K+^1;$9Q:9T'3M2A.G M^ @91\.PI4E_#'QM::JH*=I0M&W5 BZ> )RZK*ORH,LX5O)VUKDF'%FA\O?Y MYB@VGV"VE?URS7LRP!+I3Z\P!UGU3.C&$$UGN0+:)AKU*B Z!9*X#YAOTB)B M:#;*X6-_1K^DF';XR]I)::JDC/MBU.B7/V5I!Q;(WX%'QSRBF)(F7'*GB'Y$ MSWA9J!R!GE:*J2/%[2M[K@,'4E7=X,.-X$8+Y!TE03Z1Y9B:; MG3V&>5'\A5$UD^-!] B0!>0; MTJP=3, ;<&1D A0]^8Q.KQHFYU*H MVV9/UZ42N]45)0<)QI/%T@\?"=\(0I6%:B736M_F7D)$=$+(%3_TB9HE" ,Q M&TA5'H[A*L?U *U)"'*8/EGY7 I]E-,UT%9@G3LPPZ6Z>N2+ 8T<=N]X/A5K M-# \C\+M#$WT,4*Q52)]2ZODHK9VG>W5\XUV7[9M8U?:?@3:_D\*/A5*6X6X MPIB3O-E]VNPEC+]<7U?L?Z_,>D 9D(.%ES#APEQ59GC6 E51GV!X+/TGNO]1 M,B\T7RO\U0E2W*>1XZ0G],$Z^>S/OZ8^_9)RPR?@V5O H;D= MN_"/_@S8K2*5HI2BL3C]21&YBL=,%Q/P@SWD]T.E.%.@F8L69=G%G$;[4%4'7E-%HOCM6CY17A?%BIE?>PPVG;-7',J01]C#!SIPE%*L\4 MXM^<7-D&-?4]'+[_Q7:PL_UY_$:Y--9ISXT;9HRJN0E$'X_MM]&^!-18-_N* M&<.XA65 64>--7^9<>I9)R9XYY9\U5#C;M^'&27G_?"X<2[9YN:;)?:6])& M 56+QZGZ'-)2[*1&^UES0;:4GF59A:.(1Y]SDGW#'0#J3I806# !_/M$\XDA M5?A =]Q1S"ZM%798LQ+X D"&92#6^7LZFYE5WYB76X\L8[S_ZA(E]K*3RR8_=%L<'IX;/.CK#40L9=M 8$X M^ TAZNJ&P8')NB)7/0JGZ2+/";.D]P2^.^!XZ9X'9+6+=_^CL#SUVD6M6S?F MLE]FU2H>ZI:MIG7GBUI=-=:Q/_E2L9 \3%M=*JYD)0^__S;^\_BH-/ M-S>??K\2J)J9?/IX(WYY___&5X)"2M97S[%A_'DYDI M<6_ MN/ET?250U7-^/[C:/R1/E%.Y155@GD".EW@K93_D'B]D<8;-!'#+5A MFK=*R%T(/M;/=&-YASK#V\"F=X+*<#REV#!_QQ/16,^Y8]%3WUG&9#59OJ9Z ML:W\M%(>M4C!5[+JC5ES0WIZO6'UY>H-=Z\^RJO7760ML;.UG9NO^[^-Q<'G M)*[N;F7"SV\C"G)6,7CE[F]1?]AHJN*=[\G<4(_K M=^9IC='3JFZZW$;"V]**Z/>K99DW[T>]+HQ] <^T5?CJN'\#+5>J;U=HV;HJ MXB< ^)DKA+J;:7%WQ MM< H]W1%ZDF:M#>4;89-D[6>;#<7E=T+MF,KMK-28W_A]X'R>T*"XRZ\P(L3 M/!!]3X09.<,"@+;>TU7M/(3^4%BQ+KGTG< J6T;/-)O+ K\^8#6S9QE',5V= M;[=1*?[N!,X=O0*<7] LCC">G3+406;65))[=3*C6Z ,FSNYO#I895GJV<;^ MCM&9 6OT-&M_#_= 95@ZE+(>Q!.@<1=%R7,,5,\5"09>K72?O:*S6=CIV;H5 M8+=V81T]VK6PCA[M6MA+N^F;G?)3\,>>62%;UGOVFJKWK7-]]H31TI2>K9U) M8+]W=L^238CHFVMYOQXH#=/JZ=I1XI+OP7M5\X+,;3,'S[NR\['/'44ZBG04 MZ2CR="]VY99^X\'W[:>3JP>:ZW6ACW"(N3]6^J9DCD5-M0>B9FA]T1Y.3%'2 M94O3QZJER_VN9$7F2M!C*.:YEJP8L@M3K#PN_;.H&B10!GLU52H&3NQ-Z4%U MCU;0P=N%^84QA!0;!$P='\N+)NPB%RTZBP?A8=2;'[)QO&SE-X)^+][?Y17 MB@MIY5ECK*"&E];Y/>Q2TP%V%?M2&&%9>)AH\]K>_+!A=3NO[ MU'7MDAL6#'-[&R*ZWE.58*9R B:O?8@^ROK/("O?Q?(4D:\Y6\P0*[ MQ(G3Z#$K#$&2.2QMA4-;4!HE R K+< PE;)>%12OMY0UZ>7^%59X\\,J,Y1G MS&XBKK]:]F;=%;W\,KEBI)U M>%ZSLWH&,;? M!.1VW>'HJ'P65.Y:GF\,1?ZQ1[RZ)>!OW^DI6^G9UE&:R;825MEJWFI[C;#: M2O,)P-<(JV(V'P \4D/D3A]6]6'6I[&:=2%%/?6STXNZ]IT(CZ%^)QI1MYM/ MS+PZ0$VI:PZ_C^XLM?J66:OOYMS+\^[,OM#23L_6+0&\Q4OK:-*^I74T:=_2 MNKS&D?,:M/L6^[/PX8O"W6>=[U![NM)\<_;5.8(0%UOR=Q+&(%UEXSN!5>G9 M9N?C'VB,5&:,V&G'EAG*YUK;^7DO'54ZJG14Z:BRMZ__/7OV_2#Q\E1\T8.6 MMOIB'7B+(Y2K!R?QV.2;']8>G#P[5U]=4QKLU?F#S;==7QV8LOV=[%,WWWGM M7/O.,';N2LO7UE&EC6OKJ-+&M3W-8NUP.W3M5<_--T*SVV3/VMW]*SC37UG& MO-SH7=F[S[ML7KR3+W5U/;@1Q2+!\J_\>PHN'_R:/SW?M5>U/ ME+YM:.)H8NNBIDTFHC611F)_)%G#B:X/;%7^"E- MZY5C9"F!\I3P.[W"2>N/OIIKQN\#P9E.@7]HDT+L%4[S$_A=&M"&D'>IQWZD M?8(1&_>\>>RBA ]^'327NFH_Q:D319@*P3["BS /Y(E'R@L6YO#9B:;SQ[P7([VEG,%77;%+ M$NSF&A"W:,W.IF&W>O^=AFBU VA$^D'OB%Y95!I"6:8(75ETRHQ,6 MK2 +-)<64D-T!42P_(/=:3<7T_M#)-.$7F#L[F4-(] M(L3.@G8.#6?"CTI#_T768M&^5%9^P=O3FWLLMN#6X R MBO^8W6>OOC*O#)]?8V=LB,WOL+/Z3" /TSF^383'4+90E)+'8'^N-J.^-MK4];8)K D4GH M2M=9$Q0"0 2>D*%2 -BCDD8QY]QZ/F/TDG Z4Q"#V.-%&^H6I<36F3#L8%'6 ML?6;'^K6 RBU:=F515,1X%/P30+:E!B;7-.5.7&<+HA;:NL,0#*I7K*VLU0E MA+?YG)=V#U::.Q"V7(5;0HZ(L6.?QFFO5$^)Y&"4B,F[9!/6XAT7'L:;A ME!$0(?GWP&OE+R-LP,&Z50%>GFM-2!Y !D6@6Q,R1MC&Y>J7BOX3^">!!QYP&E!'!3=) M0]1JR"^*I*@( YHT4]4OI35NJ&FHEW*#K#KK% Z7\4T*IRSGK-DX(K. ,M?6 MX&PA5W+G"3=S4]"Q+E/-J[C,E"K(0C9916?NTI)\8]YCM04VZ^H]#MP1,OBI M>V$KK&VW*!FB*E4[8E<6MCEOR.ICM3QK:-"LH;8^:TBAJ.?>)IY/HF'6D?K4 MJ3?MXMT',$1$Z$^GQ$?3"EV9E M0HGJWI0"H!79,& 9DE10:PLD5;#?4Z?J0QC'DRA<#*D7D@*M/RVY^Q$/"/A# MA#UWXSR0>/P $X*WZ05.]/@^(8OX8QC0L"X$A172!: 46HDR&>18MDU) MD2LX.R(:-N%[3&/;WVE9M?2WE M%O7BG:[A^U>!7H%@!4PLGD? .--_WP]XBQA$E/_A_BMER.)3 M?B88O9Q8ZVCV0%$U2P8#IXQ%;6";HJT,^N) &MF2)8V&TEC!70[]XIVH6_"B M&E(.AW<;"J\CLG0\=\2S5'PP3/L)>VGUXYB<6GAVQ1D(CRR;UA:4[0)?%4=_ M(;Y[$_[.@I#'+WF2[ C[1R-S,!G+ TFTAI8A:OH(9$91!J(MVU;? E-LR=JZ M_:.C]6+#"+-<=-A8:<6F_52D9@H-.P>\K7>LM[C5Z'='$ "F"TQ;\FCCR84= MMZ$"JSWN45"YLE7W1-36=_:P))'O+&.RNB6WJ5PDWY;*BA<5&WV5O;O&O3E# M?GJ!1_WE2AUVKS[*JW=H0V$]>Z>:TYS]/+QU^TH)P\K.;[-"V[*-_;I0L%YQ M/R\:.B[=0**5&G85$N$?F C.7O2/O[R_&8M?KOM# +_4J^8+S>_>D&A!EXE# M1%375(9X+1!J1D^VC](]\&5[;[9,G4T( MGFWPA3D>Y_!#)W@IC78XHZ[PE)W<)#Y<5;4TA MYE>RMF.:OLV+:>IL^ZL-,S=2O ;NW".GJT M:V$=/=JUL)=VS#>[X:?@CSWS1W;/EEYWALR6P(5M+IGZ6D"4I9ZRI@K8:P'1 MDGJ&]6(Q^[D[K<_;[[Z]*SL?L]Q1I*-(1Y&.(D]W7G>H$+7UA/6V0^M]?N/T MFETXQ7LY[+KIA]+%WE8>6E_D5W9H5;UUEW2R5>V1K"N7V^-?KQ:J M4[95V*O,6)]F%Y=SORWYW -=O_0A5B,9EPN]!6[YCMGS%]M[R2$/0+5JTX7FVWMMQ7Y%BAJ%AW&K@G MS.HGZV"66N&T:?.QD9!JE1N?Q%AFS@D$H(KP2)R(WH>< M^DXC$91YZ+NTOE:)5$E88)T7;D'W@A8AR$N)T1(MY0H^ M3H+EDH# _Z$E_&AQ/:^Y5N8R"N^]F)83XU7IUI?"*K\"IJ-LARM:*^S5-W%WU< 87?QM[OX>]@,W<7?[N+O77?Q]RQTYID[A=W%W[.3E>[B[^L# MM+OXNZ-J["[2M?]T>$>/CAX=/3IZM#F9<0K^Z"[^=A=_7S&(W<7?0W1M=X6N MHTA'D8XB'47:N+*G6:B7NV3!CO>N.:D\Y-W1L;=Y[N5L[F%A]>X2'=S;AH/*1;P-8_"]&XNS+"#.;UDM9=?\!(!KOWJTQ2FU=,-^:5B M^._FK%(A%H44Y(*17SX\N5QT!U1V!E7IR2M+)"FW7Q3C$,0ZK6 MXUI9^]H"6\.\),O@L92/SBI@CIR$W- "7L]?1$O1)%T=*Q/1&(P44=/[%D+8 M%ZVA/%!&XX%M2>:Z(EI= K]+X'<)_$W?=PG\+H'?)?"[!'Z7P.\2^%T"OTO@ MMQW4+H%_0,C>)8P[>K2/'FUSY5KL)G0)_$[#=^GBL]+Q'44.3^ _.?MCG=:ROHS" /Z>LH\0U&+GI(_O_8^2N+5FW5-T4S8FDBMID/!$M_WA5LYQE'J+I&?REP)=011BE59'%:4P]EQ9L[+A>1+?H!2Z\8M_U MOP^$";F-4B=ZQ/*N1F]M ?.(^ [V$DA"P<;8O3A.\>NYDPC?/-^' M!_^=>A%,$M"^ ZPR>T2FX5T 2V.#,3]/NS Y@0MSX#NI,6.5W<-;$%.3Y<9SPEA-=7AK2[;B2+"'P1KQ\_":$&G%9S; M,$WX2+9(+H6\EP*^!*%W2GU4+H6;N1<7"*' WA+PX4/J4^:81>&"$8^1EZ\%YHA!W]+2.D'"*(M+3($2!=WSR?U2 MVZ)EY.$.#D5'B>-PM6'6$(BQ0(4V%.FX%4*PK#[PR=)+'!_QD75J<.#[$ O_ M"S-GFKT-1^'4MRE0&ULQX-,+XL*Z?5@PK)_$EV^J+0BP[0#0?.D3NC8*_+T' M<@4 XESDP8N+5<+@91@E,T!S2&<'#@+I2A>ISV!Q?#]K&Q 0>%V,DEAB58H' M*E 4$ _9B)*0>#RF((FB/A,WW)&H"STYH?*^F/B R.A%$' ,DN^X=Z9 MLUSZ6 H)NWK J8^X 28!];FY* X[L(+ +R(2=$B=%.?4+"TFOEJ?XE57^*I'D#-?X#G,XEE6^5M;L:& MG?=$U9!LN;+;OQ:(*JR?HCL'C!NE7:%4X<, S$C\:78-*C,C^X#SZXC$T\BC MZIMU>I[TMD?&UV.NG]2WH1>V;JN;VV7.VPUQJ-+YXZ(M^ L_ $>4>RYY*HITUYJ MI%5.8*QO325OZZI5'KDUD5_R\0 !0J.3]P0G[I<-"Z>YCVJ0JJ>*BRQ M*MK/WVSK93S;&^['4CV,6CL-G-3U4%."B+HHQ&[5 YIX >A9<)/0!P*$<=>" M6^?,-O$&0D(08M5 VDJ(VF6*9>(RPT5=,41"N3SXMSF\7:1>RE4I^S(!4U_R M#$&@*3JS,N',A[LE!%T!>,W2B=A;FGH116!V,^?JCKH815LBA*K:P6K\,)VC M"X6P+<"/1P[YN3!9PU^^C(?%Q]$O?\JNTAL[+>0IAEJ -8,\0Q\^^& MB"GF4+B$NCLE9[+LW=P^5DTQ#/&6",X=";#8+7-ZR#)',A'^%B ],W)10/L+ M6-#4J<+Q6[]_704$W:;,BRM6CXYKOGYLKT7?$B[!Z6%&&?C+82XG#93B=6,K M\#KNOU(>D_>R]F,(8ABPCFP!^GH^106V=*4>1GE(X1?BJAUP8+VH>%=!7>:7 M4RQD= ';Y84N]TF:B%1>* _$.!'H/+^/1Q_[_^P!)J:7N?\Q+0M-G-Z"MO4< M;*,%$_R,IY.R;G ]H4R$WT?_K-(@">$]PBBNP'\I\,.3%1Q2K(_^R:1^6J1MWOQ0 M8KYJ[$/1AX39:0T0<\Z]Z9R=ET-M L^#)WP'&*&1,.V9A@$F[6OFT@AF_AB# M3T*K3$?W&!2A &9157' M5CQH>"XB,Q)1< HF0S549M,>:P!71FDV?8$?JDHKO)#C9T/GM9"#1U(NI6BJG(R"X]E."9C.$Q$& MD E8*7@9VBD>+6;:/9.(2VH\B? 1C+Z@T_4N0@I[D5,"B^M$671902V#"J;@ M<+62Q2I:O61*>/R#ZC7+;-6L"_-+N/N#:@41F1DM>"L\[]+, DLGL%B:S0_, M=9L%L2"J0!0W?PMK6@I6*\9L#)XQH3R;\6'6"W5/'Z_DX?$LT:I3%\_#U =; M@^MUJ-,!2/H7>,J4WIG5HKF5+:]8\P)N?'%J;GP;\P:+,$[0.4#-WP\"/!'] MF28C,)&WKY?YWU4O<\6@X8#=G5@Z8<6Z5:;?B>%/DJ?_3-$(3-G'W"F@_CR3 M]K\[5+5H.^7K(P**)ZUD:3&'Y@!; J0N>RA,$Q]<*DP)PCR8O4.YBL@:#EXQ"^R^6DZ.#.EW"^9@A\;@D_.?= I:LW S^#QKSI2LPRHE M(N=DC.^%6>JS4 (6D/5E%FXQ&SA+LCT()HCEQ_&0^=2*2^7P1(K0YG4PI M,J^D/!DQJ#ZBR,<[%WPK :<'@>+NVBT-3KE'3ES&($N@!4Z";:21.KR;+R,A MUV[AEBTG!>H"0IGMK@R165/BI$(J?IOP)F7,&\#)00^HR@[7,!*HXI=0"' M37'D%HHW0 M$@RS1CQ1F@4[RR-15CFO<6<*>ZW0C E#MQ?F>V'HE"%XDS$'] M2*W1C]S-.>SVM+L][6Y/N]O3[O:TNSWM;D][]SWMH^[4U@_0)4-P#ZZ92^T. M'O\&.OY]P$[HX65Y5*U,9D^Z(Z[9 T75+%E4)64L:@/;%&UET!<'TLB6+&DT ME,;*5WB-CCOBEFUJU1WQG:':"1O<:6P]-E0-L*&9NR&C :B=D/$ILP8M1X9L M7KQ39$/:"1D-0-4.3Z %^Q@&Z$N_X$&1'6&GH&M6!?*U$-0 S3#!?STQ<7<\ M"6-0R"! MQ7"P!,Z29BM:B0,%*]8HYA8<;(9L+>=_)LLTFH+O2S[-\,1(&'Q)#CJ?=DQ[ M#9C0T4:M$X UP&SAB-;#(#23[/6VV' MA6[;^EI<[ C<>NQ\0%T%F 3MY+74#H.;:2FR7O>_U@&QF1/@L4Q!][,33( X M>(SN MT35G:OG9A0P0 IIJ%M9(<=(:RB"2PXMV.?9F? $M;%.]-2ZBRQ%H@5 MEIAY26NC*K0)LJ90W[M*9K[J#90+@[L;$BV&#DUO?\#TY:?R7DD+::E"J&&H MQGI";H:IBHPOTSG!S/*G&<\LQF!.\80URS5&*7$_%)L)QZH7J0_Z8\6T 7)% M&HE:7QJ+5M\:BX9EC63)!,AU^2EW;D^XW9>A35@RO+'?G;O.]B58 M94A,?/_,SU[M4!VRM#@L!%F]S?'+"K0[%X9\2AW'TIV9Y[V,LUJG+EOC\U6% MM%^N*.317[VN4,::BTG"SN2Q2IRT2Y&&(Y=UV%#<, .9\6@F"?*E)&6E$K,R M"BM'#5H@- 5+6>H387/SH0Q*/I]#.5 .I2Q8Y? M7*NY#8,4W*N32\/!Q1\UK6?+S3416R<7!Y=_5/2>IM@GD9#.:C3)#!B-""(. M(7$>,L$A 8'@^/PDQY3!H!R%EUH(J]XSS,ZRG$Q*REV[5ZTUG)S6*T3.M[T1J#% 0IW'(.A%Q\^OG9R<2 M>D\ZE^#]4%"UGF;KG1DYN8S0PV K^R5G)RF:T=/,H_!/^V#5U9[!<^(GLAXE MOEH^_++#=L0)L+B7)/%,/+U"B6GXAS5I^.IU>WUM052:HK$A_RY3(&0LV';3IEA"8KX0^@$V,8Y/\>.Y9&\^R,=,AMJAC51QY:H]$U=U#1U)-KT MH)T]&=K:2!ZKIO'B38F-#3V)\T, 48ZF'JV_PD^7Q0<=+^N:#Y?E_(!C9N;+ M'3,[^JN[UL//UWI8:-W1LJ[C\/?5ZIP%/ M5_ORU)_.*VD- "N6 4+4G,0Y%.#OH4]EU_FVHT?[Z-$V%Z_%?H2NF#W;?MV^ MDBZI &/SV983>$KGKN.[SK<=1=I)D6?(7N^<TZBNFZK-Z\[Q\?U[.&XLQ/RZQ^B@\N'0>(?RDQ?5CGLR/O[?,O:T< MEKDWE:=G[O67R]QWK^[V*TZ=K#41*>Q:_@YZ?Q\7G,39OH6O+ M$_:WD?"V/LOJY?K*D*/O>9P0>3G,7[R'MN.M$XV]][%>8./NA#7@==3; M [QN5[Q\3 0[U0:X]WUVNDO9>[OW')A?.KEO0.N ZXSOEJ5EZXEG(']'_\Y?W-6/QRW1_"RTL(O8Z\ M>R*0[SUNI\Q^G\5-[>GOTY"$X'7 ?<$U7>N9\MZLXK/B<;MP+8UBZL MHT(;%M91H0T+>VEWNXTGJ ]V J37G5;OX.O@^U[]U.[$=3NL'C@X='3HZ M;+9!3[H)\O3+#>NN2?R#H*TE;O^>1,X=^9AB78M/,WK7XFAM\J2AK*@#4Q-/4Y_=G@EG0DQQ):0Q+9%, M"Q?=.K$WI??K7<]/\>04WIGP@FFXP*L12X*7\K&#+1MZ-E4GT8B$76[^1#RJP/4E+KF'/OHSJ[!3T>3CB8= M33J:M'QI75[CR'D-W.;D?Q8^/,]VP 1GG>]0>[IRE);&+815Z5G'Z7G>0EB! MKK+QG<"J].SC]%O^GGS\KM5;1Y6.*AU5.JJT>6W[6JSOTK/O!XF7I^)C,DTC MVG$3O )Z.-)/W>((Y>K!23PV"9.L.SAY=JZ^:G\GOJ_U?8 IKVE)\NH /4K_ M\,ZU_[X,8T>5CBH=53JJM'=M3[-83[J_]81;5^SBEDN\JYO(P93VE\?%;>@_ MWV4LM3]1^K:AB:.)C>WD)Q/1FD@CL3^2K.%$UP>V*K/+6+^/_OQV92&UBV4) M+/DS6:;1=(Z=>D;@X@=WUR3R0O?OCI^2([8;TE=A,R59'AGV0.Q/9$W41@-5 M'&B*)4X4?:BH\EA1U ' )E^\TQ6%\DF)6MM J4*^AJ0C%L8PRGXJ-B:> 0]L MOV-;QR5E( \'8]L0K8$JB9JDC45;4E51GBBCH3;6Y+YN?E7A#1?O;%67C0H. MG@C43AA9&36@E^5:A@_9!GPH-N6*K?AH!HEA8^%>73N/6'1X$D;7G)F&(8WY M(QJX?B80P!+W)KP&UHH8@_6G_TZ]V,.?X].*#,PXTH?R4%0G_;&HC253'-CF M"#XJMCU4)D--G3"1D3.).1S$ E58:-Z;DB_I@$@:*U1]8BB[I M-J.S3J'<$8)5B(GK.4GD3;^DM_$2UN3XR>,9 YT5JJ [P3("OR?P8\*_?#N M'&!6ZS"O7_P*G!])&#C)N4"*IJT"Z:;EY[!FS3F+-IP@ZQ])PDLUC+QXZH=Q M&AVCGH)JC2?C05\7^\.1"39;!8=7'FH YPCLD:+(5M]<5T_A9;LC@J;\:6T_ MQ&Q5>Q1 SN;7BN:+N*.19PAO\0_MDL9IMUO3AG3&^C3U,/7YZBOG-4?6+SWC M-J%@-WHJ"AA.X!QW50-N?:B[)9 ]64=28T-'TAS@* >X1_>&INAGQO!#.*/[ M1JSF!498/WL!#-RI[L6K[#QJ&H=U'C6LI]>_,%^N$L317]TU&MR[9UMSN9H= MM>_K0 $$/P3=B1(:Y%[QH>MJ=^IF4%$8QX*S:E;VRED?DHO_<;]=6+EGRU;/ M7',YNC[\N8O4GPY*TY9ZDMHUZ#BV0/31;W*"*:$5R*:\Z6/J^(+C_BN-$\SO MQ=3)3 /T10@$0B NYW=U]F>YIP)/ 5_MRU-_.J_S&@"P8AD@1'LW(ML(\/=0 M2[>KL-[1HWWT:)N+UV(_0E?,GKWF@-YK\95T2048FR^/G!=X_\$[O0DK;@SOS9Z$ MH"*B59&C\-[#&P"WC_09OJW#$:-(LOT+/#J;>;Z'APF$9;;;&%]B6>8W/S2/ M6)(( IH%C6S"6^ AYVJB-B9!"$)V7T#XGOW)'H4PAG,E"\-?LT:#^(RA1@^ MQ#.O!@E6@68C+GFN.L)LK/_8PV=@& X-PK5K2>8P&\-"&A2O@#B,]GEU?/^Q M\@-_-X%@C*>]([(,(SQ2\(:6E_9"3.,F<_@>]R.3$AQU EU"Y+<(8WB_[_/9 MUJ)R$XF]Q6T:Q91\,/XN[[4MQDL ,<2MOCDM5#Y%9 "Q[R)GP0+*HJ7MH^ % M<1HA@A 0YS&,@+K\=$E,(].<-!$6PXX*"C8MF4Y2(M\="4A$T0F1*\5[(-QZ M$,RZPG3N1'>$\5(V%PQ?A(&7P"H$CV:)&,"XZ")C!.N*P@6N(08&8379LT> M$7 1\!H2 ZM0CJO$UGG4C12*0J =+(ZGI;):X'2"!'A]2<>[WFP&@ ?XFEN2 M?",D!X*]-2>%LZ#9K5/'1S > M4%R1F'2%(>WQ/(.7 <_U^*THW,URG<<8M(]?K><($_Q<,/SPE]&73\7'T2]_ MHLMO6$Y/(& -T[R&/:YBFM#2\G6*6,*F);Z&EBJ 83Z37Y:@M (>OI?3_$C+?::VW-P_CI9>@5-Y%A,M*1.C) MF_PW1!'U;BI>(\CQP@M T>)!2^"1&4'33E]8FHN[G"@P, L^(WAL.?F;W9!? M4&6N W!0G((/.J6LFK'L?>BG"\+4#MUAQQ7=I0XP04((<^_*B^.<"R07Z'$Q MZM3A>A?I@C(VXWS05<2O."1@F>*P&$Y73)53C@T.2PW\W&DJ5!'H''1I&AWJ MW!M'V8"'D25!]Z'0@&K!_U)M6CCP205I+66W]V!J7)>>..Y5R)&1-B[IG"A, M[^840_!2YXXR3#DP"$NM=M;XI2G^FPO\-.0&&\4\TSN928L+(\1L&0LV&&], MD9N( _I\"J8)6#CBLRR-' 2J+A;+\A-.FA"L+K((MR'<;F5Y?2$.=#E M3 RP8G\7>-#E;X_EL;"3SC4!LX""[PL^XNXUEF6B@-'7B>3$ORKCG5I;-? MJV\N04#%AQG7]:^"=5(@O3B#$U>+&.7$8!)8A"OM9/Z;RMDH?C(I72R ._^# M<>XZ%8PN=R85-+*;@J#KJ*]B@XY724]_725^G*GJ[I7=V?* M3GV@:J5_3H9#>D:*MA9J5UNQXX(DG_O"RR)JDVUZ;J2]PY,$TU)YAO.YC':9D]4SU*,Q_);#5LFJSUY#75WO:"K3NX7%)C?\E2M<7^T&KN]^0*[=!#N[;>TX]SZKU] ML)IZSY"^$UAER^B9IOJ= *N9/H@,_*9 M>'D'PVJ!,FSN>?;J8)5EJ6<;^SM&9P:LT=.L_3W<[_QX=G?EHZ-'1X^.'AT] MVK2PEW;3-SOEI^"//;-"MJSC!?[S<'WVA-'2E)ZMG4E@OW=VSY)-B.CWOEM] M)E :IM73M:/$)=^#]]I=9>LHTE&DHTA'D3:N[&D6Z@D7LJ:W?/!6UC<\3![S M \EQ=W;X:6>'3>7I9X?UESM%V[WZ**_N3D\^]20L?\$M_DV/#Q?+8.=BB\_M M.""[UX@3'"-N.]XZT3BG8Z+\DNJ^*U97K2Q!7P M4OQ>(>"+GCS;>SO^IV,O]EG VSM?>Q[@==3; [SN\'"Y#'A>Y>/L=)?R,EM. MIX+N9;8-VT^[]L)TEC7:S]P1H_T$2\6'O#.\ZO"J);T#K@.N<[Z:E1>N91;B MCA%;SC_^\OYF+'ZY[@_AY26$7D?>O9,04'"/%(G%-BRLHT(;%O;2[G8;.^0<[ 1(KSNMWL'7 MP?>]^JG=@=YV6.>.#AT=.CIT=-AL@U8N&KQUO7O\^.>W"_>JS[NE?,Y;I?0# M]R-)>+'SD1=/_3!.(W)#'I*!'T[_> ?3"'^&H<-PL0B#+PE\]YDLTV@Z=V(2 MY\_12EKPX3.9_7I!0O_K]5B6+$T215&V9$G\'T",]?7+S>@K?/R*9\PD0Y6^ M2A>"Y_YZX;E?956W)$M6OAH3960/84B_K_=%S5*&HCT<2:(L2[*M]_7)2+6_ MRC#R'8+'H53]BMG M\^MG]_DQ;O V?JK8_-PO6#IW1+R-B/.'Z 6QYY*KIA0\GT;[Z:(2#&1NC4]F M2>XUW.(?-BL@?[O6E2B/W)KA7SC1G1>(\/,5($#X1>!?,,FXHFQ?1=)FC&Y8 M.&,J@7*54+"5<,T:I5S5P%HO)KO>MBG!1BO?-X#&O\+%7N%E%^1JH)9+ O;Y M":!GZ'T?"']-_4MLA/:2D\#R:=EOH9 M>7&<\F9KQ0I8WXJUB\#^*\DC[:A#:$\Z6%'6#"=KJ45G*L/''V"=M2KM!G"I M"^ Q]O&P;((J,9PX4UY_PU<+&I+UE6$M_")'-J: E"91!YKBY%U M*&S$2!QF:.']WC8QQILUO?DJK+$;]6&JC/[%:WK8 0=F[]4;)*YIK^=,@1UB MK\P%E\(HC6B7">0$[X&UTHBQ72%,MW+T'R9!$]*K=7ZP7()@'O=D5;,])N4-ASCK5E MR=B%-F%C8" WL;_")1U''D@T]5 HW +#"2V$7\8Q3+""98KCRT(XXPJ*JRTW M^>R(!GP<>=X5_ITZ40)Z 9:*4^4=M=P:QY;TQYN\:=E*,\J,\>(FO;..QS=I MG@PC.9C%)(#\!/!"FWF"(/B@@86L*\^"@$YF/Y'9C-#F[UAG7J<*;@7M,>0NU8W\M:37)=33>(M&'-4- ?R MJ>\++EEB_T_:43 &EP_T4U/?P,-5UZJU+GNA6US)W.5$+S5(_,>^"[Q,7.Z\ MPLO /0C@SREK^W,=^M[T\0B>J*:JLF58NFB-Y1%XHI(N#B2[+ZJ6;FE]V31M M>[C.$VWR.&1K1Y=C#QN6)M@S#_NG8?]0;!()LAZ1.>@%5.V+ MT"5^N?DE4V?X138_M8)Y_RVFH/*63DP4IR'M\P?"Y(&J8W*($ 0 8Q,47LP M8 WJL._-#J1&B<$O8>WS6NXH\L"Z8%-B[$)5;N3N9$[,) .P@GF'W*HJ#T*=:&4UI M%0_-#R6=%XE0H0JT3)\:L63)# M?M;IE8-3:^;JQ'$X9=WQ*(-D5]S1DB%U;L&: (%Y4U-4]M@D+2)NR@P]T*/< M0 M^#9?+,&9,?.M@=]7;A!(SB(&)'9@!&3D,\"5@&;$?L$.9C#]3[4\L@+(M MM9/UL3\7;PCG5L%[ G"4($W@L:=HT\#*M*7VN&]J_6.W88-V*XBX!T M:NYY+&S7.G7O6,3GS=_'A-,([2W3?D0(\\0(8 M!*^ >!6^H,OM\;:&V!6:(1*">Z35+'\XSAZ&MV7IE;J@<&:+*U.4'B];9W"J M ,.L3+G#G"P498<+6&F4X-R"TF,<[J!WTN-XZV5N F]P3*+$ 8?G,7,;BH[5 MM(W=C 8:X/V@XMRF!+\07,7',"&"1DF]0(U8[IV[V3G8S^CG/L, _/2 Q'&_ MB#'BOX8 W-]A%"*E'[B_@89#?^@8+L-$DP;V8"0.)K(A:K9BB[9MF:)I2*:J M#R1EI!M=\JJ2 ]+/-7F5L9I0YK6>0+E-R-B--ZS,6.ZU9+2>%*VOQNK<9A6Q M8#DE %IZALJMZ)!]%X7I$FPW*!QT2'JYR:)K^ ;6&6*0T _O'DL/@0Y'RQZ" MZJO^Q,*6;]@.>DE<,&9@",&JW-+6J> IE";AX56Q.!%- <1,'C9I]5.>!*,A M="49HG1K:%QOW:IK03^]*5Q;0#8Y\-N';"LF'! '+#,F).W6<\@*K()X+AAQV#NV$%(0I9) M*6" X E\?AR=,V(I?2-$Q%[)H4?')Y7&X$OL;@E40G/++8PV\@WAQ$=98XW M^F;8<2!08*XDS22F483DYB)(1;EOD?]YR ?BGS,1_J> M0^,"CV3#&QB3)KWJ,Y1>OSI)T_HIZK"S=<0B$MY!&X.(TLQ5):9?JHWLCF$% M#$A9&)B3H!2MP#M2/\G=8J;L005G7;XI&Y:-6Y$#J$9E>7".DO2C;#7 5MB: M?/%U47A2]ISE!&\A"F+1%FIH*FW. \HYQIR;.E._W%8:RQ$S5L#4+F8KF1_ DB;@ ]RFF6X"3H%9D7=]A7<@5R2;]5&$.SC1LLP>#:<"L!^9B]K?C,9H% N3H-?)%G"JAP,@//X8.7+&$) M6&HE;XC>F)*'H-K%O(1+T^VE 'O@^#0:_C(G)&D=Y]VL@V?1T#>'I8N0A=+ M0],8\P1MQK +0**$PC"V19/X2VYF A$ MKHS91+A-P&HJ?LN#<0C^PC]@[IAKUE)R@5D$_AAPSL(+N/W'?!IP297_F+N0 M8L]W])IOB>^1>$T%55YN3^<::@:_&C-B1OSC9JI$T6/^!L=TLMV.[*D357% M 7=!_)7+&2K[V/[^;LYS\IF '*(X@*DDLU+%\MB MNP,WWS#51!.(,>-TE,ABO:#]P8UEJ2E$-GCDMYAMCM,EKI$&^D3?3TU;BCD9$%CPV%BR-.;98C:<9\(0&>2!N^ME;*1,@KFD,U13 MHF08N!3^SG?,^!X3GSA'"N(]STLS"A>+?,P6T/3R7B$*U%WQG<>8I0K7L3]C M2J:QZ?/X.,]TH9>)UKL\FJ7,,U/=X!XT$(49?X:7,M[8#TJ%&QG.=Q@1S-Q[Y62S7DXU6,I>6I3BDT!*CKEG"Z7 MC&P3%Z1JNHV@,0%^H5[XEDSN7JG8/)%[G=<*_C3[2))KMM'PA9&"GU<.\D+A*3C@)1(A<8_8#<^3&M(%=/\ X42Y]8YD0T35T3-;,OB;;= MMT3)' UMHZ^;MF5_5;]J%^_D2TFB>'@R) P':2S>.<[RZ@ON_0]P1V!8.L30 MCR)4V4\>5\+=M2S][Y_?'@/ M!M3=;I_YMC[S^&'I,7EA\SX7WN"S:>FR I]-S5+VQ:.">%0;\?@S 5!EG#=M7NZ-,N7BG:[9DU]COB7"V6M-Q#.XEH2I**!B!:_4DBBXS MH]<\/5OLFI;8^""4F++]H*J2HAA[2N-HW!\;X_%0[/=E2]0FP['8-RQ5' \E MR59L4]$4D[$6H$U7:]*X$X"G]QU0G\NJ9B*WR*:N'\&7 )2H:#.E2T4_Q)UX M(;18DF:91T"+@FA1$2V2?(YHD27-.(;GB6A1*%JT\T.+8LF ER.@14.T2(@6 M\V5]\C'-P;X/XB1*J %W$G^_1Q)8!NP M'3LQ6&"JIJ;CBS#G^PY'YR8)$?-8/^"@.<[@_D<:,Y.5&2$Y! "$![G%YCS=0&]H!T!H1W$HT'6J>GD5&'ZL !HE:? M]'4Y7XK)@>8)* 6*&D%N(<,XFQ#;/ #G_Y":*ELR5+3CR49"^ M]VB^F 6OC,GAZ85GCO\1UR_!4[<-JAM[[[T MQX I(40;VM9(0V0HU1@P13:V;7L#U?=)FX4LL>;C,)BG6]#ST&20)'1OTD:B M7A0Q^,^%T.4C<%D8:2]R1D,'>,KZ%LCZ:- ?4=*Q ;J.H1F@@9JN=] 8#P?& MR$ PJ4FW4$"&+)CY,L[R.R16 S)3Q^^#;#"V"=:,<617B)D>N)E@UM&X=OU1PQ38EJD1,2,Q %' M-K$L_32(@;_Z5^#_N&?A_&95HX\^\Y9N\)<^[BGNSTC:%")VPR0=JX& MWJ'$HIVQ-B28>XDC8RA;FN_(_X1S_>;-KL2:/@5AG/VJ8F*);+44Z\V;K98M M$]M;?)B#Q,*"+7046YDY>;UL;\O$_ 'A;(UBDR?+3:+AO<[&NQ.^J?^&<"[% M]+9@N;SX;!8\\+SP]GAG)!??' X&%5A8A:+4$3DVW#>-OCF@X&SQ_PT1)W\X MZ(QZ5L_6>IJMFPGY5C[!=I@T.03\V$L7BD]75<'1BZSF2CLW7RQC<87)X\@) M>5-5!)"*'^G)16P?!FB+AU-'\P(;G6J=<#!'?7 1 Q[ M")2#3W9V%IA3")G%;<@6(6\UYR/@[YEH:^WY+GPWC-/.P=+TYKT>IXCUL6GI M66?S$&&RXNU!<4O*6I$*(7 %"+AGGO+M\\X,H#L6"M-*MX/NUF9?H-5U#675^0Y"LU."R M@>?V5Q!%J5/G^4M :K+JMN@SWF,EOP?^'#<<<$'1".2$KSW@;_1GWJ3 M-G(JB!CB?JUF@)^;@:Q$%/;!+;.%GT4WZX;OHB1P,.,2F^Y!;8%RYSWP7JY"("9Y:D^(3% M[L6R\9PW9=X'Q:SX.G]X KT^J9\$<1'149[=#\J8QRQ]#J3>W#(E5=W^=*V3 MO"H4[CPK&EB[58.H_(K"VHZ ZPZ",#I+]TX9LJ).TN\DGRIIH,'EX?FA7%*P M<.L[)%N;[7?)%-Y/'Q&.79FJRC*/8D8L5*S*U!\J*P7N@V$;9_.N1,AT$ M2&'4B<*5D\*!*(<#Y:S141*M>QR2-='3Y6(Q\T1'LJ@YU\)H@8NE:[8EU>(8 M88KB.S,GE",2ETQ)@7G/(4$&L@L2%^^_BC:679*?K,?I%&WD%4)033<<3KKA M%.YOVH5*B==\]OHI8+ MR&7S)V>KY>Z5^,053I34L=,2Y%B;B4BBTPCPGB+S.46@D^&\6-7(5SC-5<]]K:P^4551S=1-G"52W MFELR'+*:2VWK$#C.5YOL0J7$:BZJ2S6WTIU-4%VJN95N;().N;%)!;6CLZR5%R!19-)< MQKL.Q;:SK)07=IGO_4"L)@!6?C57F&R3P%19?[RJJ.8*8T[-? +ZW7@E,HO[ M^8#,XF)P.2:.84Q>P6N/;QWO/7HL_#5Z>&)S]H]/3W&\^+W;?7Y^_BUB#[_] M"'YV!S?_ EO,?XKJU*!7W?6P]:4B]H,GDZZO7KZ',]?[G;V @__@Q9_%60"_ MNMZ&]%R_Z= V6_L_D=)PHQ2F2%[CJ;KWN]54W M_>%$Q&Y&QJO%>K&WO,W8">.A$[-K#E=',SK<'5F_N_HB\]V-KY&.KO%+NQM? MNNIN7/RJFU!U&MZ29[LFO*5J_GFUNW3R\85R)R:RFG'WISA.=."$+.M=72J% MW'FK+8471EHF'%&*M"(UD_"'XR==)XE;, V6$-Y$JSDPG?J8*PVJ>[&4)G%W MS2E-1]P_>:%[!Q"_BACU0AD5^:6&,#IE,YYON$PF9?ZT(4S^$?QDH2]VO[H< M,DLGKY[H[.H#5TK5U8FBK<-XLZKGK8VBZ\Q=&T77G\(VBJX/:6T4W5!*VRBZ M>8RV471#F&RCZ+J3J584K0 Z;VR K:2N3V, @8^1RYSXBMG AY*0^_1?^ H=R15_^=GSO?ER?JD;E$CMJ48JV) M:W.*M2:O32HV@,,VJU@CUC(G[2G%VFI)YLSQ;YWY>JZ[]7P6,^:+?U^GWLMM MX/][Z[]VC>O@YR_5@M =?<9D+9O@+BW@Z9],TU@DQ@6HA"^:A@36TTV^\L(@I,HZCW\?^E%GMC=-)TN[P"14)[V MNO'QI:5NB8&1S1]):B)%2>P].Z'+-S#(/G?/.[4:9]2!IUU_(:L=9FJYO*:9NM;B"E;;:Z*52VV>K:LZE6.*T /)H !V$=257732PG M(E,O'ZQWJ?KZ4(YBLNCK5*Q1X1N(WP4S+_8>G-ET^=WU?GK1Z7/ZGL]WHX\E M10AW=& R?:\2BK"BB?K]%*TMSW0!G 0AAVP11-Z)YXSS\$*(AGC_%H4XF*K)RP">#2\>.P\> M&+/75<@T]GZRN\ #MIX#\;?<^GO*?"\(O_H1?WR8>QL 8\,EV^CPNG^&K[W> M/X7LQ!'6F1@T-2*?+"!140:=Z EF(_X/7S7YTYFQXH+)[(>U9^;L3E:5,A/U M9"9ER[RQ:AEABI-DE&(Y_,*JY;0'9"HOL8Y4)^U,Y7O\2Y;E4F M*Y\GBU++YG.=28EB24.>ZIW"K[G+&9L\;C]!L_@N8YF^YJ^^#R_=01 "<<#W M/_GL^!\8N3QU+O%,_+4KA"I:=G!6?MNU!&JRTV9%:D11FQ6I$V%M5D0M7MJL M2.T9;+,BJC*3+)3 R*2*>O%[%TH\O48PVO'_"(/EHDF$M"M7E&)&I61:Z3*K M4IG.)$U+Y]G"EEHR\^-5.]@J4V:4%@3;9%PIM@D=F?3FAUP*\L29O.F .7,B M>'W-W[SJIJ_D<#XB-S82)],71LNW#QB_>*C'?A)1;S^Y9>_ 5!+ P04 " #Z@P)-TD@#7S0- !% M@0 #P &UD+3(P,3@P-C,P+GAS9.U=7V_C-A)_+]#OP//3%EC'<;+9=H.D M13;9M#ED$U_L%,6]%+1$VT0E4B6IQ.ZGOR$E6;(DTY+L;)R#@*(KBS/#&^A)R(DY>R\TS\X["#"'.Y2-CWO/ Z[%\/+FYO.+S]__]W9O[I= M='4]1'\XQ","*X)&>,X9]Q=HZ,R(CU$7S90*3GN]Y^?G WPG]'H_[Q:?_D],.G_V:I>; 0=#I3Z)WS@R;^$5UQQHCGD06Z3K1Z MCVYO+P_0A>>A!TTLT0/1BA+W()8E(_.@J9@\[V1L?#X^X&+:.SH\[/?^^'H; M-4/G^^]01'LZ'PN/KG#H-PG/<8\RJ4 )DF'Q*/O+PJ&+QUAF.>8%EEBM_J=/ MGWJF-$,MA>JJ14!20R98C@W]LJ@7M6N_>]Q?Y2SE*:<.97>*<5#DB O6"$0D#?7<<:EY;S MNH26LT%!>8N3N3,K9]$EY3R4/1&IRKFB,LUW7.!CF#JRG,T4E=LDJ5/. P6: MHU_D4(%8PP(E>9L4%E.B[K!/9( =4@F ,'+ZA*EK+OPK,L&A!ZWQ=X@].J'$ M[2"LE*#C4)$5@I"E)#]K*6>8,:[,0&A^ZS=!0-F$QS_AA>[VIX)[9 2H1/KA M\>%FG8XJ'LA[FJYWQ9U0:XF9^X4IJA8W(%GXIKX.HM#5K!1+'1(M7 (S #7: M]@_[,$LD[-E'$(4B62@C[*R7EY 7'DKBWK.?S;.#/2?T#.,M_(Z98PH;8R!@ MQ&>J 6>JV7J^^&WBC)WX: C*&BC=3Y83V8!+H\FEAZ6,$:6]59'6[K=C<-92 M$-)S*W,) T/UD^0>U3.RBSYC3T]H:#@C!&;2=X\,ARZ%DA]:5V[ER@&&X5O- MB*+0-'7\:A@W./?#MLY%[U;T:YU=P=DWL,[VR86GB&!@P1,I>+5(87?C234W M+DDDXA,45=+VU'K.N\1R=NWQ9WG#7"J(HPK.*U+8G?>QB?-T)C9=J8]V**&?W'V)*V-_SXC"65]Y-!QM;/H:2,2'E%I"-HH%]=,/?" M,:MSV#@/@-FA4!&9J\\>=_Z*L/$ &OSY6AK8L?>C7HE1Z7A^+'*S)6X,BO6/Q%%!Y[Y,O?(:R( MAP1V;Z UD5!X283"E(T$UD&:"REA*DY]5P]S+U:Y'6X_Y>%FAC%=W1/VS-"F MD991KL55;5Q=8RI^QUY(TH:N.2#9)=@]_"GO82T,&6GH*\'Z9>O89HZ-!U_Y M0!P"_07Z*?3+.Z(>R!-A66?5\W8#L58(] _S$$AJ0&D5\8RB4%Q+"X?:<$B6 M A<.#)_1WD_^FU.F?H=2W67!C;]R[CY3SZN'B&:2[:#H%Q8:<24H6\M[9.I! M244&)DE5+48:#QD#O(@[-KP1(7%O*1Y3STSNVXX;=67;<7*T=O"(ZS&0B&M" M7^:!WBFULTE]:'S!@L%*3@Z(&,YP7>>OY[:[][BP .2^'V\PXL=T-8B,Z-:Y M]9V;-O']!)I5=Q)CUP/Q="SADDLE3>/"=D\'"A>&JQX$MJW##I0/>: ,%3#I MF!5(H4\$#3S,HODA*AF$PIE!35%!BYG:F(FZGVG,!Q+$K5D3$YMDV'U^LF9P MB!R<"M2QAZG ?NOD1DZFT=9:;^JYB>40YFRQ#J@IT@Z!CV40B*7'DT1&?@N M_0IW)B]>/^RYU,0.MUV%/]&[I,(V!+\_D="19J\&QA=6P8["VE%1]"Z2VX+M M6T31:L"HL7 [0 I!U0H1M18CWSQLT@ HS6JPHN5H??S5%D)I\?("L90:B-@D MP^[S0GBU0ERE]?C&\Y#+%BU9DYJ1_3FS!EU9$5ZXKE$8>\4SE+N6:H=&(:+: M=(T+ \FR^NQ13?3N"I9)M#W[50%'>F676=B!MS/+NDJ8:2#!CH]B2';3ZK,% MP@L#05\G<4./Z(. RY>U@% NP0Z$0LBU A"2>J+SA)D-2HN$'2-!![X$=E2( MO:]8Q1O1^\DM9],1$?[V0*E1@1U'Q3!N/1QE%$&I)KI$Z]+5RK18:X:UY M[%&<2M-.#4X[.@H1WC4'A-I99@?^WA"/2#M_D1"H\AC84IH=%X50;)48Q^K M4<+QWI"WB-D]8M)WC6&2$6''1B% 6A\;*Y&Q%@XO 8,'%-DBI(-T.HD9!U"*(8CU0K,B2DK7,_B0H? M0=$;<[[% 0%7U L5T>N=Z"9N\N6G$+]Y^1KM:&MR:##DA%]B]+J*#5')I>'99L5AG"MA-FQ]:6 MYWS;(6UG0UKNU&Y\QK;:-ZG: NR@J'L0N$4!O-;_TPG"'L@$F=Q?ISHMU7E' M4C_P8%*)WF'A:'Y[UK!>('A A Z[]Q*QB8 "]VJ:,@.M7/O%6B429H),SCN^ MVTT2)/T)] =SWTL(%%6ZCNRWOW:O.G&CV4!>8O;54L@;L=K# M8^)5,A@H2PR^U?QOQ-9\!]]H,C"4F+QR\J+$\K->-JT7_%I-^W4&AG.A$"M- M0;8FTR"*DAG>/^P5RZL8IU-$C;N9X&"5]=#>QI M#=18S: M0Y^TA_H?M]&DF1;-5"A-QE@5H F#KO2D-B9W@<8M<)C/P;D%#/6;NJIL2FMI M5:>,+_G1384T4*0D26:I)M+*N?RUE3*YU)O5]$B8],-6/LEG\:Q6_9++/&VE M0#$A:#45,GSQ545^-0H+1:EJD;-'C5DC()2RMID'"I!^Z*7>#VG.Y3RM6 MGW"9IS5(B-.A&@W..U5.PW^9.UYH[MI$15%T:(3G1%Z:3A[(L$9K*)44C:,L MBN<=1Q#8K780HYZG-3SO**&_H\L09%(5ZM;]5? P2&JG4*N]Z>HFA=BF>0#/[\3!CL)U59'ZE"_28,AV>7N*#^ XSY.O? Z)F/9CR4.DNQ3NRN M0X5?B3\F(K6_%M,*[%WN8\K*6B$RX:4A[\/03?^),BR _FFV+C)6F3N*L589 MBVOR97T/[Z"CO)K-)1=SH!3..'8 MM.,:>YIGHM+&-N/>MYG(>LJZ"-:JY'L$VTR4O\2>TL+]U'Y]>I-50\KI]@YX MJ<*KHTBQ8"]'C^2X/W&_8H:G,#]A07*SM95FGR;GY*\:7)3\?83"C%R->(_Z M4.DE@'2?4!P5JC.\'2M7.UDUXKWL>-?Z8[Z>:&'E:YZ!P9RP992+1R;UDI"X MYL;R54@RR^/1,Y M1C-!\OUTER+WJ5O_QF5 %0SGR4 D&[GZ)+QCC:.R=6V.-_+)38NO-4&WH\].C7U MIY&BA%R/6O>3RW@#&[?03F2]A=UVR7W ^)+>8F T*32)A3)K<.+PUUM)16L+ M/[UE(&$%J#?-;/K(J,IU^8K4^]3_[P!MBA!F_ET,Z?R.L_\D?V'JBQ]X?$%( MX5S7!;PA)5![ >(MAH><,049 =*H75<'2JFS[:?-L M(2FH'/%5,'83_5Y:^8!=6A&W-M*]LBU.SGO-13)^K'P/B3/ZCO@ ZA?1W)V- MUBT-WUK.RZT:=[@"BC3/'VVB TJ$E MCU8[U3[!5G^=9\I;7+@\@,%S768PDW]V40QG-V7?MRAW]I:3G%F_GJP&Z.HS M[F6P+C4CSAW(INFYC9+O2Y7I]RCP.IS!]GDU8K FM%"!/P?4$L#!!0 ( /J# DWU0X)S MR! &;C 3 ;60M,C Q.# V,S!?8V%L+GAM;.U=;6_C-A+^7J#_P9=^ MN0/.<;)IM]U@MX7SUDN1;(S$N^W=EX*1:)NWM.0CJ22^7W]#2K+D6)0H60[% M[ $%NI'Y,L]P.)P9#LGWOSS-:>\!,T["X,/>X?[!7@\'7NB38/IA[]-=?WAW M>GFY]\O/WW[S_B_]?N_LXJ[WAX#!X?'_?]"??"?2^<#R8D0(%'$.USS!Z(A_F@U^^G'7R.23GN MO=U_<[3_-O?+;1@%_G'OA]RG4X;C/GV@YKCWYN#PI_X!_/=F?'AT?/C#\??O M_I4O'2Z6C$QGHO=7[V^R\(^]LS (,*5XV;M(J?I[[^KJ=+\WI+1W*POSWBV6 MA&)_/VF+I@"!=0'_L)=#^73/Z'[(IH,W!P='@[3@WK??].+"QT^OCNW;N!^C4NS]N=^7 W3P]NA UO[N+/2B.0X J'\>""*6E\$D9'-%\UY/MOKI]G*-^#GV M _2DA$@DDC>0Y0:E30VV(_-.@&S)QF\F*QD9A9S(MD\IXIQ,"/9K$FS8Z(N0 M/D(,UV5XC9;%# OB(=HBF$M04',\I *S ,;X 3>G?K.I]L@\17QV0<-'?AGX MA&%/-"=SLZDMR3PCW*,ACQ@^09SPF\F(@9:#&21'HXO68"4*A-]B#P/;[RE6BD7?ZL@)T!#(&HG<7.QY)B9/E&+J%-0@M0_8B/# @H[WU/>(D MP)P//= ^L87&?PM)(#X#!?"[5$6_AJ'_2"AM>6G?NN?6901XFXP,?&$1]L^? M%CC@F&].2VW1K26D%2)>CC7M"D7#[MJS",+Y7)F8\3^R)?EN!MY*?B7.0AHW MD_C'3QS#JBTM5@\:.",T$EA.\=B)&&&FBC4W$79/6FMLO!.A]P4:!^K :1I1 M%,C9K+Z.(N;-$$\^MBH\V_7:L@RI;F_Q(NV8A5.&YBV["+5[VA+D+=3[\V,H M,!^'*\]^Y8CR&S9% ?FOZ@I,51Y2XJL_"MRX5/V?8>XQLD@\NYQ;!Y4]L&[' M^$F<4$!8DTNVJ'28P^D'-SB]HG:W',_Y5)?!&;X70-4U8E^PD N4U,)B>8>] MQ!>3ZADS@4@P9DA&R8><8\&S*=N^..^,0#?Y.I;5VQ/A'9.Y6QZO_.J,@!WH MT_)>=HNPPJW:Y;QKT'77>-'R7&E,P&[Y4L?1;%],FO7^,I*RX65=$71/J%)E M+S%UZO;?2:[L:!(UHV*W'#I'+(!%C:<.8_N2H>_!$K*61[>JG]VBS.1&;B7, M941%V=ZWF$(1_S3D@BNRP#Z7^[-+5:O]4=Z6CMURJ="KW@$7JOK9/4J2;";* MF))RLG#@[5CUU^PVX8&7A;1D_M :+Z L#GR98Q%_E02TD!<2=SQXUO,NR3', M^E D !' G[6.J4SHD3L494(Q]_\T66#.GSP:*?\E_BF.$X[1$^:G$9-I&VDW M%-UC*OMIJ]U!+7P)7U56T@3Q>Y6:%/'^%*'%0"(?8"IX^J4?IX =)AE*WR6? M_]PT7,%J+09J5,42!J.1JBYOA?I5M'*$"!!UBA9$()I3D3H8U16MX%%^OX[F M^$=[=%5(QEH9&U3*; BY.CQ+BA"GB+$E: \5;=!0;U;7"BK]TJ?#4E+#%H)D M5I4.P?-B-F@]PQ,,$NR#:LLM0!_#P"L5_LIJ-K" .4 $OB(/4E^#N3(EA=3'C,<;!-5D%U>SC*5<] L*6J$WR7U,]F82^^\*@R]] M,EL#B1 O>KC49MCE\)NM*B-FB^ M1G0ATW")AZ]"SC/#;*F\*D0_!3[ARD'$?J7:;=J:#>0W8H:9B1-14- RO97C M4%S6&M5UK-:2"C;H'['$BJYT%8I*6J)X@4B:95@NVL5E[5 =+C 32YG5)I6^ M-!L6TEW4>P6E56Q@N,5<,.+)L#^X[.6<+RYKG^K*^:DM;H=VF:""_70O"E:9 M:!ZIG1?P?HFG77\-*MK 8VQOEUG8N9#^D*V3CIB7-@C_W(CGKY^(34H,>#2/ M-Q+ZX(3/T_H3%LXWXH!I9Z$N!-<+&9"LCE__>'"PUWO$\N2Q^AO^6C 22G_M MP]Z;O5[$@;AP$4=$NXI./WDRH#^]!J FGG@&^=UK@%R^)*W 'AZ\!K!9/"L# M=O@:@%4%'#.X;UX#7(V7D*$\<@WE,SLJ#]9P9MK H5$V7P+6LTHSL*]N M<$T2W3/X#OEX9O!-]AXS^$TV5F_Z-0JE9L7FEI)S5XP#*R2,.'?%*>7 M?A SG5N7S)Z ;IBU, ;:\!%E3'IR\JS*D0-_T$EQW MAKDNKV"7/=KG8*P,K[&8A?[:5:$&O-#5M8<*N)\(YPG([D2;*Z(K;8?R6!C* MY^+S4G8H3<MJI82 M.H%#)0.;*V G=5#=Y),NTY*7OQ,Q.XVX #%C(&U)X(8#![D*8VMS">NW9-6_ M>0&S:"TD7C37G?"%]H.3294U83\S\#1)E?U7A=G( MR7 RXU*[CB>;"*66B).Y7,:(JRT>)Y.Z2O$;QUB8*HN*E0/*L3Y:=H+GTRKV[ILZ=EA@/4L>:!P_4.NY B#W,@- M>B;3$\YP_/^5,CY_\F8HF.);&,[SR40]A.R4(C)7 MZ93Q/_Q_1W$\(-$=R8O%QMB;M-T-KB@?.:T@4PD:\T\%%S*(T:L[)_BH6T9L"F?R!@*I\LXZ>Z5C;BT!/DH6Q@:S30 M(7QQC'(+?$4-= C?:EXUQ5?4@+6KB*0.!!I-]O?UY:WLI\97Q\MU*SU9(.1# M5,!IEOBLZ=)F/.&V:[/;7# 7V^W:M,@%#B3#9/,P]E5$20FLN3JJVXIEI-G# M NJEA8K+M TJVL0S#M4C.MG3L5C>1A&'B))?_ ID1DUT F-UJF!IE4Y@4+-" M>R.,*:R*5BSEZ:RF_B7G$:AYLPE66<\VFBLY*RKNX=27MTW]-0E4%%L]'I,< M1C 45C--I8[1'%Z=X-DE5=<]M&Q[.'MA2.[0*$FE/YKYIEM2PKS4G^5\T@ M@^" DR?\6YEII4%)SOA2)/8F9.73+8L.551>LVEDU^5,!F')9V\E+(=@3+>6-5<8>FF0)5LF3\3 MJ%6TU\E3*=O!KWM^R:$ T':,,3]9X.2YONV8HPMQ.WG.;]L)5'%ZP,FS?]OQ MI"0WSL;"C*59^2LC)6QAV MP"K=(1PW;V;9SB'8+BE7O'YH>VN5G_1<^+2/:(A MCY270/C-!-9U#D..$O?R(WY,%#2 !-X%\$\/QZ\-K"YBO@PF(8L'P,+EO!F$ MYR^R!?F;?!PC]\Z;83^B>#W@FGPK( MR!U.!&87Y &/9RR,IK,Q#OZ)$>-*A\2/_ WGF:FG[0+"EE::"T28>LCB M&DPM^+NCZ_=F<$@93"*Y:"M;$@O?T[1R"\\&(;\R^6)9V02>UUD8W8M)1#>)K !5JPV[;Y(:#%GY&[3KHNKDHE";"?5D M1*/L.WE!60,UFGUS0^W#MQ&0 4-SA]D#\7!2XF0Y!F+ U49+4"U6??XT(T/F ML<2/[O#?0A*(ST T_"Z=O%_#T'\DE'9W_=V('*?W.6ZNP-JB-E?CLLBWV:)F MTH+-=3JAKQ:89G07O'60L*0J2%Q,7/WZ;=$+;)"W;:HP?^YZYBHR*ZI9D@)) M67K7=*44%!6V^>J-D?1J"MN@N]9[T.6H&C5E[9:=NNJSHE(G3,4:BT.1^?Q< M=ITVFYOSHE#_.)DLUY 7YNN*DUER6TI(,XWI9!+=UO)C;$^';MNP#0/X=S5]L#]\ (4\Q1^C^3UF-Y-DR&(,-Y'@ @7R8@0-^+JM M= CI!G%*:NOAU+1A50LW'-B\)J[),2=]A!;8U(9*<7*_51T>!_0 @3Q@>8!1 M>@;JZR@Y9QY_[.C:IBC-SL2/6#AE:-X5:C^& O-QN'K>?O4T"[]A4Q0D1Y>D M,1U2XJL_"G+QTE#]&>8>(XLD/2^7FP>5/3"OQD#H"967 7PU2-,/G4*I^N1W4%KJ;*QV>QC*G']71*DFA@[*TSEB 2A,GGK2W MELH.MW5.,76L$=II4D)S*"+)CLU54G[P>2 MI'L "G_\#U!+ P04 " #Z@P)-=4NL((<7 "Z3P$ $P &UD+3(P,3@P M-C,P7V1E9BYX;6SM/6MSX[B1WU.5_Z!SOMQ5G4:V)[N;<>TD)=OCB5.VI4B: MV52^;,$D).&& A2 M*W]]0> I$B)+_ )4#M56\F8PJ.[T6CT"XV?__:V<08O MD#)$\,>SBW?G9P.(+6(CO/IX]F4^',]O[N_/_O;7/_[AY_\:#@>W=_/!ORSH M0 I<.%B -X+)9C>XA4N$D'#AY'\-=Z:PV&[^^9QL'X8^3_ZK1FZ8G+.!V))4BJ@,\AL(?X:ALV& MXM/PXG+X_N+=&[//_BHF_)D2!\[@ K>\<\LKNL8THM-SJ M8":'J@GF+6*60YA'X35@B$V64\IE(M]!8@7'V'Z"KV/+XO+9Y:?&E'*H/"Z] M!#!L;-MRG8%38\,V/7UCY!"4_O0?#[T 1\Z&[7O\ IG; NH5INH&37%FV9X# MQ?;8?VP'S?2IND;SAF"7 LOU@/,(7(]RRD/.E \$KQ:0;CJD0@E(&B/2'4#T M*W \^ B!^+L%5B\Q16-H!0*$S: %.=F?'2@%BSN#+Q![,*)YLB%O51G5FM-V MCW[TK7V<8W-I073*>8RSWMPW4X(6U[L%GY:?06!':"8Z.Y4&QQWXB80BJ;55<1V@>M,3+.76)]XX-SZ+C1-'4 M%KM9?IUZU%H#%GQLE'GJS=HP#\EI9W ;3DS)BH)-PR9"Z9EJ(CGC_7Y](BYD M"[*W[/>&*)O0%<#H-SD55U49<9 M_T@QXT+Q?PN91=$VL.QB9AWO;''M=@'? MW&N'8UB22KJ@[#&%PP_]H/0>VG8I'K.I[O$M?'8Y5(^ ?H.N.*"$%'9WP;PEPFP>+ZN8C/[F2OYE>Y+ASM4BG5JFZ!"D7SM(\E"H*)PJ M&ZX V([$L32"CLO"+T,_9XG)5F3V"Z_4->2'./3;+< ;9)_> M.(T)M?GQ17?W_*1@3X3_BEU^>'#X5O>8GQ:09>VA-F?43T'?]?\(W36Q#S( M%6B1U5-6>B -U]BGGTP@S( VV5(' MQ'S;$7^;BDTG(,FG)M]TZ_N!282QBQE)=&UAA1MW8 MZO*_CE>6?^(0$=NSW D-DE#';^@8[LQF'<,H<[R"BX6W@3& M\US.5HDUT %?$+ -U3;!G;\@KL%ZS.4;E_+]ZWAA=@/_S^;Z0 8B54;2@?'> M$_* ,)2*9P9"*0VUPBOC1D6P^HUTP/D+%%=JH3U^X9)L!9\\8?],EH'YZ2>G M3CQ7W'X5;)"!2-E1#,(T 5R>#Z7<&'LL(]_@F![B"^A^JL!77-;M'?1>\@VL MX*0*)R=%?J$!-_(@E=?/?SP_/QML*2*4VT0?SR[/!A[C8)*MG[W:4S3W[I@( MT9]Z@ZB2QRR.?4GFCVCRE]\=3;)%7T25#\92I=!6$10H4LLC1"].!]%BK3]" M^[+?:"L[&[< M*BJ9O_$53$8J]NA=:I)&,O\FC36S;;$X1L<64(C/^7FP8'Z6Q94XJJ']\3($3@]X4K\P[!5+D>02D;[G@LNS&/R@*]N<#T%C 37 M1_'TW-:U _TIHZ=%X?):=A4B3RIB$#Z!#P;0K=$%+>. MW\I.S>=5Z].5NTQ1*@9QBFRA=8*.LQ*DJ;!7M8>O"E4DA4,JU)/J[6C3?>1J MYTBP153D@?X87O*6Z#'230CID#V*"*B? 0K#0-V1@ZL9)EL8M4I+:U"?!)3B MCO@1L$E50J%#;64AEV0YIHAB/QWJZ1%HN5>8TMO6IFI*X>J@KO6.G[B('%]G M4^K2E3+\"-[0QMNDTBWY>V=0<<&1"]7![SKX[I%@N/-KJ-UYV&9C]P90ND-X M):N(97!@4:^NZ#L#>)5EST2_=0I-YEK'?S4.(DU&^8Q+#8HL468F];A(_YHK M'&L-^9T&Y3DAY22)ES]FZ]Q3-\-95WJ$^C"O"74/S[*BTZ^XBQZ[0UUG.TQ9 MJ<.'AML>W9.DBOW1B9^JG/(K+*$T]9T=+NR6H:EX.U$KM0J[8ZZ2"B!'RNL"#FJ+.AY@/ M%5(7+1$?7[S3=PNWH@)@OJ>&E>.O2"A+A$]=7#C42KUY50LBGJ9A(E( M4*V$3*RCWJI""SY53EPDI:%^>&\X@Z^X7/$OS>5N"86.)X:/)M]H)#:S6#XK MTE5E!#,QS"VHH=A;!V9?YI_)"Z18L-5\*QY;HE!4YX64G]\,,O%V301G+G]6 M&DH/SC)K5AS^XC4H641W[CW;Z 4)Q:D(2Z7.>OVIV3(^_=Y4MB32KMFJ>4N; M0MATV[K\(1+'7Y7Q];M\VJ- %7&GW9QMC1ZYAH9VUTSV7>_R&L?!)7#5X_P$ M0P,-D;#0OC,Y2- R#>*6H?:@@?K%J'(Z;O:Y:OR=J=+>H+ P@@><@"I(B,N4 MF)'&*U?[]Q0?(1!_FY65&;YG=T,VSP@'B?7[E\G&_/!%>!5=%P[>]AEOQ&6Q M&;3("J/?,LO4-S2XKFS*N106?+O(Y>-\A9;P'O,U!-C*LBF+^VG!AFM3R+T# MEB#]+B_G-ME0/[RIU\1RF_809DT^(J%8<][D"I-?I\._SC_C>JS"6VTE M!JB=894J2B-)F^7-*M.S;1@SLM64>M6'#;W J;@&LW@E\M_^VLPAYDK %\R$ M1@%M^=K;K0=YH\6:> Q@>_'*F^T6?.#,JW0-COT]B[E>K7].XN"YT92WG#,P M*>JE.0\Q\_PZ,)I3);!^MY%:7F%E%/OB&\L[((.TIR8%E/:TC[34R;(G6$@7 MI4/E!+TB%4EV*BF3=7!7L&"T.T':P[XIN]9DEWM-$A4J"B:[UVOB7L;LT>YN M5TDB*V-V9"L4/7(1!@6+&-^L$+T(]&0A(S>HFQHY"9,-11W*'@ >?=/R>"MB M8+6B<"5EYV09@%+PF%51K^_/.JK".N44E*JOK'>F"'EJI]IN@[\3MD4N<%CH M;T_/Q,AKJ<6D!YC+[XTB$;-:?W^BR\ GNKJ#5MNUYM_=DUV) UOJIP\$8+$J MP:/K>!4=FVJI?>5&:_#B95%5#OJ\]\H:@3-%;'79I,77VSK_6,4[3ZW M8;I+LL:#&^EZF%&5D71Y"LQQKHR&E('FJT;W4EH MH*3FD)XW69)8IQDQJ$')0AVG;%3)>!?3X7D6M+C>B83!R7(*=ESGK5UL+SA+ MH.W+73O3%U/06(==$N6EY[H/$LWT>H\F= 5PD&5^P 7! L<>"\BR21H:U"0Z M^-Q//,J/S9PD..7NIN*6FWQ68H 3QZ^)0F51H$A5FB8D7ODA]/IG#DF93FXU MWXSZ2%HPAHZ@=Z[8/VRC \K%&E%["JB[D[R1"VUZVZXO"35S2J7KOR5X\P1U MW^8I7$W":3PR3[39A _TI&TNT\K^!=+J[-EQ5Z/DJK"K,FQ]1\/,3D/ MB[^;(KR)GPFQ7Y'C&'.%400/728NQ]X1.@<.?"*NV(N3)4=L2QAP/E/B;3-T M8M7>.G3[E.60_Z0P_>DT]7XGA8VF'(TTN+*=2EFM#8&\R N8V\40'*9,Y7:&4+\'8+150("5-(9GRK(UUC#IU4BJ7!<_64(3MX M\7E! 69+2"FT+PJ(H#2$(3A&&?SW-C^YT!))LU>*^D!VV/PHB]$8,P3KX7Y M]2'\ENH$:6B^$Z%>[(?N2!B?M.]TO,>FZ9N\0AJ]U4."/%A.'N2P*GU*LQV*;0 M1D"4NY][SXSKRP@X;ADH%?LW!^]ZQQ"?!4M/0!E "SHV!N$,V*CL6N?TJ1\5 M!SO!Z7>$AIOQP&2804=$+(E[< MD,P08@6=ZJ_, 4MF":O45O7G3E^<3"!RF^O-@4ASE%[O8G^I)4 H#J,G^T%& MN',]@&EKE+LXE:Y@")<\0"HO#2T_#[Z(D;*?MPP@2!5Y.SC(5Q&F!H; M*XUIOH#;HWRI/PT@+RVBP+&=5F8CAT+Z8_U*R0]-(FU$BD-F_I6*]S\]NTKU MU#OAU"I5XI4Q'_J0$U(![WP3M ])(5466]&V[4-J2 7T\PQ1[0I$WD3M!?>Z6=]FHCH1L7XZ&6(5.3PBG'NE\F?)O-I.KH@>'WI/CPZ" M\9'%:&[2L$YR)6.?$<7ZKUAVE:\0T:S_>FF'T>&(;/W79TL&(R/43T^O;2B[ M+B+1Z2B^RFG'$?*GHQ>7R)"(T->DZ5:X$U NO%/D&S2CYDBG9"B(=Y1]DES+ M(V1IH:5 ]5?, 8E87Y>"K^;P5XI.'5[[.:"-=MY6<_'70[.*4U]K]9>@M#?7 MXO@7ZD%;'-&8098L%Y39U( ZR9FPY5Q TO-H'=EL.#MCV_]']'[=? UHG.HW MP+$$Z@PY/_XA0G_T#5@R.(#W"+'XZK4$W3O,9]1/(,AFVE$;NX2ZQN'1M@* M+W#J^)6EY->]8B@_&G,KS-=0H2TIQRD+Q;H(SI$@!4R4$7I7[%P[(V:\D0LC M[^,S67@^]J;))[1:NX*H60DRI7KKR'H8OP)JB\H .5D.AVVT/-PFMZMDY1L@ MJQ_Z>Y(3E1_N4*CW=YZX_7C/+>"\I_]*CZ,96Q^\L<>5>)KSBF->#RW9V9NM M0W;0%TD3>>#F5CW);M]5)>I'\(8VWB85RN3O];-"N7+C0HCE_^_FZ.V)X']Z MP$%+Q$_/.#7BHGN,X^+C#BWE$+&>B1Y916V"6*:OC"FE+M<=7PMUBF#. EG^SU>^R@BO_$AN MUFWI1J?H%8U\EW#TJ!:;N&M(%VN ?9V+?>9#N.P>^]@U3;^RTVNC[7,Q(^/WBO,2D8JF>"H:N%?T")/Q FOM!2!'OO%'J-P#35.I:+I> M[;2#*.=D&;-]@YA6TUNO>$(C>2_S=(_\.=A6TH9;F4K/'1_A(F7,@_:M1_?' MN+\M,@V_[-L_U4:K;0TWY 2H:.6L>CFTC+C:HQ"]3A>]8;9^+8=7'S+D5BW>Y:%,?5Z%C[HE'(#A.TD'OCB3Y5N&XS#$XRC2HCT!ND+254..N[0CK+^9:"T0 MY4C;TYZ2II,414)\5V3*2.LJ>WU9 MXP43"?<,;O?G-EE1L#'GWD5T-7I? 6,!WGY![GI-')N?H>*Z;.IJ9]T0J#'B M*=YZ2'UA>\\9"<$:?UH[I97F.PBY>97)=DU2*BW/,:V%O@KT@I4)+JIOFMZV MEU!KJL[:TUS?[SDZOS>:Z:I>+$V5*4#"3*EWF%<:2FO%YB-!I52Q.;6/MIRT M2%E,\6+DI9_E=S0-GZ_ \3+O+13VTYM;]3WUS+C$/",RO1)AT )E?_\$];&6 M>X)12052E!&#)@<+&T(UD) FA_/*8%I)*S$Y#%<"^5IN%NUALL)X0!E@\<+!'FDWH"F#TV[X./G&0+?\0E:W89#GE M!S9OYW\*BK#=0F91))'Q:WP%-5:GO+.%^$08S\-S:'%54U8*QO8-I"YGY 4%0A7Q2Z5&@2P3E[0M M%.49;]):W@%$I2$0 6OD'@OK_\V@!=%+4 +P";HS^ )Q'/K3 -XX/DDK_OH/ MPH_%K_Q7P30^ &_O",Q&E[BK60ZI9KQUJ=?>N?)J6W-+, MVC?AF*"J4!+7++*69*E;^^D/3[Z*( $^D.SQ8U7]U?7U=__VK__PO_[E?Y^=H?D^3PX]NW7[Y\>;/= MQ9OPS2;$U\IZ>$_3] MY@?Z\#EZ'P8!]GW\BCY*J2;HYN;J#;KT??29/ARCSY@*BK=O!"U?*DBL%L1_ M_"ZGY=?'R'\31D]OG>ET_E8^^-T__"_$'_[Q:^P57O@REX_/WO[G3S?WFV>\ M=\^\($Z(-(47*;&J5V?K]?HM^RM_.O9^C!F5FW##C*,A(%(^0?]U)A\[H[\Z MFSEG\]F;K_'VNW^E#/\E"GW\&>\0D^''Y/6 __A=[.T//OY._.XYPKMJ*?PH M>DO??QO@)_()MY3#FG*8K2B'?Q2_9I[U':)/_OSY6JG0ND"+O_26"^G3?U#/ M+(B)OR8XV.*M%)2^7F,N1IU9FA&E9,--@:!/;1Y&E8HS6CLW?F0$C_'9D^L> MWE*??8O])):_.>->/!-&_D?QZ]\N-QL"@(1 \B[TO8V'X\O'.(G<32*Y,1W_ M^)W&"V]3^>DK!0TB'(?':(.-3,(_CZ$4O_F/]*6]3UZA<08'9S_??X>\[1^_ M\[:_S>;+B^G%S/EM/EW-R?__-OMM]MV_9M20)(=^E03_^U^X)/TJEY" A&]L M:.BTT_ R*OJ@&VVDI.3'!A7%$V\W(0DWA^2L\"EW4;C7\B?)/]2VRELX!,5W M[JO[Z./+8$M^$QU)I/#<1\_W$B+DU3&*<- *2T*]C&F(Y:!2ZY7RP+H8B3H M(S?8(L$!Y5A,D& R# [#Q/4U<#B %58%*QQR5G"%%?#7 PYB:@(FY@A@:N+E M%;C5MN)8@?S>BS=^&!\C_$!&^7=$FO_IX#=5U$8&\ H13<8?Y$,["CCAWZE M'!%C"3L&#VP@I]% 'T0<&'L J$&':3!0F=4L,.RW#.S$T%,&]?U6B_F'KQO_ M2*>IXD_79-:ZQV1&JAK)^Z/;,_RWX>:X)W39E&THH77]?;9TEL[ZMWGCN.?G M @*6[-._>DP E% )T(:+\&:0 %$5/*&L9A9&4_;I7[D B$DP;$:EBJI0EG.T M\RR(^-I[2**1ME]3CR 9,YI P<^5VDP(%! ?>/ICF *U4ZP2@2-*9O0G+NUA M49.*?,8;[+T(E'["R6?\@H,C;IYKM*,!DV+H"ZCK7//%]/Q\6DHGHI0-B_ ! M3LBO&">T35F!9 N#&: 8-C(VB/!!A!$2G,8QM[)A$4=E$;=H$>#QWASWI;'= MT("0XW@FZI^B,-9<$%6\!#"N5TMB,@R>+Y1 G2!&="0C?2^J,@2R]VF270[- M8QCZZQVR*@6H,1Y$QH MA@.[,=*#=BM3[>""Q2G&ZD-%R29]S!GH3/TJ9)N@A"SY*?:VM&:&I-]R;O]: MMTQI\K[UN8*!<-K+0!?D?^;I/(&M^&Q2%O3'C$>Z]/@*M;(XG %F>0-D+%"! M1[J*^ JY2#B<$1P=+X";%[3 =C8G,+4:4-:BM:/2_+S=?*7;2C2)X,OE>1&! M^05Y^$2E%_T8N*[SVS/C6.MK7C#7LT1?H_>=^TJD]QE],G-_AP.\\Y+:O46- MUT#&ZGJ9](/S:CI=%H?H ZF3LOW(/7N+Z5^%^ M'P;W24V-7_.+-J'3*(U!.D=^$C!*J2)*%GD!$H0)H!AIQ&@#H:IOG9V2S@=" M]HSHO.&$0?&E[:8%K.E9" 9W?SW&"T3*+MZB+Y0\]IF-*+%X]XKV7N#MCWL4D^G0D<#A ME::L_$EAO?#1]YX8:]A!N#NFBM&CVQ< #BL/X6=,C>:QA7@^J[$8_+[*S=^ MOHO"%V^+M^]>?X[IG/_VP%;+:#E]EFW-*2R" '6,SE:IRDK$R%Y&D4+C\0GLRD#3J?7A\3'9'_[2(H&'1SHB&991J"V;@LN1_,[ R!FSN M(EF@RG*@01;_JEI# -AB<6H,NK5-1YRCZR,W-^[3M<(C&UP&V\^83@?)E.A+^/ <'F-BVP^TM\L=^6H_X?TCCDK. M8/JVY1T] ]%T/=197LQ6I]*U/_VXA)SAA:C+&K2YR0*($ M$*5@%R%=%7#T%!C:U97.09VY6D>0O'@?1HGW=S92W>Y$%[7@Z2J,$[JY3D^X ML#%>E6WIOFXS&]:4R63#ZEPFPCG:*-RA]_@Q0==Q?&3Y(&/!XF[*!&CR.HP) MG"H3'"*\]X[[>,+._?'Y #6!)ZVRH5Q!DU]#'R_DO2:6["'E9=SHU#E."/F/ MKA?]XOI'3/WL'F^.4=UB>0L"MA-?(^FTO?/B?#9=R-Q7L&!@9(Y(N2#&AL,U M8S3T@K4R#1[2#+/1F:$^&1[2%D[?MK"2(+>* 6F.;&Y/D+PC2+RMYQ\3[P5G M8O$^&7C[D1B#KAX>$Q%X/[A10,)N?(?Y)BC?05:-?KW0MIFQ]"&PR5+TQ4R$ MB1SC/ @D:[XSE6-.!WS)'A'^?/%^@K@(0,D.@/6<$^O%F?6"D.WR<0MZ 4J> M:4\$\AS>YG< #YBN'K+"KI@*@C:NOSGZ8 =C!H%F(9?J[4.!1*PXQNIY$/^C MS9C!.!KL3L\6$O3L3:"SK&VD9J=6'RAIY"IEMX:.@AL4W#O3#9=%&$CQOW]Q\>[N&=N+8HXU1+.*=NV)8M/&/=I5NY@Q:YR"R.BHTF0M?M99YH#.[:6F&[_"R4J[BM,]V871&:-%./&3B21FPG0G! C$>D.#JVP!.S@#L M^ MPZ$&@,>HE#/2B"X_.)&VP?"Y?*KIYS_%IZQB;$\8X.X[@;KP 7R=X M7_;:IJ?M[HK5B:+M">LI799D6V",'KK=H3Q%]"NEB1A1JYM=/6HWR[0+;6M7 MMX?5HXI.^P]H86M*!V)B'ZK1)D/@_8'6H&I]'_XD.,Z9&-HU?O/U^7):BW%& M#QK>;92:P2AEB.HVFM4A6JT9#)@+^%$#.3,#1#KZ[AB30!+'EYN_';V8';EG M/T88OP_WKJIK"2*+Y/CUWO*$GA=RO[_'VR(]BUE8/]LL#%K7M!3<9 M0YQE7?XIF4V09,<:(F4,08L'(8W&[^X09-$V,PC=T*!MCP['Z! "-QLE,#57AK4C8WE1JHV,VK=$+>=3>2% M&AS<'"?T5\H*O0A>K#;_27"S>C+9AAF4,3)&C!7Z)6^&-"Z WB!FPR[*W"F> MU!D&:MFL2VR0:VJMK0J9=%V%^TE<1HVW D0,[= M47P9D:\2//%C&.)NDPW]/4NL:%^VIX >+-/WHC;$8<'?0F*3G']>&Q;RUXH+ M[O+\58Z_/&N%,A%&$S:&-Q\OM6RZ4XI:,,KZ[^8SSI$%F0[X:P@_;;_%2 )3 M)M7UEGQH;^>QVU?YJ02^%4(;P>2UC&,RT=G*:M:ZTUK#\8,-7_TH80#)Y7Q6 M%]$R>5!>("2*-Z5(+*TO1#\N558E/N21M19Q#L3.+/2]QYL(NS&FQTK'<^)B MO\?O)/SE_F#/K?-,O^U F/N#$4K+BSS#1,/<'W\W(;&]Q95QT:\W MTS<<'"O0/7"$+'^>;SU,7@<)\2W6EM6"C^>Y?:.!,:>"$3[+I3/]1L2/7N E M^.S&>V'W?*8B?OMAL;V]63R\39YQ1(*A)/([2Q(KX#M4 "Q_B&\]\GTB7\KR M%/F$Y3<: \MZF*Q=+8>=*&>B_6[FRAVM?9(6!IF)?E_!4(7HH2)BY8?Y_81% MNU/G:K[??(!L-YV;#[RMEH#8KNU/UF@;"$312^H(\.E_?2!AX,7U M"=3CR^3*C:)7+WABC7@5'UOO78L8TQ)(WPV7Z6D0=JLD':/9#SG:$^0F2)+G M[9EA@#>$ZDY!=7;M(\YH0T+/R&OS&-0WTXC J#ZL6/,"/.R,CO4MIZOS!JR! MGEOL34>GK8[ V%(<86RP"Q2*2O+0RY>'V0U![^Z)-BRTRBY6'T_3J.V$@ M]G>27&#R:WIE#5-E0"O=)VZ4C,5.2W,[/>(G+Z#-U^NM93.*=@Y"Y4#;S?S? M7"R^8U]1+O#(A?%K=DT!^= ?OFZ>B3/ASVZ"/^QV6+D$8%F(;R7:&VMF .+S MN=/K\#!!7%J4+O=]+P7^88)2F9$4&E&I$1<;ID?UJ#\-:X+]"2=HFR]"&NM, MSWX Z2WPMON0G4\#E]/Q@(CP@L4]SS?J%I.:[]D][ZLGE/XU6P0!XN:UJZK< MPLN(6SW/.XB:V8PZ/\DDM%&..&PKRD'T=GK1V\+97#.DBL.X!B:#2OIRXE5> M=U[_K.44ZD0 H^G*N0)E,+=U]ZE7-8H@;^/6 M[FZ\'4D(XF-$;YZM^9CU[UE&3*TP!EXVF^;F"2BE*BZZ)#-Y2ABEE.&@U*?" M E9BT\CE9V.)KBSOCE,;O$@;^-0&7IT-;,).RW_+$&PV'P@<<41+(0A]'-_N MWN-#&'M)_7!5\X9-"*K%,/#%Y5QTP$,X+0(UAO2CIME;2&JV9'+""J MP3(@6 KW>X]GH'0_*']H6_5]:]ZPB26U& 9NMIBN!)8RA4 M:;AITM :BII=L("B!K.,#$7OO7CCAV3(Q T5;V8TQH&T4\%,0OS%6@-[*.,! M7B8WI"4J,=K2$B- KMKM-;&L,.AHT:WJSMB2R-CP;=QRCTZ:UG-3@(-U(+1B MC&:,CQ[-E8T&.Q@/"L]A<)\0&:[<@Y>X/KOUG>X/X>@%T\OQ/AYI=\3K.#[6 M+>\8T[&,:B/A3,:K=6[D#@/$N-#M8L8'<49("%Z-]C91WLKYRT W-V3W_=&,;=UN:-53EO<^*T30OY]MYBP=L=.9PQ?8 MO7H]*',2+(#W+KMKY!AK9&-7L@8?<@]2I3KP0%R_?'OR',Q :KR*N9I6^C[L M^FQ'?2H\?PQ+L2I74@Q;(UAV%9+,',N\F9M&OHJ=#;D84W47A4^3NX5/..O2=9I]*LP /QWPB M>WE,GL.HI@E]W1LPPV]9#),]PMFJ:M@5ZS@92?"AMJ..%4.L^_04X2=ZZB#F MVKK#:ON"H\?0EKZS"H6UU 3(+52X4^04E9891>B@2U[Z84,\#1DRN A&V6KE M\B^G-D&2S @57AC+9K*MNES)OM ^WS53BOX$V!S M5<9>UR6<^7HZ6U9M:3 R4+L9;72H6,T=4 ?-*68;12J6<=6*V)U(%IS_=.:8 M:0L\B-4VV2H_!C-8F?:/NEA5;%A,^)+K:#*[-DJ=#$=_0/_T9CK+EEC_@(@P MD^ET>CI#^@-:SR?S\P4KUR$_GCNS8C[(_I ;UMBV/[TYV'O!_NM(!CEUL8YPY2Y?P\.VASBE)-H!]F(VF\JCRBDY).C1MG-X MV"U YAWO7 M*P]#M8^"H8#S-_*:A0('G-0HD-!*JVHLU&@%@X:B"EY.F5;-P&$1 .V[MT?J@R-!H,9G>8A!':+R[< MXP?WZX>O!QS$^!T.\,Y3G?=M>LLJ.FM%,?#&"VUS9QO\*>Y=-TR2+0FLT"B2XB4>XNF^R"FX:OK'P- %\J6?1= M[GPF]Z!2EZ/(RE&=H$\XR5] !0NRGE0>-\J:7+,*9K6&@<'9(<(;CZV+DY]] M3'^X#+:7^S!*O+]7K9<;O6H5;\WR&#C@:K:6F,OH3E!*F6W_Y&E#0:YWK9VR MUDQ5MT%5>_#3]]@B!#4-!0)#+Y8UJ42,V]UG_(*#8U/SF*:W;(*O7A1]#[R8 MSL3:29$D/+LM90I^>@!A<==42 # MAYPYLT;T,>((O&G+$*HS+-YOGO'VZ+,#5+3OOB \0OA5^ZP&""N,! 1%<5CM M=G<5[NG,4]R ZM-5GJLP3F)6=OGHQGA[Y[[R+C.-HV(7HG;!VT%2 ]=>R.[R M[PNG _,\D6"*&%=1G7S&&"/)>0P#KSV#.8,;S&+TZ %FI;#2]4.,.MZ\RXNM MD11THCK&B%,MJL%$\GSA]!-RQI!G6+09ST!8:?9U0/,[LBKO&\<_\M= M>@R8_N&;""WUB&H56VKLW;F0];TH&+T,MO1@??)Z'>S":,\$4>0?NF_9+6W5 M$LUK7"5==D\+IXQRI*TV&!A QYF&CF#IT# J.]U5ME ):P),41*K M;2L+=5!2%EY[PF\<^TA^5ZZ(K7_64B644@"#,>W"697 )"J&Q!V!C)[]4JB^ M5'/:J&:C%JK1T60Q5+TEK$."EF/I 2)[$@0.*7LCCSFO!@,KGQL%%-JJ50F$ M>K7LP^#$N:I!4+2!10C:SDE]3 G#.W$)\1TM\FXZ; M=XNROZ8*0BPA?G C>G%]+-L9-FQ&*!^WN.BGDL$DT*W%:IZDE77B!-\4Z$D] M1UZSS>O,?H1<56MRLOQR6:WZ8T#(.S?V-IK?CC\+B TF@)'GS%7 F"!&;!R@ M:*.74]#K0/2*&_2"PD?!Q>K D9EA-,BX39YQE*UY-^UNF]& 1I)*,"-/7#0@ M;((8F]R50O [U4-:@^'R+]A[>J:;9^X+CMPGG+;Z92U*1C5Z:;EY(VIKC3<& M-+_W_&.B[ &I>AH0H4($@[*(Y72IQJ(@-PZ\M=--.>+5Z :%JI*[U>$G;XPQ M(*6IH$+]/"!:VI04.LNI>MH$7MC0EX;Y+EO\;COVXX>_';T7UZRY?Z4+%?W]5&UK#OX9/WET M)2U(/KG[JJWXRL>LNGB1MX%73-/U*NX5&2%$*4$Y>2=]'#-][+EYM2,5_;Q" MO>7A+ )"C*1BW"5U)*P"UG^]#+,=;++A84+G8* MB2HS](",.$IRJ"#_*B."_$I(\!-.GL/M=?""XP1C.OQ4PD+C!0O8:);"P)'F MLNJ<4^'-,BDE((#TKIQCK-S0*-%W.PH538/ C21YL:B%;[\$Y.,^>X?&QK3Z M[UL?<32$,O'#^;0P"G'J*.^5*0/PGK1#&2 _7.VY <)4Z4-*%7D!^FOHD9'L MA?SB.-!M[AJ7K@[F"'Q'Q^4]9'#!(%[*!W9#U!38IV.ZKMT@XM9'UXO8O4;Z ME76UKUB,3G5R&$RA5O(4,Z7'[_(:585M-LZ1%K-^8-I'8Y:("I M7==69"#=Z\*(B>X6^HN8HECT&#$RW-"A1G&/M-9;HPHQAE<<7]!=8.WP8O\6 MZ@&TU8XJ0/=5#Z"R=C !O=G:!*)Z,03V!NR/7N E)(Z]T+M"$O*=/"+-91SC M)/Z$E5/J^I=LIO^UDF@/9^?3U;G,_QG%,T829301)\HNY #*__M452RMI]JY M0KN@6CMK^;^6-Q8F ,U6Z3XL$^IW=%WSX4O(?N;K8/7 ,5,!'24,J" "H&V9$RASR9"#O(/*@CY-Y'$:E]#,-/-4M,Q M]HB01OR?PG1,]Q^Z9%+3K^TA4I\_X0!'KD_OBMGNR3!"EV%I6UYQ59IB&&YZRV+RTR"* M?DHPFYZ+A0Q!DE^"5" J+_R#27[Z5=4IJ^H65<6<*NA2J*9WYG,A'2.! "T, MMU\\7_EMY9]M0D?P-$B;+QS1*TF^"X2$=I([39);\^N2,Q0<.*\;I*?*1NR7 MFTUX#!(O>+K<_O4HMO<;/DS]NP ^7BN00>0\7ZR+ )AD#>LSVBA''!8A?>J= M[R(68:JQ%Z GP0@1-8X^4Y[Z.IF-!*XOKIZCA2*)^Q6YF[\=O=CCU^ZE HT! MB%J^7H729OO"0/@%1P&5H?8D_'O?\:NGSQ?N5'U$I/R,8O^7N9MX"+SA>@3P6F@*]9B!=3A.VKC ME+2!='25[^0=O5)=6$>_C9[<0(ROG_$&>R]T"X5,>\0M>+E:D)-]7>7';$44 M!$1M)#6)RA?+4\CE>4Y0QI7-GN4-DH5ZJ88M?YLXM6"P,JK[-YC]F- %9M41 MI/6'&%.\X;?=!ENQJM)0?6Q*900112&:T3BWJ@\A*0(H&@0?\,KE8>U1&R%: MV ,Z'C3 0"< U!EV=(B_9PX77W[U3'.)D]?'@O&<3$;.?-Z<'W!O%@R()Q,6 M8T1U>PLT#OBZ%A@%CBN<6QO 91N.%;FUI^4-"(P,O88G:ZGW7ACC%_3 _6!6 M,,7P"([GFSNZ*8Z!#R9G(MX1X5A%0?3B;707MRI? D%LE20&_KF<.R(]W2PV=(NV7$80F5J*;H2 A78D M^RG]Z=)GWD)OF@FVZ)XP]G'Z9W;)Y02Y5%I>(2SD141@=OTKH4X$C1+O[YC> M#!"/+#C:L3J_7Y$NVS%#L2KT5TJ8%I4S<_T:>U__F_]NC(&H(WIU E>7+S'R M0'<;2#6H1D,%.BTNXPQT.J(;0.YB-A\TT!%QTSC'@MZW&>@&L'HIT(4!CW-I MF,LBWS<2Y4R@VS+*:7^&,46Y3\3*K>:"N1='$(LR:4P^-("B:-XLBLYR5[BJ9Z,N P/MD]:T^7UO:/./MD?=];(B2T."K[9>E M9YS.)^;_',8'CP3=^"H,6$U'K#K_KGS2[FEVE1CZ!X-7RW/1I":EA5)BPV[4 M5 6#_G2:@>A4=^Z[)\6: &$6O@TVXQS=A M''\DJE"IO.!(YCRW!QPQ_,7O\"Z,,'_NP?V*XP]?B>1AM/4"-WIE=9\T&Z#Z MA#Z1[^DZ( Y!HJXBY@_)T>+(/: :!H/>3-XVPMF@[ZE /_"C;9E,*!,*/3*I MD'B>R<6G2)D<2 H",[$8CV57.J M=SO/]\B/(PH'#;ZL!G:=\> @>D]F JP37\/Y#=73UF%X(H*)]UT41_24%OB9 MBWYT"00@9><4#C'0[PSJM'RNG3UI%R(H*)-ZWG!:00 M6NEYG.\%N1_ZA3/(M>)@H?>T4)M5F M (():PGR'O/_O@Y$1XSXSGT5!QS);Z(C^;J>^TA&=KKBIO[&;8C9!5D+"0V< M='7AI!CDO5:^E[Q^H(F39(<$/]ZLC'-$.99@(]KPYF$#7FJ'0\X.KK##&%J8 M=0-&"?)MC3JNB)"=>C9VG]RKHT![)H^!\Z[G-5\4-&*VQ5N>-7R5#PH6NT3*.9+ 6.7O%I4G&%.QN%)N*I^N$ ML^5J)IN;IR#C![9%>C*RRAUBUWGLJI_@A;8DI5BL^8WJP53_K:$,;-!]I(;#!2.TLI[692LH=[<((<;8,&^+' M3(1T74$,99\9GC[906D[+#D(0IW.*8+@*Z/_/KU$[B\IP/&ZC.BMO8>1^@1 MF^7!TY7+BH":M[-T"8 &$954^I[NS-;U?QP7X)L\NQ[5M98;"7239QQE1>_\TBI]UZA\&Q:T52*9--*< M-R"6TL\=O1%WLHUG@; 7 [ U0JZJ3\9HQ,9H5ZDI($#K_+J\%L^"73I?IFDC]_FQC;]# M&(8-Q]($=V2!D-I"YR!A':!- C9[]X19>AZ(BNOBR(Z(6JHR.Y*V':@Z"2MR>A76(?C7!%GBSA? ME&>,DA"]]_PCOTEPM\.;A-8]LR?/'JDX2,B#\@(!Y@LV#4VW, QY8WPWX[>B^M#GT/M#WTG(:C[-X )1_P02OT] MHN6GK :* FN3(I:+E40])S',K: F.4 G518%7;!:%WM@JO2=(C).589TR;W;J+X(4<'_07A23!:5L3]FK.:II&PC5WE6%APK] M86 ACSCQ&IM/6(V)TR>M N*$O;[3S)U5NE8KR8@JL0DBE*"@T%6E4ANDW#R/ M']*%A832LXIXJ#8"+!CB*Y_,D+V=A[?O7F6C@J/KRU8DM \?:R#3U&JG$TD0 M>)G+:>"TR^FJC,,890S1XRO*L2SV/1Q-RQZ+MCKIYE-A'5I.1?Z2MM@:2\>? M/M!4'2E:FATXI-">5/3Z*'; ..MEU%@"H4T )EPT2&7@\-/303J>(-;*BUTT MQL^B9RQ&4 $QD!7*[0T[6 $ [9J.KL"VCB6!D7P=""%_WV: ME: T)8=*07I7L9QRZ*HX-'#U79!"3],LL/G# V%5_FSZQS&4F_;4$\[AGK9G QD2G2?D G/<^AO2=3B,Z;FKU3]&HS' M5\IBXD:R>CU',[<."(Z(/O2KA@G3DI6."=K_S$K(JG4&P$^MOKRW?7-]6G]^C^SY>?/_SY M]N;]A\_W_XP^_,?/UP__-68XUFTY&-D-&)[UU6H5#$ SKR8ZV)]"JZ!"]0, M!K=V^N2&,WG:8GS97TV%FL( XX" _IA4?@$4$BV"\,)QU- 8TZC3346^8W2* M$]#C_Z*7"84 KS?S4/%MIGHTPC\_, M$V:<05'"O#F[2#1;-G(RRYYQI?$#58F>:&B6"UQ:%]DZ6Q$CWHQ4J4 MJI6!3\T4GM"SR%;L15$-6;3R6 DF]J2!G7S596>VC '.I-N,9 MF28LI[/RE*DXGD]R#=!@9T@=-.0@*J1V8YC7J ;91LTA,/&3ZQ_HDHBW85?M M\?LSGW"P>67G>%W_YV#KQ>Q&!KRM7YAH1A1V8Y]OH'6X1V1T3HBE&P*$Q0"EW<_NL?1"Y&ZM@A8];154%>*8+#C M=3&;2]!*4DC00K]R:D ;>OWHYI1TBSFM7 ="6*S5.EP12VIS=%YY.B$>?\9L M?R5X^CGPDDH8:+]F=P5*2R;M-8N+V6PZYZM0IP"AM^P)THC2'A8PBJ6H(?15 M! 2[^M8M2@VA=#E2M%':PJ*4$53%PI2^N7H8=>,HR8VXY%_ET9;\BDCTU=L? M]Y6!Y?3O%D;4$Z8&L[P+9R8APP@ X:*K"HZN"D-[N=)!J#M7:VG-;[V@WF\+ M?[?EMWFF)A,2>5&T( #IMQU4<'15L.*W50Z2^NV)EB"SG## K_S8_\=CL(TO MDRLWBE[)8/"+ZQ]5_5:;WK(YZZD7Q<1]UJ+[%R,I6F\@1G2"W 1)NH@1!IH' M]:IMU@^CH?UQ9\5>B_N1R]P@PWM%K))O)>ZTY\&!"P&%WVI#-QS M-A=[_/0:4H8^29\V&/R>LD!>\ -*N:",#&A!:)3H-C\]L)S+6^!;H!S\_,3@ELDR MCYT??HG5. <]:-$>!^T #WXP0R$JKV'J,(Q7$8 '>H54!JLDZY7>,)YR&>LP MWMT,Q6%Z!52&;GQN1; LRM71SIL=S=#<=@N MSKG#5/U1#]XU+JZ!994)QXWA=H-W':%18MI\B%JLSZ>ML3W6P;L_RU0.WE4X M'^/@K8&#=H ?P>#]Y7+#RAZ)7$3@@/RXX;(CM&(GE9!93R M0E),Q+@BR191OHB(BHBL2 J+A+0E&E6O0E23COI[S'['WZ.NVG74'X4-.[/U M>D4M>*;Y%:CA29Q=EMXQM;J%_@]PT-98:EZN>SQ>*< M#TP,RRVY'#%Q/S;Z7M#[ 6AMOB?] MNS<2:&&L5V790/YV]PF' 7G!#Y]>[\31_?AR\[>C%^&*]G-:;UE. MPS5$TF]9-EVL12=.3I?Y4$89R?8&,7(%;;MY=O_*SG+*WNY0CC)*22-)VW[" MW+_"CLG7A4J$#= I$UY=2_46.N[PUG.3R-O<'Q_C ]YXKI^8!!'-]V'"B9YP MVJXW6R]F\W)@8>THT$%R0G&.U5@BS2!V*,67V./< K^%(7'@TF8:G@1*#[52Z7OBJOY\B0P'21Q]$2ICR86 M]:IS.0BE.C/JHXH^O>KMF'YKZ$BC!]QRB-&P66^QY;.[]4RG4#7OP$04M4 & MX]IR>5$.)I&D.Y8PTINBI0B2TAU3[.A-64?_JP('C&8TEF)%@XT@%C33*D:Q MLJJJZC]]SN*BY0ES@^+TM2/J.[)"W0\UZ^##+_-W52:WO#^NI7VE*^77'*NU M'X7G-]3"JY^'1$*+PU?GJYD*$>"%ZWWIYQ3UD_ K49O=+A:G(#7EM\6=^)H MW]VFCYA[$@(C&7M][UG-5LLR.N3V,*4$M#?<72VNB/E"W]NR?UP&VSOR]>4,Z'8GVC*X_CWY#:\G;QID>J%M M$VQ]"&P2W->B,BO/>((*K%D5:)XYG4>D[%'&'WZX [">8\EZUB)(GW LQ)S> M/LZHHM0[-_;BVUU>@W?'V MP'+_'\2;R#D+'W)$8>OS%PW'3N;%A>8XAJO6A MB$'9R?EJU1CM)H@)15&:%XO\6@B&-74R35VAZ2B6U;2^U;]+ P(6EU)ME[-JG ?1=; M'VKEAXDQH:#^QC2UYF!8R U->H"H?L$V*BJE,%B,/9^N\] H)%.CP$!=JTY5+WAD6DU(AA$'M7 M$BN2G%SP8P3!]SOZ4])IJZ0M'&DX8AY)398!PA)=T?P81ND%NPE=Y/.V8N=8 M#I"O^G>S=*-I%X_M!=5WYO/IW$D1RZZ'W(51=J]U@@H\TVSQ=6+A2A?],="J ML18Y:['U^4UFK4W!6B-)/7O!42E8=#3WN,.)?K/I;C1'&4XZ]6(F")FW"R?# M]Z@>(IST8*S?<3C1[&C=W=R=#[AD(L@N.04!/F.?^LQ#>!=YY!%,_G/+2N=C MCU6PE?RH!X)VC\9TE%;7Y6>S\]7YC)^;D?&!\,QZ,Q6C@V"+'D+$&"/.&>59 MVSQ78]=*L[%;J>Y4CEU3\GJ* M/N*T3Q^V!\S/8BIXA%^\\!CGY*H?JE4OV<^P%)(8+"\XZR+X8Y9#29IY7(,M MHO2G*&_DK\IX1@]>,]^M2'KJK @.PG"#\3;^2#1E"ZWZ5^>94H&":;-H)MG\ M:EZ!V^\E%W;JX0?$-Q&&OTC/>+8SE$7&L:W0TJ^5B-6T$S"$/V/9*O=V=Q7N M]V' .H$V.X+J11B@*J0Q&&HN%M,*;&9TZ;R;4^;M8D> Q9Z49O#+:(D5!J9I MK-(4 )0-GJK 89V-(*'W$(J#];+F&,>?<$)D=.-G1<>,5B0 X*@CEXF/+LN# M)DGQ!!V4L9@@>@T6!2G=>A^FV80Y2H>P!<-K+A-,<^ )"K@)6/4!9 N*+MY> M!61M,XX"TGRH9[_3=8_\*Y"0SI M?/J72#GKJ>@WF3'A?9@3DM,Q/BCFC%#$.=&;7:FJ-.<+(ZL]XX8VQ*QD"-:! M.T&"#Q*,D."$WKTBRHOUJZ3<[&]@#6P/Q\@QH/:EV@8 N1/5RHC=XU:A):;J M!J[*IRQ'GPH1M/W(F2W7XBK'NV)K4[N!H[L.LZ(.O"TMV-55/2CDF"ID \LU MH)!P56D.,E<@EO[D[O'E5T\YS\X_8C/+S_$UR5?3_2%Z QDE@'ZE)*!JX=MK MX>AJ82W#KG"60OI]=3UC,4'P+P:L[99-E27JZ2\PA.!-BS6VE2 M]NT:36Q[=]%QJOP[IW'W+$KT"+YW?3?RV,F0=SC .^]DW;/A8-)L5-+O/:R8IVD^[>M/.:?YN4#E8,Z1D M*M9@C?[0?3P,V>A4(^4UR:?O3"V;,O?C--J==L='6B_ F\5^1FR21]WA,Z%D[NH)+7LA=3)%VF(>) M*SW;K11EI*'H1?5\P=I61W2=J-.S[J48I.,DT#%)-Q"4(Y26Y4#R;4(+1Y&\ M%MZ-;B/6'W/+[IF\P]']LZN\,E7S99OYN99$!M5YJYG,VR5E7OLT080X"B/> M:G4K[E(E#!#C )33#Z&]4]0^YMH?7'&O*FC.;^2\A;F OJ7@47]7%T75OP2&PK(D1OZW4*"/$T49U3$@KJ.FU4B+N:9NK:8PB%,YIAIIE18: M"\*NX_AHA"[Q C"RN!0&OG:QF-6CBE,<#Z)::5B-)D^I&B2$BI[7!)^<.>"A MPP9,K6_)GP0#"V-O%)$O%"AAE"8C0DD;U:K@\0?T3V^FLRRW^P.:3:;3Z>D0 M] <4A $>'9@*OJA&468N(/@<7&\K9G[U37:KG[4+H5,!##8+%HLL@:.$Y"(& M<+?=/M1R\FJ-H0=UK6.5T*#0OH<5T\KCTLKRDMK';:^,ULBB7=LP=9S5A=P5 M49S!M;QPV9]:LU2MJOX)@-4H/>KH9)_.5$3[ZD@=&H3:.C\Y 5D&IR\LM68Y]#?DD^L M\7$K7P,"4I4L)B%\N:S"$VTR'08)D<3G5[(2Y\>Q[3J9@?1-F_"PV@1ZZ)CI M'!1U]NITAL!:G;.J(*>T%C3R[ET?_^0F1RK<9;"](D;'&Y;5WNXTCARWH 2$ M3TWQ3%SX8E4%6!BS5"2C>\[$&]?QYO9(4"'= MQ*!C #\12_8_N-SM/-]S$\QN>@VW1]I4"//;EI**D2(*\]*U3]KU_]/!3!RF%D-"$#.4/6I MFAH+@(>JM!RM! F%)8"RQIV7W(1Q32(H'[";VPFN^CYRX:Q$3QO:"4)>IT9I M_#"A__2/6WY%?,0F;)>EHQ.*%1FPU*V=_H[4WV/Z#R-]F+C^(-*OFJ6WF"&6 M@%%*^O(: B&WNED/L9_ZNZA?L8MNI1PF8X*33<_RG:J*C:I8JTEIY/7 ML]B*BC5R!(9*HR>6P%-O%EL)XF=B>=5<*/N;I00P96@0,Y?RR U[&6R>TU9T M1T=T&PG_$=/?&M^>AI M]5*5?A#IR&>\P=X+O_.S_H+:JB*[T/QY.6^DA-R.2ODIKQHN]4<,W1@W*R6 5NQ MPZQ@!\$*9;Q0D1GZE;-#E!]B#.W7#ELQC&-F&*#BXFZ!050==[ GS @OKPZX MW=UHE$2JG[R18(,8#Y9B, H7]VN$4ET)YGRD?UBL/ E ]#U="5L-^," FYUS-YM#4CQ%P3^)!Z'VHY);7H MM6CC 5?-&76U\O!PH$45!HC(/0X&BDP& P?*-N+*N,C(C0$:K94;-SI.W4P- MD)()8#'"#KEJ9HCY9T'0D1/ R'M.APQ&":@)0I]ZE5'1K)=]?%2X6#4XRF: M049"DEJ\_>!& 3V:>[G9'/='G\Z^W^.=MZE9;&Q\T2IFFJ0Q<+3Y^4("B%-% MDBSZ/D<8"?7R[$[N+\:
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�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end

Large accelerated filer

Accelerated filer

Non-accelerated filer

☐ (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company